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Abstract 
Melanie S. Joy, Pharm.D. 
 
Disposition of Mycophenolic Acid and Its Glucuronide Metabolites in Subjects with 
Glomerulonephritis: Implications of Genes and Effects on Kidney Outcomes 
 
Under the direction of Philip C. Smith, Ph.D. 
 
 Glomerulonephritis is the third most frequent cause of end-stage kidney disease in the U.S. 
population.  Treatments include immunosuppressant agents such as mycophenolate mofetil.  
The purpose of undertaking the studies included in this dissertation were to assess the 
pharmacokinetic alterations of mycophenolic acid in glomerulonephritis, to evaluate the role of 
patient-level demographic data, clinical data, and genomic alterations on pharmacokinetics, and 
to evaluate determinants of treatment-related outcomes.  We evaluated the pharmacokinetics of 
mycophenolic acid in 45 patients receiving maintenance mycophenolic acid therapy.  
Pharmacogenomic assessments were conducted in 85 patients to evaluate genotype 
frequencies of drug metabolizing enzymes (uridine diphosphate glucuronosyltransferases; 
UGTs) and drug transporters (including multidrug resistance protein; MDR1) and mycophenolic 
acid disposition and relative risk of autoimmune diseases.  mRNA expression patterns and their 
relationships to genomics were conducted in 45 patients.  The pharmacokinetics showed 
enhanced oral clearance and reduced metabolic ratios in glomerulonephritis patients.  
Pharmacokinetics were more highly influenced by serum creatinine/creatinine clearance, urinary 
protein excretion, race, and gender, than single nucleotide polymorphisms in the UGTs or 
 iv 
 
MDR1.  The expression of transcript for drug metabolizing genes and transporter genes was 
variable across SLE and SVV treated versus untreated patients and healthy controls.  The drug 
transporters were expressed in most patients, while the UGTs were expressed in only 50% of 
patients.  Differences in transcript expression by race, treatment, disease, and genotypes were 
demonstrated.  A disease-gene association risk was found in the study; the relative risk of SVV 
was increased in patients who were heterozygous or homozygous for the UGT2B7 C802T 
polymorphism.  Kidney-related outcomes, as assessed by urinary protein to creatinine ratio, 
were worsened in patients with the UGT1A7 C622T polymorphism and improved with the MDR1 
C3435T polymorphism.  Composite outcomes (dialysis, death, or transplantation) were 
increased in patients who had reduced transcript expression for ABCB1 in peripheral blood 
leukocytes.  The conducted studies demonstrated the highly complex relationships between 
drug disposition, patient-level clinical and demographic data, and genome-level variability.  
Numerous opportunities exist to further delineate these relationships in cell-based assays, 
animal models of glomerulonephritis, and larger translational studies that assess serial 
measurements of drug exposure and transcript expression. 
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Introduction 
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Introduction 
 Autoimmune diseases account for 15% of the ~ 500,000 patients with end-stage renal 
disease (ESRD) cases in the U.S, just after diabetes mellitus and hypertension. 1  Additionally, 
while the exact percentages are currently unknown, these diseases afflict some of the ~20 
million individuals in the U.S. with chronic kidney disease who are not yet dialysis dependent. 2  
Antineutrophil cytoplasmic autoantibody (ANCA) small vessel vasculitis (SVV) and systemic 
lupus erythematosus (SLE) are two autoimmune diseases that often afflict the kidneys.  ANCA 
SVV typically strikes an older, predominantly Caucasian patient population of roughly equal 
gender distribution.  SLE nephritis, in contrast, affects a predominantly younger, female, African-
American population.  Although the natural course of ANCA SVV and SLE nephritis heralds 
poor outcomes, standard therapeutic approaches using the combination of glucocorticoids and 
cyclophosphamide results in improved, but less than optimal outcomes.   
 The current treatment approaches for both ANCA SVV and SLE nephritis are based on 
therapy with a regimen of either cyclophosphamide or mycophenolic acid (MPA) as either the 
sodium salt or mofetil, with or without glucocorticoids.  Data from the University of North 
Carolina Kidney Center suggest that both cyclophosphamide and MPA are used extensively in 
both glomerulonephritis populations in North Carolina.  In fact, ANCA SVV treatment data from 
the University of North Carolina showed an 84.7% remission rate in patients treated with 
combined therapy (cyclophosphamide and glucocorticoids) when compared to a 56% remission 
rate in patients receiving glucocorticoids alone. 3  However even with combined therapy 
employing cyclophosphamide plus prednisone, approximately 40% of ANCA SVV patients who 
initially respond tend to relapse within the first six months.  3 Two recent publications have 
described the use of MPA for inducing remission of ANCA SVV.4, 5  In one study, 35 patients 
with moderate renal involvement who were prescribed mycophenolate mofetil or intravenous 
cyclophosphamide were followed for treatment related outcomes. 5  Birmingham Vasculitis 
Disease Activity Scores (BVAS) (mean±SD) were lower in the MPA versus cyclophosphamide 
 3 
 
treatment group (0.2±0.89 vs 2.6±1.7, p < 0.05) at 6 months.  The percentage of patients with 
complete remission at six months was higher in the MPA vs cyclophosphamide group (77.8% vs 
47.1%), and serum ANCA titers were reduced to normal in 41.7% and 16.7% of MPA vs 
cyclophosphamide groups, respectively. 5  The side effects were similar between treatment 
groups. 5  Another recent study evaluated remission responses in 32 patients who received 
MPA (as mofetil) and prednisolone as they were not candidates for cyclophosphamide therapy. 
4
  This study reported complete remission in 78%, partial remission in 19%, and non-response in 
3% of patients.  Fifty-two percent of the initial complete responders and 100% of the partial 
responders relapsed.  The median relapse-free survival rate was 16 months.  Relapse-free 
survival rates at 1, 3, and 5 years were reported to be 63%, 38%, and 27%, respectively.4   
 For SLE nephritis patients receiving a regimen of cyclophosphamide and glucocorticoids, a 
71% and 50% five-year renal survival rate has been reported in Caucasian and African-
American patients, respectively. 6  Mycophenolic acid and cyclophosphamide have shown equal 
renal outcomes. 7  Hence, therapy with MPA for induction and maintenance of remission has 
gained favor in SLE nephritis. 7, 8  A recent meta-analysis reported on the use of MPA for 
induction and maintenance of severe lupus nephritis. 9  A total of 307 patients from four 
randomized controlled trials were included for assessment of MPA versus cyclophosphamide, 
and two trials were included for MPA versus azathioprine.  In the induction assessment, MPA 
therapy increased the relative risk for a complete remission rate (Relative Risk 3.10) and 
decreased the relative risk of infection (Relative Risk 0.65) and leukopenia (Relative Risk 0.66) 
versus cyclophosphamide.  Mycophenolic acid was similar to azathioprine with respect to SLE 
nephritis prognosis outcomes and side effects (amenorrhea and herpes zoster). 9  These data 
show consistent results demonstrating the viability of MPA treatment in patients with ANCA SVV 
and SLE nephritis. 
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Glomerulonephritis 
Treatment Issues  
 The published data for MPA therapy in SLE nephritis (as compared to cyclophosphamide) 
have shown at least equivalent renal outcomes (if not improved), and reduced side effects of 
leukopenia, amenorrhea, and infections. 7-9  The data for MPA therapy in the treatment of ANCA 
SVV is more sparse than SLE nephritis, but the limited data from generally smaller sized studies 
has been consistent with the data from SLE nephritis. 4, 5, 10, 11  
Even as MPA is gaining favor in the treatment of SLE nephritis and ANCA SVV, several 
limitations to treatment regimens currently exist.  The primary limitation is that dosage regimens 
employing MPA are based mainly on regimens used in renal transplantation. Clinicians typically 
treat patients with a protocol based on targeting a dose of 1 to 1.5 grams twice daily by initiating 
therapy with 500 mg twice daily and advancing the dose based on maintaining leukocyte counts 
above 3.0 to 5.0 x 109/L and minimizing gastrointestinal side effects.  Additionally, there is no 
goal for MPA exposure (area under the plasma concentration time curve, i.e. AUC) that has 
been established in patients with glomerulonephritis.  Data from the kidney transplant literature 
suggest that MPA AUC 0-12 targets of 30 to 60 mg hr/L are effective for patients receiving triple 
drug combinations with MPA, corticosteroids, and calcineurin inhibitors. 12  The second limitation 
is the inability to predict the patient’s overall response on outcomes based on measurable data 
such as pharmacokinetic variables from patients with glomerulonephritis.  Few studies have 
been conducted that have assessed the pharmacokinetics of MPA in glomerulonephritis and 
none of these have attempted to evaluate the contribution of pharmacokinetics to treatment-
related outcomes.  13-16  The third limitation is the absence of data that evaluates initial and long-
term kidney outcomes according to phenotype and genotype differences in drug metabolizing 
enzymes and transporters and/or differences in disease severity, both of which may lead to 
alterations in pharmacokinetics of MPA in patients with glomerulonephritis.  Together, these 
limitations reduce our knowledge and the ability to prescribe specific dosages and regimens that 
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may be beneficial in glomerulonephritis patients as a whole, and for individual patients within 
this disease category.  The exploration of possible genotype-phenotype relationships may be 
necessary to improve outcomes for these glomerulonephritides that exhibit resistant and 
relapsing characteristics.   
Alterations in Drug Disposition 
 Treatment approaches for glomerulonephritis in general have been borrowed from other 
disease populations, hence, the disposition of drugs used in treating these diseases have never 
been rigorously evaluated in patients.  Treatment of glomerulonephritis is complicated by 
several important pharmacokinetic concerns. First, incorrect dosing of prescribed medications 
may occur due to the unique loss of drug in the urine.  Urinary losses are not normally a 
concern for drugs that are highly and reversibly bound to plasma proteins such as albumin, 
secondary to the intact glomerular filtration barrier.  However, the relative impact of urinary loss 
of bound drug that may undergo a clearance mechanism has not been established in 
glomerulonephritis, where there are varying degrees of proteinuria.  A second reason for 
incorrect dosing includes an increase in “unbound” or “free” fraction in the plasma associated 
with hypoalbuminemia.  Increased “unbound” fractions can result in increased elimination 
through pathways such as glomerular filtration, tubular secretion, and hepatic and extrahepatic 
metabolism.  The contribution of reduced kidney function (e.g. glomerular filtration rate) in the 
setting of serum albumin abnormalities requires clarification regarding the impact on unbound 
concentrations.  A third concern in proteinuric states is the presence of altered body 
composition, edema, and increases in the volume of distribution of medications.  Chronic 
proteinuria may alter various independent and dependent pharmacokinetic parameters including 
Cmax and Css (maximal concentration of drug in plasma after a single dose or at steady state, 
respectively), Tmax (time to maximal plasma concentration), Kel (terminal elimination rate 
constant), T1/2 (elimination half-life), Vd (volume of distribution in central and peripheral body 
compartments), Cl (clearance), and AUC (area under the plasma concentration time curve).  
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Pharmacokinetic parameters in patients with proteinuria that differ from those determined in 
“normal” populations could potentially result in drug under- or over-dosing, and reduced efficacy 
and/or increased toxicity, especially if the unbound pharmacokinetic values are sufficiently 
altered.  One limitation of the available pharmacokinetic data in patients with kidney disease is 
the absence of data for varying degrees of proteinuria/albuminemia and concurrent alterations 
in the glomerular filtration rate.  Comprehensive pharmacokinetic assessments in inadequately 
evaluated diseased populations, e.g. glomerulonephritis, has the potential to result in more 
appropriate drug-dosage regimens for potentially useful medications and hence, may allow 
improved efficacy and safety for medications.   
Chronic Kidney Disease and Alterations in Drug Disposition  
 There are several examples of reductions in albumin binding of drugs in glomerulonephritis 
that leads to increased unbound fractions. 17, 18  The highly protein bound drugs (protein binding 
≥ 90%) are most causally implicated.  On the contrary, increased alpha-1 acid glycoprotein 
levels have been documented in chronic kidney disease, potentially leading to enhanced 
binding of basic drug moieties. 19  More recently, it has been reported that chronic kidney 
disease is associated with qualitative and quantitative reductions in metabolism via several 
different pathways.  When rat hepatocytes were incubated with serum from patients with severe 
chronic kidney disease, the levels of CYP450 protein and mRNA were reduced by more than 
45% for the 1a2, 2c6, 2c11, 2d1/2c2, 3a2, and 4a1/4a3 isoforms. 20 Hepatic acetylation 
pathways were also diminished; Nat1 and Nat2 protein and gene expression studies were 
decreased in a rat model of chronic kidney disease. 21  Studies in patients with chronic kidney 
disease have revealed reductions in the nonrenal clearance of drugs that are substrates for 
CYP2D6, 2C8, 2C9, 2C19, 3A4, 2B6, 2E1, N-acetylation, and glucuronidation pathways. 22-31 
Drug transporters also have also been suggested to be altered in chronic kidney disease.  
Protein expression of intestinal drug transporters (P-glycoprotein (Pgp), multidrug resistance 
proteins (Mrp2, Mrp3)) were reported to be reduced by > 40% in rats with chronic renal failure.32  
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Activities of Pgp and Mrp2 were decreased by 30% and 25%, respectively, in a rat model of 
chronic kidney disease, suggesting increased bioavailability of certain drugs. 32  In the liver, 
reductions in organic anion transporting polypeptides (Oatp1, Oatp2, Oatp4), and increases in 
Mrp2, Mrp3, and Pgp proteins have been described in rat models of chronic kidney disease. 33-35  
A conflicting report, however, suggested no change in Mrp2 protein expression, but enhanced 
mRNA expression. 35  Quantitative changes in kidney transport proteins also have been 
described in chronic kidney disease including reductions in Oat1 and Oct2, and increases in 
Pgp and Mrp2.  34, 36, 37  These data support the hypothesis that drug disposition may be altered 
in patients with chronic kidney disease in general, but there is currently a paucity of data 
regarding drug disposition in glomerulonephritis. 
Mycophenolic Acid 
Pharmacokinetic Disposition of Mycophenolic Acid in Renal Transplantation  
 Mycophenolic acid (as the mofetil, Cellcept®) originally was approved in the mid-1990’s for 
prophylaxis of rejection in renal transplant recipients.  Hence, most of the data pertaining to 
MPA pharmacokinetics has been derived from the renal transplant population.  It is thus 
instrumental to fully understand the pharmacokinetic behavior of MPA in the renal transplant 
population in order to comprehend the deviations from this behavior that may be observed in 
populations representing off-label uses, such as glomerulonephrits.  Figure 1.1 demonstrates 
the proposed metabolic scheme for MPA and includes the chemical structures for MPA and its 
glucuronide metabolites. 38  
 As shown in Figure 1.1, the morpholino-ester prodrug of MPA (mycophenolate mofetil) 
undergoes hydrolysis by esterases (in the stomach, small intestine, blood, and liver) resulting in 
the absorption of MPA (LogP 3.2) most likely via an active mechanism secondary to the 
structure having a negative charge at physiologic pH. 39  MPA is presented to the liver where it 
is glucuronidated by uridine diphosphate glucuronosyltransferase (UGT) enzymes to the 
phenolic metabolite mycophenolic acid glucuronide (MPAG) and the acylated form of MPAG 
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(AcMPAG).  Glucuronidation can also occur in the small intestine and kidney. 40  As the MPA 
metabolites have enhanced polarity as compared to MPA itself, they are primarily eliminated in 
the urine.  It is estimated that 93% of a MPA dose is eliminated in the urine; primarily as MPAG 
(~87%) and secondarily as AcMPAG (1%). 41  The urine is responsible for eliminating only ~3% 
as unchanged MPA. 41  Mycophenolic acid glucuronide undergoes bliliary excretion from the 
liver and the excreted metabolite is subjected to de-glucuronidation by β-glucuronidases of 
microorganisms in the gastrointestinal tract.  The de-glucuronidation process results in the 
formation of MPA and this cycling process is referred to as enterohepatic recycling (further 
described later).  A comprehensive discussion regarding transport of MPA metabolites is 
provided later in this chapter.      
 Central to MPA disposition is the wide intra- and inter-patient variability demonstrated in 
renal transplant recipients. 41, 42  Additionally the time period after transplantation is important for 
assessment of MPA pharmacokinetics; the early post-transplant phase (up to 3 months) 
generally has been associated with lower Ctr, Cmax, and AUC 0-12 values, while the later post-
transplant phase (> 3 months) has been associated with higher values for these parameters. 41  
There has been a keen interest among transplantation specialists in developing therapeutic 
drug monitoring tools using Ctr and AUC 0-12.  However, variability in Cmax and the presence of 
enterohepatic recycling complicate the adoption of an abbreviated area under the curve method 
for assessment of exposure.  The current recommendation in renal transplant recipients 
receiving triple drug therapy with MPA, a calcineurin inhibitor, and glucocorticoids is to maintain 
an AUC0-12 of 30 to 60 mg h/L as measured by HPLC. 12, 43  Recommendations based on EMIT 
measurement methods which can overestimate MPA concentrations secondary to the presence 
of AcMPAG, other drug combinations, or other disease indications have not been established.  
Table 1.1 lists the mean±SD pharmacokinetic variables for MPA (total and unbound) and its 
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metabolites, MPAG and AcMPAG in adult renal transplant recipients receiving twice daily MPA 
dosing. 44-49 
Mycophenolic Acid and Enterohepatic Recycling 
 Mycophenolate mofetil is a prodrug that is de-esterified by plasma and tissue esterases to 
MPA.  MPA is 72% by weight of a dose of mycophenolate mofetil that is available to the liver as 
MPA. 45  In contrast, MPA is 100% by weight of the dose of mycophenolate sodium (Myfortic®).  
After metabolism by the UGTs, the MPA glucuronide metabolites that are produced in the liver 
are, in part, exported across the bile canalicular membrane and expelled into the intestine.  The 
MPAG can either be eliminated into the feces (6% of a dose in humans) or transported across 
the intestinal epithelial cells into the blood by uptake transporters. 45  However, most MPAG in 
blood is from the liver and not via uptake from the gut wall after biliary excretion.  While 
intestinal transport has not been established definitely, it is known that OATPs are expressed in 
the liver and intestine, and MPA pharmacokinetics are altered in the presence of polymorphisms 
in OATPs. 50-52  β-glucuronidases in the intestine can cleave the sugar moiety of the glucuronide 
metabolites resulting in the release of MPA in the intestines and subsequent absorption into the 
systemic circulation where MPA is once again available to the liver for metabolism.  In humans, 
renal elimination is comprised of 3% unchanged MPA and 87-91% of the dose excreted as 
glucuronides. 41  The renal elimination of acylMPAG in patients has been estimated at 1%, with 
potential increases possible in renal insufficiency. 45  The proposed disposition for MPA and its 
glucuronide metabolites with reference to enterohepatic recycling are presented in Figure 1.2.53  
 As noted in Figure 1.2, the MPAG can undergo transport across the hepatic basolateral 
membrance into blood for clearance via the kidneys or can undergo biliary excretion and 
subsequent enterohepatic recycling.  Hence, as kidney function declines, MPAG plasma 
concentrations may be elevated, with subsequent shunting of the MPAG through the biliary 
excretion route.  It is plausible that enhanced recycling could then lead to increased MPA 
exposure through an apparent decrease in metabolic clearance via diminished kidney function.  
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Although effects of diminished kidney function on UGTs have not been reported, reduced 
metabolism should be entertained because reductions in the expression and function of phase I 
enzymes (cytochrome P450s) expression and function have been reported in patients with 
declining kidney function. 54 
 The impact of enterohepatic recycling can be visualized upon review of a plasma 
concentration-time profile whereby a second MPA plasma concentration peak is demonstrated 
in the 6-12 hour portion of a 12- hour dosing interval (Figure 1.3).  The implication of the second 
MPA peak is that the total exposure to MPA is enhanced, which can contribute to efficacy and 
toxicity.  Dosage recommendations based on pharmacokinetic assessments that fail to examine 
the concentration-time profile through 12 hours may under-predict exposure and elevate the risk 
of toxicities. 
Drug Interactions 
 Several potential drug interactions have been described for MPA.  Early reports described 
small increases in plasma MPAG AUC 0-24 with concomitant acyclovir, suggesting either 
inhibition of secretion or competition for secretion, likely by the multidrug resistance proteins 
(MRPs). 45  Additionally, a small decrease in ganciclovir renal clearance was reported when it 
was co-administered with MPA. 55   The most clinically important drug-drug interaction in the 
renal transplant arena is that of MPA with cyclosporine.  Notably, cyclosporine is suggested to 
inhibit the biliary secretion of MPAG by the MRP2 transporter resulting in reduced enterohepatic 
recycling and lower exposure to MPA. 56 The accumulation of MPAG in plasma may result in 
competition with MPA for albumin binding, thus increasing the MPA unbound fraction.  
Glucocorticoids are known to cause induction of drug metabolizing enzymes including UGTs 
and also have been purported to reduce the bioavailability of MPA. 57, 58  Other therapies that 
have been suggested to cause induction of UGTs include oral contraceptives and rifampin. 59, 60  
Sevelamer (Renagel®) has been reported to reduce MPA AUC ~25% secondary to modification 
of protein binding and/or interference with enterohepatic recycling. 45  Metal ions including 
 11 
 
calcium and iron have been documented to decrease exposure to MPA secondary to chelation 
in the gastrointestinal tract. 61, 62   Reduction of intestinal glucuronidases secondary to the 
antimicrobials norfloxacin and metronidazole can reduce MPA and MPAG exposure (AUCs) by 
up to 33% and 41%, respectively. 63 
Uridine Diphosphate Glucuronosyltransferases 
Uridine Diphosphate Glucuronosyltransferases and Mycophenolic Acid 
The UGTs are metabolizing enzymes that are responsible for creating polar metabolites of 
endogenous substrates (e.g. bilirubin and thyroxine) and xenobiotics through conjugation with 
uridine diphosphate glucuronic acid (UDPGA).  The UGTs primarily metabolize drugs with 
nucleophilic functional groups including oxygen (carboxylic acids, alcohols, phenols), nitrogen 
(amines), sulfur (thiols) and activated carbon centers. 64  There are two main human families of 
UGTs; UGT1A and UGT2B.  Isozymes of UGT1A are the result of modifications within Exon 1 of 
the UGT1 gene.  Isozymes of UGT1 that are involved in MPA metabolism include UGT1A8, 
UGT1A9, and UGT1A7, while the predominant isozyme of UGT2 is UGT2B7. 41, 65  MPA has 
relatively lower affinity for UGT1A9 in human liver microsomes leading to a high Km (low 
affinity), whereas the affinity of MPA for UGT1A7 and UGT2B7 are higher (low Km) as depicted 
in Table 1.2. 65 
The transplant literature has documented considerable variability in MPA pharmacokinetic 
parameters and inter-individual differences in UGT activity have been reported to be on the 
order of 8 to 30-fold. 65, 66  Additionally, the efficiency of UGTs for formation of MPAG and 
AcMPAG is variable and is tissue dependent: MPAG (kidney > liver > intestine) and AcMPAG 
(liver > kidney > intestine). 65   The role of one UGT versus another in MPA metabolism may be 
dependent on the dose and/or overall concentration as well as the specific organ.   
 UGT2B7 has been suggested to be involved with the formation of AcMPAG.  As acyl 
glucuronides have been associated with idiosyncratic drug reactions, there is interest in 
evaluating the role of this glucuronide in MPA-associated adverse events.  Regarding the UGT 
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protein, the N-terminal location is responsible for the enzymatic activity within the endoplasmic 
reticulum of the cell, while the C-terminal portion is thought to be responsible for anchorage to 
the plasma membrane and binding of the co-substrate uridine diphosphate glucuronic acid 
(UDPGA). 64  Decreased function of the UGTs could lead to increased exposure to the parent 
drug (MPA), while increased function could lead to reduced MPA relative to inactive 
metabolites.  The repercussions from the previously described circumstances may be increased 
efficacy balanced with toxicity from MPA itself versus reduced efficacy and potential toxicity 
from the acyl metabolite.  Glucocorticoids, oral contraceptives, and rifampin are the few 
published examples of potential UGT modulators; all are purported to be enzyme inducers. 57-60 
Genetic Variations and Uridine Diphosphate Glucuronosyltransferases 
There is large variability in the expression and activity of UGTs, and single nucleotide 
polymorphisms are thought to be at least partially responsible. 66-69  Distinctive racial 
distributions in the frequency of these identified polymorphisms in UGT genes have not been 
thoroughly evaluated.  The presence of the promoter polymorphisms UGT1A9 T-275A and C-
2152T result in significantly lower MPA exposures and less enterohepatic recycling. 70  
UGT1A9*3 carriers (C98T) have been reported to have higher MPA and AcMPAG exposure, 
while the UGT1A9*2 (G8A) and UGT1A8*2 and UGT1A8*3 single nucleotide polymorphisms 
appear to exert little change in pharmacokinetics. 70  The UGT2B7*2/*2 genotype (C802T) has 
been reported to confer higher unbound and total MPA. 70  Recent reports have associated the 
UGT2B7 C802T single nucleotide polymorphism with prostate cancer; possibly implicating this 
gene in disease risks. 71  While not directly relevant for MPA, the antineoplastic agent irinotecan 
(Camptosar®) is metabolized by UGT1A1 to the active metabolite SN-38 and the UGT1A1*28 
polymorphism confers increased neutropenic risks.  This pharmacogenetic finding and clinical 
consequences have been incorporated into the FDA-appoved product literature for irinotecan 
leading to decreased dosage recommendations in patients who are homozygous variant for the 
UGT1A1*28 single nucleotide polymorphism. 
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The influences of genetic polymorphisms on variations in drug metabolism and outcomes 
are important to consider in patients with glomerulonephritis receiving MPA.  Unlike renal 
transplant recipients who demonstrate primary alterations in glomerular filtration rate, patients 
with glomerulonephritis may have variations in pharmacokinetics secondary to low serum 
albumin, proteinuria, and altered glomerular filtration rate.   Since targeted MPA concentration 
ranges for glomerulonephritis have not been established, it will be necessary to account for 
multiple aspects of patient variability including single nucleotide polymorphisms, in order to 
enable better empiric dosing strategies. 
Drug Tranporters 
Drug Transporters and Mycophenolic Acid Disposition  
 The polar metabolites of MPA (MPAG and AcMPAG) require active transport for uptake and 
efflux from cells.  Mycophenolic acid has been shown to inhibit human OAT1, while MPA, 
MPAG and AcMPAG can inhibit human OAT3. 72, 73  This may lead to interactions with other 
substances (e.g. para-aminohippurate and estrone sulfate) that are substrates for these 
transporters.  For MPAG, OATPs are thought to be the primary transporters involved in cellular 
uptake, while MRPs have been implicated in its efflux from cells. 74, 75  OATPs are members of 
the SLCO family, and they can transport a multitude of drugs with various chemical 
characteristics including statins, digoxin, and methotrexate.  MRPs are members of the ABCC 
family; MRP2 has been suggested to export MPAG. 56, 76  Breast cancer resistance protein 
(BCRP) is a member of the ABCG family and it has also been implicated in MPAG transport. 77  
While we have not previously evaluated OATP, we have identified MRP2 transcript expression 
in peripheral leukocytes in our laboratory and hence alterations in MRP2 may be important in 
MPA lymphocyte responses.  MRP2 is localized in the bile canalicular membrane, intestinal 
wall, and apical membrane of the proximal tubule. 56, 78  MRP2 transport of cephalosporins, 
azidothymidine, statins, and products of phase II metabolism have been described.   
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Genetic Variations in Uptake and Efflux Transporters Relevant to Mycophenolic Acid 
Information concerning the effect of polymorphisms of drug transporting genes on MPA 
disposition has not been completely elucidated.  Homozygosity for the SLCO1B3 T334G allele 
(in the presence of the ABCC2 C-24T allele) resulted in lower oral clearance of MPA in a 
population of Japanese kidney transplant recipients. 52  Naesens et al. reported significantly 
higher dose-corrected MPA trough levels and more diarrhea in renal allograft recipients who 
had the C-24T variant of MRP2. 75 None of the studies to date have sought to evaluate the 
effects of concomitant polymorphisms in uptake and efflux transporters as well as in UGTs.   
Rationale and Overview of Proposed Research 
 The objective of this thesis proposal is to evaluate pharmacokinetic and pharmacogenomic 
factors that may be associated with altered outcomes to MPA therapy in patients with ANCA 
SVV and SLE nephritis.  The goals of this research are to understand and improve treatment 
responses to MPA in these patients.  The central hypothesis of the thesis is that the metabolism 
and transport of MPA are different in individual patients with ANCA SVV and SLE nephritis and 
these differences account for variations in systemic or tissue exposure and thus influence 
outcomes in these kidney diseases.  The specific questions that will be evaluated by this project 
include: 1) Are there alterations in pharmacokinetic parameters for MPA in lupus nephritis and 
ANCA vasculitis as compared to the published values from transplant recipients, with reference 
to glomerular filtration rate, proteinuria, and serum albumin?, 2) Is the olism and exposure to 
glucuronide metabolites of MPA (phenolic and acyl glucuronide) altered?, 3) What is the degree 
of transcript expression for metabolizing enzymes and transporters in peripheral blood 
leukocytes? and 4) Does the presence of variant alleles and/or genotypes associated with 
altered conversion of MPA to glucuronide metabolites affect pharmacokinetics and disease 
outcomes?  This research will evaluate pharmacokinetics, expression phenotype, and genotype, 
and will correlate the findings of these studies to determine associations with patient outcomes.  
In addition, these studies will be the first evaluation of their kind in patients with SLE nephritis 
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and ANCA SVV, and should generate useful pharmacokinetic profiles for MPA to assist with 
appropriate dosing.  The studies proposed in this thesis research program are innovative in that 
they fill a void in our knowledge of the disposition of highly protein bound drugs in subjects with 
glomerulonephritis and the role of UGTs in altering the kidney outcomes of MPA-based 
treatment strategies.  The contributions to the treatment of ANCA SVV and SLE nephritis 
patients will be significant because of the expansion of knowledge regarding this common 
therapy as well as exploration of methods to individualize dosing regimens to improve treatment 
responses.  Clinicians will benefit from this research because it will reduce some of the “guess-
work” involved in prescribing appropriate treatment regimens for patients with ANCA SVV and 
SLE nephritis.   
Specific Aims  
The specific aims and methods to address the objective of the proposal are cited below. 
Aim 1.  Evaluate the pharmacokinetic parameters for MPA in subjects with ANCA SVV and 
SLE nephritis with variable levels of kidney function as reported by glomerular filtration rate, 
proteinuria, and disease activity.  Preliminary data from the University of North Carolina 
population of patients suggest increased total and renal clearance of MPA in patients with 
clinically significant levels of proteinuria.  Additionally, patients with glomerulonephritis 
appear to exhibit alterations in pharmacokinetic variables as compared to published data 
from transplant patients.   
a. Perform noncompartmental pharmacokinetic analyses of MPA using plasma and 
urine collected from 40 subjects; 20 with ANCA SVV and 20 with SLE nephritis.  
Analyses will include total and unbound plasma concentration data. 
b. Develop a compartmental pharmacokinetic model for MPA that incorporates the 
components of renal elimination and metabolic clearance. 
c. Develop a statistical model to evaluate the effects of changes in clinical 
characteristics (e.g. glomerular filtration rate, proteinuria, serum albumin) on 
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pharmacokinetic parameters deemed to be of paramount importance in affecting 
exposure of tissues to MPA, and ultimately renal outcomes. 
Aim 2.  Evaluate the exposure to MPAG and AcMPAG in subjects with ANCA SVV and SLE 
nephritis as a function of variable kidney function as reported by glomerular filtration rate 
and proteinuria.   
a. Perform noncompartmental pharmacokinetic analyses of MPAG and AcMPAG 
using plasma and urine collected from a subset of subjects from Specific Aim #1.  
b. Develop a compartmental pharmacokinetic model for MPAG and AcMPAG that 
incorporates the components of renal elimination and metabolic clearance. 
c. Develop a statistical model to evaluate the effects of changes in clinical 
characteristics (e.g. glomerular filtration rate, proteinuria, serum albumin) on 
pharmacokinetic parameters deemed to be of paramount importance in effecting 
exposure of tissues to MPAG and AcMPAG, and kidney outcomes. 
Aim 3.  Genotype ANCA SVV and SLE nephritis subjects for known single nucleotide 
polymorphisms in UGTs 1A9, 1A7, and 2B7 because these have been associated with 
altered pharmacokinetic parameters (AUC, Cmax, Ctr) for MPA and glucuronides and may 
explain part of the variability in patient outcomes.  Determine mRNA expression patterns for 
UGT1A9, UGT1A7, UGT2B7, ABCB1, ABCC2, and SLCO1A2 in leukocytes of patients with 
glomerulonephritis. 
a. Genotype subjects with ANCA SVV and SLE nephritis for known single 
nucleotide polymorphisms in UGTs including UGT1A9 promoter enhanced 
activity SNPs (C-2152T, T-275A), 1A9*2 (G8A) and UGT1A9*3 (T98C) (both 
associated with reduced activity), UGT 1A7*4 (T622C) (reduced activity), UGT 
2B7*2 (C802T) (associated with enhanced formation of the AcMPAG).  
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b. Develop a statistical model to evaluate the association between key MPA and 
glucuronide pharmacokinetic parameters from subjects and the presence of 
variant alleles in UGTs. 
c. Evaluate mRNA expression patterns of drug transporters and drug metabolizing 
enzymes in leukocytes and determine associations with genotype and 
pharmacokinetic parameters 
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Table 1.1 Steady-State Pharmacokinetics of Mycophenolic Acid and Its Phenolic 
Glucuronide in Adult Kidney Transplant Recipients 44-49 
   Cmax (mg/L)  Tmax (hr) Ctr (mg/L) AUC 0-12 (mg h/L)  
MPA total  23.2±11.9  0.9±0.2  1.22±0.42 61.3±28.7 
MPA free  0.21±0.03  1.37±0.19 0.02±0.005 0.57±0.05 
MPAG   111±26.5  3.0±1.2  75.8±40.0 1040±290 
AcMPAG  1.95 (0.88-5.35) 1.63(1.25-2.0) 0.33±0.40 32±19 
 
 
Abbreviations 
AUC – area under the plasma concentration time curve 
Cmax – maximum concentration in plasma 
Ctr – trough concentration in plasma 
MPA – mycophenolic acid 
MPAG – mycophenolic acid glucuronide 
AcMPAG – acyl mycophenolic acid glucuronide 
Tmax – time to maximum plasma concentration 
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Table 1.265  Representative Enzyme Kinetic Values for the Conversion of Mycophenolic 
Acid to Mycophenolic Acid Glucuronide by Human Recombinant Uridine Diphosphate 
Glucuronosyltransferases as Depitcted by Eadie-Hofstee Plots.  
 
 
 
 
 
 
 
Abbreviations 
Km – plasma concentration at one-half of the maximum rate of metabolism 
UGT – uridine glucuronosyltransferase 
Vmax – maximum rate of metabolism
Enzyme Km (µM) Vmax (pmol/min/mg) Vmax/Km 
UGT1A9 276 106 0.38 
UGT1A7 159 85.2 0.54 
UGT2B7 123 39.0 0.32 
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Figure Legends 
Figure 1.1. Structures of Mycophenolic Acid and Metabolic Pathways.  
Figure 1.2. Depiction of the Disposition and Recycling of Mycophenolic Acid (MPA) and 
Its Glucuronide (MPAG).  After MPA glucuronidation to MPAG in the hepatocyte, MPAG either 
undergoes efflux at the apical hepatocyte membrane resulting in biliary excretion, or undergoes 
efflux at the basolateral hepatocyte membrane resulting in uptake into the blood.  The former 
pathway is contributory toward enterohepatic recycling, while the later pathway contributes 
toward renal clearance.  Abbreviations: MMF – mycophenolate mofetil; MPA – mycophenolic 
acid; MPAG – mycophenolic acid glucuronide. 
Figure 1.3. Mycophenolic Acid Plasma Concentration Versus Time Curve.  This patient 
was receiving a Cellcept® dose every 12 hours.  After the 4 hour time period, a second peak at 
6 hours occurs and demonstrates the enterohepatic recycling phase. (Joy MS data) 
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Figure 1.1 38 Reprinted with permission.  
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Figure 1.2  
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Figure 1.3   
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Abstract 
 Lupus nephritis is associated with urinary protein excretion, hypoalbuminemia, and renal 
function declines, which may impact the pharmacokinetics (PK) of mycophenolic acid (MPA).  
 The primary study objective was to evaluate and describe the PK of MPA and its 
glucuronide (MPAG) in lupus nephritis. Secondary objectives were to determine the single 
and/or multiple effects of clinical parameters (urinary protein excretion, serum albumin, and 
creatinine clearance) and demographic variables (age, race, and gender) on total and unbound 
MPA and MPAG PK.  
 Plasma and urine were collected for 24-hours and assayed by HPLC with UV detection. 
Noncompartmental PK analysis was performed using WinNonlin v4.1. Statistics included 
descriptive analyses, urivariate and multiple regression tests, and T-test or nonparametric 
equivalent.  
 Time to maximal concentration (0.5 to 8 hrs) was variable. Unbound MPA was  2.6±1.9% 
and oral clearance (Cl/F 343 ± 200 mL/min) was ~ 2-fold higher than previously reported. 
Multiple regression showed MPA Cl/F was predicted by creatinine clearance (Clcr) and serum 
albumin (MPA lnCl/F = 5.358 + 0.0092 (Clcr) – 0.078 (ranked albumin), R2 51.1%, p = 0.0195). 
UP:Cr ≥ 1 g/d had lower trough and area under the curve (AUC 0-12) and higher Cl/F versus 
UP:Cr < 1 g/d. Serum albumin < 4 g/dL had higher MPA Cl unbound and MPAG Clr 0-12 versus 
serum albumin ≥ 4g/dL. Recycling AUC (AUC6-12) and equally gender and age predicted renal 
clearance of MPAG.  
 Clcr and serum albumin were identified as primary contributors to MPA exposure and should 
be considered when evaluating dosages.  The results of future studies should clarify the 
interactions of other variables on drug exposure and treatment responses.  Clinicians need to 
be mindful of clinical changes that occur throughout the course of lupus nephritis in order to 
maintain efficacy and reduce toxicity from MPA therapy.   
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Introduction 
 Mycophenolic acid (MPA) has been used as an immunosuppressant agent to prevent renal 
transplant rejection since 1995.  As there is inherent variability in mycophenolic acid 
pharmacokinetics within transplant patients, several researchers have sought to describe 
mycophenolic acid variations that occur from the early post-transplant period to several months 
after transplant.1-3   More recently, it has been suggested that therapeutic plasma monitoring of 
mycophenolic acid may help to improve immunosuppressive outcomes. 4  Area under the 
plasma concentration time curve from 0 to 12 hours (AUC 0-12) of 30 to 60 µg h/L and trough 
plasma concentrations (Ctr) of 1.0 to 3.5 µg/mL are suggested as targets for combination 
immunosuppressive therapy (MPA plus cyclosporine and steroids) in kidney and heart 
transplant patients. 4-5  These concentrations are based on high performance liquid 
chromatography (HPLC) assays.  Target ranges for MPA in single or double agent therapies or 
for use in autoimmune diseases have not been established. 
Since 1999, mycophenolic acid therapy has been evaluated for efficacy in patients with 
lupus nephritis. 6-9  Similar to renal transplant recipients, glomerular disease patients often have 
diminished renal function manifest as reductions in estimated glomerular filtration rate (eClcr).   
However, glomerular disease patients also commonly have protein in the urine and alterations 
in serum albumin.  Both urinary protein and decreased serum albumin (in addition to altered 
eClcr) conceivably could lead to pharmacokinetic alterations of highly protein bound drugs such 
as MPA in patients with glomuerulonephritis.  Hence, a comprehensive evaluation of total and 
free MPA pharmacokinetics in lupus nephritis patients on stable therapy is warranted.  Analyses 
of the impact of alterations in urinary protein, serum albumin, and eClcr on pharmacokinetics 
could provide patient-specific factors that may be important for individualized dosing. 
The primary purpose of this study was to evaluate the total and free pharmacokinetics of 
MPA and its phenolic O-glucuronide (MPAG) in patients with lupus nephritis.  The secondary 
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objectives were to determine the effects of clinical parameters (urinary protein excretion 
(UP:Cr), serum albumin, and eClcr) and demographic variables (age, race, gender) on total and 
unbound MPA and MPAG pharmacokinetics.   
Methods 
Patients 
Patients with biopsy confirmed lupus nephritis receiving maintenance therapy with MPA 
were evaluated for study enrollment.  Patients were required to be on a stable MPA dose for at 
least two weeks.  Concomitant therapy with other immunosuppressants was allowed and 
recorded.  Patients were fasting at study initiation and were fed a standard diet in the research 
unit throughout the study period.  The following clinical data was measured at the time of the 
study or abstracted from the medical record:  eClcr, UP:Cr, serum albumin, and serum 
creatinine.  The study and consent form was approved by the University’s Institutional Review 
Board and patient consent was required prior to participation.     
Pharmacokinetic Study 
 Patients were admitted to the General Clinical Research Unit (GCRC) to participate in a 24-
hour inpatient stay for pharmacokinetic analysis.  Baseline blood was drawn for a trough plasma 
concentration.  The patients were then instructed to take their morning oral dose of MPA.  
Additional plasma samples (7.5 mL) were obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours.  
Urine was collected during the following intervals: 0-6, 6-12, and 12-24 hours into acidified (15 
mL 6 N HCl) collection containers.  Heparinized blood samples were immediately centrifuged for 
10 minutes at 4C, plasma transferred to plastic screw top tubes and stored at -80 until assay.  
Urine volume for each collection time period was recorded, and 2 mL aliquots were stored at  
-80C until assay.  Unbound plasma fraction was determined by filtration via a Centrifree® 
Micropartition device (Millipore, Ireland) with a filter cut-point of 30,000 daltons.  Temperature 
and centrifugation conditions were optimized to enable filtration of 10% of the total plasma 
volume.  The unbound fraction was assessed at the time point corresponding to the Cmax and 
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evaluated in spiked plasma separately.  The unbound concentrations were then calculated as 
unbound fraction multiplied by total concentration.  Linearity of binding throughout the evaluated 
concentration ranges was assumed.  Samples were assayed by HPLC using a variation on the 
methods of Wiwattanawongsa, et al 10, using methanol-formic acid 0.1% isocratic mobile phase 
(52:48) at a flow rate of 1.0 mL/min, suprofen as the internal standard, and UV detection at 250 
nm.  The HPLC system consisted of a Hewlett-Packard series 1050 pump/injector, Hewlett-
Packard Series 1050 UV detector, and Axxiom ODS column (150 x 4.6 mm I.D., 5 
micrometers).  Plasma and urine standard curves for MPA were linear over the range of 0.2-200 
µg/mL and 1-50 µg/mL, respectively.  Plasma and urine standard curves for MPAG were linear 
over the range of 1-200 µg/mL and 5-1500 µg/mL, respectively.  MPAG concentrations were 
represented in terms of MPA-equivalents by multiplying each MPAG concentration by 0.646 
(molecular mass of MPA to MPAG) and reported in µg/mL.  The amount of MPA available from 
a dose of the prodrug was estimated as 72% of the dose (molecular mass of MPA to MPA 
mofetil).  This calculation was used to determine the amount of drug excreted in the urine in 
reference to the dose of MPA actually administered from mycophenolate mofetil. 
Pharmacokinetic Analysis 
 Noncompartmental pharmacokinetic analysis of total and unbound MPA and MPAG was 
conducted using WinNonlin v4.1 (Pharsight, Mountain View CA) linear up-log down for AUC 
determination.  The following parameters were reported: concentration maximum (Cmax), time 
to maximum concentration (Tmax), concentration trough (Ctr) at 12 and 24 hours, area under 
the plasma concentration time curve from 0-12 hours (AUC 0-12), apparent oral clearance (Cl/F), 
apparent renal clearance (ClR/F), and mean residence time (MRT).  For the purpose of 
pharmacokinetic evaluations we made the assumption that F = 1, since others have reported 
bioavailability of close to 1. 2  AUC 12-24 and AUC 6-12 were calculated.  The AUC 6-12 was used to 
estimate entero-hepatic recycling as performed by others. 11-12   Urine analysis was performed 
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by multiplying the concentration by volume for each collection period (0-6, 6-12, and 12-24 
hours).  Amount excreted in the urine (Ae) was computed for the 0-12 hour time frame by 
adding the Ae for the first two collection intervals.  Apparent ClR/F for the 0-12 hour time frame 
was calculated by Ae 0-12/ AUC 0-12. 
Statistics 
 Descriptive analyses for pharmacokinetic parameters, demographic variables and 
laboratories included means, standard deviations, and medians as appropriate.  Univariate 
assessments of the key clinical characteristics (serum albumin, UP:Cr, eClcr, age, race, gender, 
steroid dose) versus each pharmacokinetic parameter of interest (MPA Cl/F, MPA ClR/F, MPA 
unbound clearance (Clunb), MPAG ClR/F, MPA AUC 0-12, MPA AUC 6-12, MPAG AUC 0-12) were 
assessed by Spearman Rank correlations.  The correlations and resultant p values from the 
univariate assessments were analyzed for possible inclusion into a multiple regression model 
for prediction of the pharmacokinetic parameters of interest.  All data that failed normality testing 
were transformed by various functions to ensure normality was attained.  Model building 
consisted of using multiple regression analysis with forward addition of variables as well as 
backward elimination, noting any significant changes in coefficients of the primary predictors as 
well as the R2 and p value resulting from the various models.  The final model was selected 
based on significance of each variable on predicting the dependent variables in the model as 
well as the overall R2.  Race (white and non-white) and gender (female and male) were coded 
as 1 and 2, respectively. 
 Comparisons between clinical groups based on urinary protein excretion (< 1 g/day vs ≥ 1 
g/day), serum albumin (< 4 g/dL vs ≥ 4 g/dL), age (< 40 yrs vs ≥ 40 yrs), race (white vs 
nonwhite), and gender (female vs male) were analyzed by the nonparametric Mann Whitney 
Test.  Upon review of our data, it was not possible to compare eClcr groups as there was no 
meaningful cut-point value for evaluation.   
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Results 
 A total of 18 biopsy-confirmed lupus nephritis patients completed 21 full twenty-four hour 
MPA/MPAG pharmacokinetic evaluations.  We report the results for the 18 discrete patients.  
The patient demographic composition included age 36 ± 9 years, 83% female, 60% non-
Caucasian, and weight 82.3 ± 22 kg.  The non-Caucasian patients consisted of 7 African 
American, 2 Asian, and 2 Native American.  All patients were receiving the mycophenolate 
mofetil prodrug of MPA (Cellcept®, Roche).  The average MPA daily dose was 1860 ± 764 mg 
and this was represented by twice daily dosing in all but one patient who received 1000 mg 
three times daily.  The distribution of doses given twice daily were 500 mg (n = 6), 750 mg (n = 
1), 1000 mg (n = 7), and 1500 mg (n = 4).  eClcr was used as the assessment of GFR in this 
study. 13  The mean (± standard deviation) clinical laboratory results at baseline were serum 
creatinine 1.1 ± 0.8 mg/dL, UP:Cr 1.3 ± 2.2, eClcr 114 ± 49 mL/min, and serum albumin 3.9 ± 
0.4 g/dL.  Fifty percent (n = 9) of patients were receiving concomitant glucocorticoids, with a 
mean ± SD daily dose of 11.4 ± 8.9.  No other immunosuppressants were prescribed.  Two 
patients were prescribed oral contraceptives.  
Mycophenolic Acid Pharmacokinetics 
 A representative concentration vs time profile for steady state MPA and MPAG 
concentrations in our lupus nephritis patients is presented in Figure 1.  The mean (± standard 
deviation) pharmacokinetic parameters for patients with lupus nephritis are provided in Table 1.  
In order to eliminate differences secondary to body size, the apparent oral clearance (Cl/F) data 
was adjusted to a 70 kg patient based on a scaling method that uses a power of 0.75. 14   The 
Cl/F of 343 ± 200 mL/min suggests that MPA is a moderate extraction ratio drug whose 
metabolism would be impacted by changes in unbound fraction.  While the mean percentage of 
free MPA was 2.6 ± 1.9, five patients (28%) had free MPA percentages that were greater (range 
2.9 to 6.3%).  The mean MPA area under the plasma concentration time curve (AUC 
 0-12) in our 
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lupus patients was outside the range of 30 to 60 mg hr/L recommended in the first six months 
post renal transplant, 15 with 39% of patients exceeding and 22% failing to achieve this range.  
Examination of the AUC 6-12 to the AUC 0-12 suggested that recycling accounted for 37% (± 16%) 
of the AUC reflected from the first daily dosing interval.    
The mean MPA trough (Ctr) at 12 hours exceeded the range of 1.0 to 3.5 µg/mL that is 
recommended in transplant patients 15, with 28% of patients below and 33% above this target, 
respectively.  The Ctr that resulted after the first 12 hours was ~20% less than the Ctr following 
the second dosing interval, however the difference was not significant.  The time to maximal 
concentration (Tmax) varied in the range of 0.5 to 8 hours and would not have been appreciated 
in shortened sampling schemes.  A three hour AUC profile would have under-represented 
exposure over the dosing interval.   
As suggested previously 2, the clearance of MPA is primarily the result of systemic 
metabolism to MPAG.  The apparent renal clearance (ClR/F) for MPA represented ~ 1% of the 
Cl/F.  The ClR/F of nonmetabolized MPA was 1.8 ± 1.4 mL/min, which was ~ 2% of the eClcr in 
the evaluated patients.  The kidneys contributed to the excretion of 1% of the total MPA dose, 
assuming all MPAG formed was via the liver.  The amount of MPA in the urine over the 0-12 
hour interval (4.8 ± 3.3 mg) was ~25% less than the amount in the 12-24 hour interval (6.5 ± 9.1 
mg), despite the dosages being consistent, but this was not significant.  The eClr was similar 
between the 0-12 hour and 12-24 hour dosing intervals.   
Mycophenolic Acid Glucuronide Pharmacokinetics 
The MPAG pharmacokinetic results are presented in Table 2.1.  The MPAG Ctr after the first 
12 hours was ~15% less than the Ctr following the second dosing interval.  A calculated AUC 
ratio of MPAG to MPA resulted in a metabolic ratio (MR) of 7.1 ±  4.8.   
The renal clearance of MPAG was 53.5 ± 52.3 mL/min, which was 44% of the Clcr.  The 
kidneys contributed to the elimination of 96% of the total MPA dose through excretion of the 
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metabolite, MPAG.  Hence, the kidneys were responsible for eliminating ~97% of the total dose 
of MPA.  The remaining MPA was likely eliminated secondary to excretion of the acyl-MPAG 
metabolite by the kidneys (not measured) as well as by biliary secretion of MPAG that is not 
recycled.  The amount of MPAG in the urine over the 0-12 hour interval (565 ± 310 mg) was 
~28% more than the amount in the 12-24 hour interval (441 ± 341 mg), despite the dosages 
being consistent.  The Clr was similar between the 0-12 hour and 12-24 hour dosing intervals.   
Unbound Pharmacokinetics 
 Our patient data showed that 2.5% and 9.3% of MPA and MPAG, respectively, were 
unbound in the plasma.  Since the unbound MPAG was less than that reported previously 16, we 
reviewed our data with normal plasma that was spiked with MPA and MPAG either alone or in 
combination.  The blank plasma that was spiked separately demonstrated similar percentages 
to that found in our patient data.  The combination drug and metabolite spiked plasma showed 
an increase in unbound percentage of 4% and 11% for MPA and MPAG, respectively, 
suggesting competitive binding to albumin as reported previously.   
Since the normal percentage of unbound MPA is ~2%, if one aims for a total Ctr of 1.0 to 3.5 
µg/mL then an unbound target would be 0.02 to 0.07 µg/mL.  Likewise, if suggested total AUC 
goals are 30 to 60 µg h/mL, then unbound AUC goals would be 0.6 to 1.2 µg h/mL.  Our data 
showed mean unbound Ctr levels (0.1 µg/mL at 12 and 0.13 µg/mL at 24 hours) that were 
greater than suggested, with 44.4% of patients within the range.  With regard to unbound AUC, 
the mean exposure was greater than the upper range of 1.2 µg h/mL in 33% of our lupus 
patients.   
Regression  
 Multiple regression was performed to determine which clinical factor (UP:Cr, eClcr, serum 
albumin, age, race, gender, steroid dose) had the most effect on pharmacokinetic parameters 
for MPA (ClR/F, Cl/F, AUC 0-12, AUC 6-12) and MPAG (ClR/F, AUC 0-12).  MPAG clearance 
 40 
 
parameters were included as increased MPAG may result in enhanced recycling and 
subsequent increases in MPA exposure.  Models were constructed by forward selection and 
backward elimination schemes employing the pharmacokinetic parameter as the Y factor and 
clinical variables as the X factors.  AUC6-12 was also included as an X factor when ClR/F 
variables were assessed.  The eClcr and serum albumin were the two clinical parameters 
contributing to MPA Cl/F.   Ln MPA Cl/F = 5.3585 + 0.0092 (eClcr) – 0.0776 (ranked serum 
albumin), R2 51.1%, p = 0.0195; eClcr p = 0.0265, serum albumin p = 0.0586.  The regression 
equation for MPA AUC 0-12 demonstrated similar results, which is expected given the reciprocal 
relationship between Cl/F and AUC 0-12.  For the MPAG ClR/F analyses, the AUC 6-12 was 
consistent in models that controlled for either gender or age.  These two models were:  1) Ln 
MPAG ClR/F = 6.6009 – 1.3519 (gender) – 0.5257 (ln AUC 6-12), R2 39.9%, p = 0.0282; race p = 
0.0405, ln AUC 6-12 p = 0.0687, and 2) Ln MPAG ClR/F = 13.1896 – 2.2901 (ln age) – 0.5105 (ln 
AUC 6-12), R2 39.9%, p = 0.0300; ln age p = 0.0434, ln AUC 6-12 p = 0.0776.  No significant 
predictors of AUC6-12 or ClR/F for MPA were found.   
Comparison Between Groups Based on Clinical Laboratories 
Given the importance of albumin in the regression model for Cl/F and AUC0-12 and the 
prevalence of increased UP:Cr in glomerulonephritis patients with reduced serum albumin 
concentrations, we wanted to explore the differences in PK parameters by distinct clinical 
groupings. (Table 2.2)  UP:Cr was selected as a clinical variable secondary to the high plasma 
protein binding characteristics of MPA and MPAG.  It is conceivable that highly protein bound 
drugs may be eliminated in the urine bound to protein in patients with proteinuria and/or they 
may be preferentially eliminated by metabolism secondary to increased unbound fraction.  A 
cut-point value of 1 g/day was selected based on the premise that UP:Cr less than 1 g/day 
would be less likely to alter PK.  The MPA data shows that Cl/F was significantly increased (790 
mL/min vs 305 mL/min, p = 0.0464) and Ctr12 and AUC 0-12 were both significantly reduced in 
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the high protein excretion group (0.88 µg/mL vs 5.0 µg/mL; p = 0.012 and 33.2 µg h/mL vs 91.9 
µg h/mL; p = 0.018, respectively).   
Since MPA and MPAG are highly bound to serum albumin, albumin was also selected for 
evaluation. (Table 2.2).  Several findings of this analysis were of borderline significance.  The 
MPA ClR/F was found to be increased nearly 2-fold in the low serum albumin group (p = 0.073).  
This finding would be expected given that renal clearance would be directly related to eClcr as 
well as the unbound fraction of MPA.  Clunbound was found to be increased in the low albumin 
group and this finding was of borderline significance (p = 0.051).  Although the renal clearance 
was enhanced 2-fold, the overall contribution of the kidneys to clearance was low given that 
only 3% of a MPA dose is normally eliminated unchanged in the urine. 16  MPAG ClR/F was 
increased in patients with reduced albumin (p = 0.053), reducing the amount of MPAG available 
for recycling to MPA and potentially leading to reduced MPA exposure.  With regard to MPA 
AUC values, we found slightly increased MPA AUC 0-12 in our high albumin group (p = 0.128), 
reflecting the reciprocal changes in Cl/F.   
 The differences in pharmacokinetic variables between age grouping (< 40 years vs ≥ 40 
years), race (white vs nonwhite), and gender (female vs male) were also evaluated (data not 
shown in Table 2.2).  The MPA MRT was found to be greater in younger patients (21.6 hrs vs 
8.23 hrs; p=0.066), but this did not result in a significant p value.  Additionally, the MPAG ClR/F 
0-12 was found to be increased 6-fold in females as opposed to males (66.5 mL/min vs 10.7 
mL/min; p 0.047).  The eClcr, however, was only ~21% greater in females than males. 
Discussion 
 Our study is the first published report that has focused on describing the pharmacokinetic 
disposition of MPA and its metabolite MPAG after chronic therapy in patients with lupus 
nephritis.  Additionally, in order to achieve clinical relevance to our work, we have described 
relevant patient laboratory data that were found to portend variations in pharmacokinetic 
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disposition.  Our multivariate regression assessments for prediction of Cl/F and AUC0-12 
implicated serum albumin and eClcr as the main contributors.  Although there is some degree of 
correlation between serum albumin and UP:Cr, there is also a fair amount of variability between 
the two measures in individual patients.  The combined, correlative contribution of UP:Cr and 
serum albumin cannot, however be fully evaluated.  Hence, it is prudent to assess both the 
serum albumin and UP:Cr when evaluating initial dosing for highly protein bound drugs such as 
MPA.  The multivariate regression assessment of MPAG ClR/F determined that log AUC6-12 was 
contributing with gender and age also contributing equally, although in a separate fashion.   
 The resulting MPA PK parameters for patients with lupus nephritis appear to be comparable 
with that what has been reported for renal transplant recipients, with the exception of Cl/F, 
which is up to 2 -fold greater in the lupus nephritis population.  Reasons for enhanced Cl/F 
include increased systemic metabolism secondary to either up-regulated glucuronidation (single 
nucleotide polymorphisms in the UGT1A9 promoter or steroids), increased MPA unbound 
fraction (available for hepatic extraction/metabolism), or enhanced renal excretion.  Regarding 
glucocorticoids, patients receiving concurrent steroids had similar Cl/F estimates as patients 
who were not receiving steroids.  Also, steroid dose did not contribute to the Cl/F in the 
regression analysis.  We are currently evaluating the contribution of genotype as a factor in 
altering MPA clearance.  The unbound fraction, implicated as a variable leading to increased 
drug availability for metabolism is important in our patients given that 40% had albumin 
concentrations that were < 4 g/dL.  The regression analysis for Cl/F implicated serum albumin 
as a predictive variable.   
 Enhanced renal clearance could occur secondary to increased free drug available or due to 
loss of protein bound MPA with the urinary protein, both cases resulting in an increase in Cl/F.  
However, when we evaluated ClR/F between patients with UP:Cr < 1 g/day and those with 
UP:Cr ≥ 1 g/day, the ClR/F results were similar.  It is plausible that the magnitude of difference in 
Clr was under-appreciated based on our selected cut-point for UP:Cr of 1 g/day.  Further review 
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of our data shows a confounding effect of serum albumin levels; while 29% of our UP:Cr < 1 
g/day had low albumin levels, 75% of our UP:Cr ≥ 1 g/day had low albumin levels.   
 A previous study of 16 autoimmune disease patients (containing six lupus erythematosis 
patients) who received 1 g MPA every 12 hours reported a mean MPA AUC 0-12 of 70.6 ± 28.7 
µg h/mL, which was comparable to our study. 17  However, it is not clear whether the previous 
study normalized AUC data to weight or body size to enable appropriate assessments.  The 
MPAG AUC 0-24 (2017.2 ± 1124 µg h/mL) was 2-fold higher than what would have been 
predicted in our study based on extrapolation of the AUC 0-12 data.  MPAG is minimally active 
pharmacologically and it is important in enterohepatic recycling and MPA exposure.  While it 
was expected that eClcr would predict the MPAG ClR/F secondary to MPAG being a polar 
metabolite that is primarily excreted by the kidneys, our distribution of kidney function did not 
encompass late stage CKD patients to enable a display of these relationships.  Previous 
clearance data from renal transplant patients has shown MPAG plasma clearance to be highly 
correlated (R2 0.86) with estimated glomerular filtration rate (eClcr) and the mean ClR/F values 
for MPAG in patients with mild, moderate and severe kidney disease were reported as 21.7, 
10.0, and 5.0 mL/min, respectively. 18  Hence, a patient with severe kidney disease could have a 
4-fold reduction in MPAG clearance, resulting in an increase in MPA AUC through recycling.  
Our regression model suggested that ln AUC6-12 along with ln age and male gender were 
predictors for decreased MPAG ClR/F.  An increase in recycling AUC predicted a reduction in 
ClR/F of MPAG since less drug would be available as the polar, renally excreted metabolite.  An 
increase in age predicted a decrease in MPAG ClR/F, which would support (indirectly) a role of 
eClcr.  Most of our patients spanned the second to the fourth decade and thus the effects of age 
on eClcr were not appreciated.  Refinements and validation of our model will require addition of 
representative patients with more severe reductions in eClcr to fully understand the role of renal 
function. 
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 A study in renal transplant recipients used a multivariate analysis and demonstrated that 
24% of the MPA Cl/F could be explained by proteinuria (yes/no), eClcr, and diabetes mellitus. 19  
Our data showed that 51% of MPA Cl/F could be explained by serum albumin and eClcr, two 
readily measured clinical laboratories.  The contribution of eClcr to MPA Cl/F was unexpected 
given the low percentage of MPA (1-3%) that is normally excreted by the kidneys.  However, 
patients with diminished eClcr have been documented to exhibit decreased hepatic metabolism 
postulated to be due to the CKD state itself or the effect of CKD on the accumulation of 
endogenous substrates. 20  In subjects with both decreased albumin and decreased eClcr, the 
MPA AUC lowering effect of reduced albumin (more drug available for metabolism) may be 
balanced by an increased AUC effect secondary to a reduced eClcr. 21-22  Along another 
pathway, states of inflammation can have variable effects on drug metabolizing enzymes and 
transporters. 23-24 
 Regression models for a quantitative prediction of the Cl/F based on the serum albumin and 
Clcr, when validated, could be used to guide dosage regimens.  For example, in our current 
model, for each 20 mL/min decrease Clcr, one would expect a decrease in Cl/F of about 30 
mL/min assuming a stable serum albumin of 4.4 g/dL and an increase of about 180 mL/min 
assuming a concomitant reduction in the serum albumin to 2.9 g/dL.  Hence, the effects of 
moderate reductions in serum albumin would have fairly significant effects on increasing Cl/F 
versus moderate reductions in Clcr.  Since increases in proteinuria often result in concomitant 
reductions in serum albumin, the combined contributions could enhance the Cl/F of MPA even 
further.  However, more patients with significant proteinuria are needed to provide a more 
definitive conclusion regarding the contribution of proteinuria (somewhat independent of serum 
albumin) to Cl/F for MPA.  Although requiring additional validation, the regression equation for 
AUC0-12 could enable calculations of dosage modifications depending on the targeted MPA AUC 
0-12 with the assumption of linearity within the clinically obtained plasma concentrations. 
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 While we report the contribution of serum albumin and estimated glomerular filtration rate 
(via eClcr) to MPA clearance, there are some limitations to our research.  As noted previously, 
our patients had relatively preserved eClcr, with only three patients presenting with more severe 
kidney disease (stages 2 and 3).  The full contribution of reductions in eClcr to alterations in 
clearance would require assessment across the spectrum of kidney disease.  Similarly, since 
only two patients in our dataset were nephrotic (UP:Cr > 3.5 g/d), the full contribution of UP:Cr 
to clearance may actually be under-recognized based on our dataset with less significant 
degrees of proteinuria.  Additionally, the combined role of albumin and urinary protein to 
elimination of highly bound drugs in patients with glomerular diseases requires rigorous 
assessments.  Future analyses of our data include assessment of the contribution of genotype 
for drug metabolizing enzymes and transporters to drug clearance and outcomes and analysis 
of the contribution of Ctr and AUC to patient outcomes.  We hope to better define appropriate 
concentration or exposure targets for lupus nephritis patients.   
Conclusions 
 MPA therapy in lupus nephritis patients, as opposed to use in renal transplantation is further 
complicated by urinary protein excretion and hypoalbuminemia, in addition to altered eClcr.  
Serum albumin and eClcr appear to be the primary contributors to clearance estimates of MPA 
and should be accounted for when dosing MPA.  Similarly, clinical changes that are associated 
with either response to therapy or progression of disease may necessitate future adjustments to 
therapy to maintain efficacy and/or reduce toxicity.  MPA therapy individualization is possible in 
lupus nephritis and the results of such interventions require prospective assessments. The 
acceptable AUC target for MPA therapy will need to be defined specifically for patients with 
lupus nephritis to enhance clinical outcomes. 
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Table 2.1 
Pharmacokinetic Parameters in Patients with Lupus Nephritis 
Mycophenolic Acid Parameters 
Tmax (hrs)    1.69 ± 1.86  
Cmax (µg/mL)*    21.0 ± 16.2  
Ctr12 (µg/mL)*    4.06 ± 5.15  
Lambda (hr-1)    0.11 ± 0.07  
MRT (hrs)    16.3 ± 19.9  
AUCMPA 0-12 (µg hr/mL)#  78.8 ± 74.1 
AUCMPA 6-12 (µg hr/mL)#  33.2 ± 39.0 
MPA Cl/F (mL/min)+   343 ± 200 
MPA ClR/F 0-12 (mL/min)+  1.85 ± 1.42  
Ae 0-12 (mg)    4.81 ± 3.34 
Ae 12-24 (mg)    6.53 ± 9.10 
MPA free (%)    2.56 ± 1.97 
Mycophenolic Acid Glucuronide Parameters 
Tmax (hrs)    3.36 ± 3.56 
Cmax (µg/mL)*    55.1 ± 42.7 
Ctr12 (µg/mL)*    28.2 ± 25.2 
Lambda (hr-1)    0.08 ± 0.05 
AUCMPAG 0-12 (µg hr/mL)#  518 ± 460 
MPAG:MPA    7.09 ± 4.76 
MPAG ClR/F 0-12 (mL/min)+  53.5 ± 52.3 
Ae 0-12 (mg)    656 ± 310 
Ae 12-24 (mg)    441 ± 341 
MPAG free %     9.30 ± 5.23 
 49 
 
 
Free Mycophenolic Acid Parameters 
Cmax (µg/mL)*    0.44 ± 0.54 
Ctr12 (µg/mL)*    0.10 ± 0.15 
Ctr24 (µg/mL)*    0.13 ± 0.25 
AUCMPA 0-12 (µg hr/mL)#  1.76 ± 2.60 
MPA Cl/F (L/min)+   27.4 ± 30.5 
 
* normalized to a 1000 mg dose 
+ scaled to a body size of 70 kg using 0.75 power 
# dose-normalized to 1000 mg and weight normalized to 70 kg 
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Table 2.2 
Clinical Grouping of Patients and Pharmacokinetics 
PK Parameter      Mean (SD)     P-value 
     UP:Cr < 1 g/day    UP:Cr ≥ 1 g/day 
     (n = 14)    (n = 4) 
MPA % Unbound    2.09 (1.64)     4.10 (2.42)   0.2017 
MPA Ctr12 (µg/mL)   4.97 (5.53)   0.88 (0.22)   0.0118 
MPA AUC 0-12 (µg hr/mL)  91.9 (79.6)   33.2 (9.87)   0.0176 
MPA Cl/F (mL/min)   305 (146)    790 (423)   0.0464 
MPA ClR/F 0-12 (mL/min)   1.70 (1.37)    3.35 (2.14)   0.1630 
MPA Cl unbound (mL/min)   32695 (40245)    21565 (5982)   0.6235 
MPA MRT (hrs)    19.8 (22.4)    6.41 (2.60)   0.0176 
MPAG AUC 0-12 (µg hr/mL)  564 (497)   355 (294)   0.4418 
MPAG Clr 0-12 (mL/min)   53.1 (47.8)    68.0 (79.14)   0.6235 
Metabolic ratio    6.40 (4.37)    9.52 (6.00)   0.2327 
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Albumin < 4 g/dL   Albumin ≥ 4 g/dL  
(n = 7)    (n = 7) 
MPA % unbound   2.20 (2.09)   3.35 (2.41)   0.4452 
MPA Ctr12 (µg/mL)   4.38 (7.85)   4.26 (3.51)   0.3176 
MPA AUC 0-12 (µg hr/mL)  80.4 (112)    85.7 (48.8)   0.1282 
MPA Cl/F (mL/min)   522 (408)    342 (238)   0.4557 
MPA ClR/F 0-12 (mL/min)   2.98 (1.71)    1.46 (1.55)   0.0728 
MPAG AUC 0-12 (µg h/mL)  280 (262)    769 (538)   0.0728 
MPA MRT (hrs)    13.9 (4.50)    32.8 (29.9)   0.1061 
MPAG Clr 0-12 (mL/min)   80.7 (61.3)    36.4 (37.8)   0.0530 
Metabolic ratio    5.19 (3.44)    9.04 (5.19)   0.3176 
MPA Cl unbound (L/min)   36.0 (30.6)    30.7 (51.3)   0.0513 
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Figure Legends 
Figure 2.1.  Representative 12-hour Mycophenolic Acid (MPA) and Mycophenolic Acid 
Glucuronide (MPAG) Plasma Concentration Versus Time Curve in a Lupus Nephritis Patient. 
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Abstract 
Background:  Mycophenolic acid (MPA) is used off-label to treat many forms of 
glomerulonephritis.  
Objectives: The objectives were to evaluate the pharmacokinetics of MPA and its glucuronide 
(MPAG) in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis patients with kidney 
manifestations and to determine effects of clinical (urinary protein excretion, serum albumin, and 
creatinine clearance) and demographic (age, race, gender) variables on MPA and MPAG 
pharmacokinetics.  
Methods: Twenty-three patients at steady state on MPA were evaluated.  Plasma and urine 
samples were collected over 24 hours.  Analyses included noncompartmental pharmacokinetics 
and statistics including Mann Whitney test and univariate/multiple regression.  
Results: MPA clearance (Cl/F 288 ± 154 mL/min) was ~2-fold higher than previously reported 
from transplant patients and predicted by weight and race (ranked MPA Cl/F = -11.766 + 0.2035 
(wt) + 4.9578 (race), R2 41.8%, p = 0.0045).  Estimated creatinine clearance (eClcr) < 60 
mL/min resulted in higher MPA exposure; total AUC 0-12 and AUC 6-12, as well as unbound AUC 
0-12.  The metabolic ratio (MPAGAUC:MPAAUC) of 8.67±5.57 was lower than previously reported in 
kidney transplant recipients. 
Conclusions:  Diminished kidney function (e.g. eClcr<60 mL/min) demonstrated enhanced MPA 
and MPAG exposure in ANCA vasculitis patients.  However, unlike kidney transplant recipients, 
patients with ANCA vasculitis had enhanced Cl/F and diminished metabolic ratio, suggesting the 
need to comprehensively evaluate the role of disease-specific factors on MPA 
pharmacokinetics.   
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Introduction 
Mycophenolic acid (MPA) is used off-label for immune-mediated disorders and is FDA 
approved for transplant rejection. 1-6 Three studies evaluated the efficacy of MPA in small vessel 
vasculitis. 7-9  We reported 3-fold improvements in disease activity (Birmingham Vasculitis 
Activity Score (BVAS)) in patients experiencing disease relapse compared to those defined as 
treatment resistant. 9  While patients with kidney manifestations of vasculitis are similar to renal 
transplant recipients in that they can have alterations in glomerular filtration rate, they also often 
have altered serum albumin, urinary protein, and markers of inflammation.  
Since inter-individual variability in MPA pharmacokinetics has been documented in 
transplant recipients, therapeutic plasma monitoring has been suggested to improve 
immunosuppressive outcomes.  10-13  Area under the plasma concentration time curve from 0-12 
hours (AUC 0-12) of 30-60 µg h/mL and trough plasma concentrations of 1-3.5 µg/mL were 
suggested as targets for triple combination immunosuppressive therapy in kidney and heart 
transplant patients. 13-14  Target ranges for MPA in autoimmune kidney diseases such as lupus 
nephritis and anti-neutrophil cytoplasmic antibody (ANCA) vasculitis have not been established. 
The primary purpose of this study was to evaluate the pharmacokinetics of total and free 
MPA and its phenolic O-glucuronide (MPAG) metabolite in ANCA vasculitis.  The secondary 
objectives were to determine the effects of clinical parameters (urinary protein to creatinine 
excretion ratio (UP:Cr), serum albumin, and estimated creatinine clearance (eClcr)) and 
demographic variables (age, race, gender) on pharmacokinetics. 
Materials and Methods 
Patients 
Patients with biopsy confirmed ANCA vasculitis receiving MPA therapy (as mycophenolate 
mofetil [Cellcept®, Roche, NJ]) and at steady state were eligible.  Concomitant therapies with 
other immunosuppressants were permitted and recorded.  Patients entered the General Clinical 
Research Unit (GCRC) for 24-hours to assess the pharmacokinetics or MPA at the dose and 
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interval they were prescribed.  Patients were fasting at study initiation and were fed a 
standardized diet.  eClcr (calculated by the Cockroft and Gault equation 15), UP:Cr, serum 
albumin, and serum creatinine were recorded/obtained.  The study was approved by the 
University’s Institutional Review Board in accordance with the Declaration of Helsinki.     
Pharmacokinetic Study 
 After obtaining baseline blood for measurement of a trough plasma concentration (Ctr), 
patients were instructed to take their morning dose of MPA.  Plasma samples (7.5 mL) were 
obtained at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours and immediately centrifuged for 10 
minutes at 4C, aliquoted and transferred to plastic screw top tubes and stored at -80 until assay.  
Urine was collected at 0-6, 6-12, and 12-24 hour intervals into acidified (15 mL 6 N HCl) 
collection containers, volumes recorded, and 2 mL aliquots were stored at -80C until assay.  
Plasma and urine samples were processed and assayed as described previously. 16-17 Unbound 
plasma fraction was determined as previously described. 17  Plasma and urine standard curves 
for MPA were linear over the range of 0.2-200 µg/mL and 1-50 µg/mL, respectively.  Plasma 
and urine standard curves for MPAG were linear over the range of 1-200 µg/mL and 5-1500 
µg/mL, respectively.  MPAG concentrations were represented in terms of MPA-equivalents by 
multiplying the MPAG concentration by 0.646 (molecular mass of MPA to MPAG) and reported 
in µg/mL.  The amount of MPA available from a dose of mycophenolate mofetil was estimated 
as 72% of the dose.   
Pharmacokinetic Analysis 
 Noncompartmental pharmacokinetic analysis of total and unbound MPA and total MPAG 
was conducted using WinNonlin v4.1 (Pharsight, Mountain View CA).  Concentration maximum 
(Cmax), time to maximum concentration (Tmax), concentration trough (Ctr) at 12 hours, area 
under the plasma concentration time curve from 0-12 hours (AUC 0-12), apparent oral clearance 
(Cl/F), apparent renal clearance (ClR/F), and mean residence time (MRT) were recorded.  Both 
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concentration and AUC parameters were dose-normalized and the clearance data were 
adjusted to a 70 kg patient based on a scaling method using a power of 0.75. 18   We made the 
assumption that bioavailability (F) was equal to 1.0 as reported previously. 11  AUC 12-24 and 
AUC 6-12 were calculated, and the latter was used to estimate apparent entero-hepatic recycling. 
19-20
  Amount of MPA and MPAG in urine over each collection was determined by multiplying 
concentration by volume.  MPA and MPAG amounts in urine (Ae) were computed for 0-12 hours 
by adding the Ae for the first two intervals.  ClR/F for the 0-12 hour time was calculated by Ae 0-
12/ AUC 0-12.     
Statistics 
 Descriptive analyses for pharmacokinetic and demographic variables and laboratories 
included means, standard deviations, and medians as appropriate.  Bivariate assessments of 
the key characteristics (serum albumin, UP:Cr, eClcr, age, weight, race, prednisone dose) 
versus each pharmacokinetic parameter of interest (MPA Cl/F, AUC 0-12, AUC 6-12, Ctr12, ClR/F, 
Clunb, AUCUnb 0-12, and MPAG AUC 0-12, ClR/F) were assessed by Spearman Rank correlations.  
The effect of cyclosporine on MPA could not be directly assessed secondary to only three 
patients receiving the drug.  The correlations and resultant p values from the biivariate 
assessments were analyzed for possible inclusion into multiple regression models that predicted 
pharmacokinetic parameters.  Correlations with p<0.15 were selected for incorporation into the 
multiple regression models.  Variables were transformed to insure that each followed a normal 
distribution.  Model building for analysis of determinants of the parameters identified above 
consisted of multiple linear regression analysis with forward addition of variables as well as 
backward elimination, noting influences on the coefficients of the primary predictors.  The final 
model was selected based on significance of each variable on predicting the parameters in the 
model as well as the overall R2 of the model.   
 Comparisons between clinical groups based on eCrCl (< 60 mL/min vs ≥ 60 mL/min) and 
UP:Cr (< 500 vs ≥ 500) were analyzed by nonparametric Mann Whitney Test.  It was not 
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possible to compare serum albumin groups as there were no significant deviations from the 
laboratory normal reference range.   
Results 
 Twenty-three biopsy-confirmed ANCA small vessel vasculitis patients completed the 
MPA/MPAG pharmacokinetics study.  Patient demographics included age 53±14 years, 57% 
female, 78% Caucasian, and weight of 87±19 kg.  Non-Caucasian races consisted of African-
American (n=3), Asian (n=1) and Other (n=1).  All patients were receiving the mycophenolate 
mofetil prodrug of MPA with the exception of one patient (prescribed mycophenolate sodium), 
who was included in the analyses as the pharmacokinetics were similar.  The average MPA 
daily dose was 1489 ± 596 mg with dosing divided twice daily in all but one patient who was 
dosed once daily.  The distribution of doses were 250mg (n=1), 500mg (n=9), 750mg (n=4), 
1000mg (n=8), and 1500mg (n=1).  The mean (± standard deviation) clinical laboratory results 
were serum creatinine 1.3±0.6 mg/dL (range 0.7 to 3.4), UP:Cr 0.42±0.50 (range 0.04 to 1.87), 
eClcr 84.4±40.1 mL/min (range 18.3 to 182.2), and serum albumin 4.4±0.40 g/dL (range 3.6 to 
5.2).  Thirty percent (n = 7) of patients were receiving concomitant glucocorticoids and 13% (n = 
3) were receiving cyclosporine.   
Mycophenolic Acid Pharmacokinetics 
 A concentration versus time profile for one patient at steady state MPA and MPAG 
concentrations over 12 hours is presented in Figure 3.1.  The mean pharmacokinetic 
parameters for patients with ANCA vasculitis are provided in Table 3.1.  The scaled Cl/F of 
288±154 mL/min suggests that MPA is a moderate extraction ratio drug whose metabolism 
could be impacted by changes in unbound fraction.  The mean percentage of free MPA was 
1.0±0.6%, with all patients having free fractions of ≤2.4%, similar to expected free fraction. 11-21  
The MPA AUC 
 0-12 was outside the 30-60µg hr/mL range that was recommended in kidney 
transplant patients within the first six month period post transplant, 22 with 22% (n=5) of patients 
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above and 30% (n=7) below this range.  Examination of the AUC 6-12 to the AUC 0-12 suggested 
that recycling accounted for 34±10% of the AUC, which is within the published range. 21-22   
The Ctr at 12 hours exceeded the range of 1.0 to 3.5µg/mL recommended in transplant 
patients 22, with 22% (n=5) above this target.  The Tmax varied from 0.5 to 5 hours, severely 
limiting applicability of shortened plasma collections for AUC determination.   
The MPA ClR/F represented 2% of the Cl/F, consistent with previous reports.21  As 
suggested previously 11, the clearance of MPA is primarily the result of systemic metabolism to 
MPAG.  The ClR/F of MPA was 5.8±5.8 mL/min, which was 9% of the eClcr in our patients.   
Mycophenolic Acid Glucuronide Pharmacokinetics 
The MPAG pharmacokinetic results are reported in Table 3.1.  A calculated AUC0-12 ratio of 
MPAG to MPA resulted in a metabolic ratio (MR) of 8.7± 5.6, less than previously reported in 
renal transplant recipients. 23  
The renal clearance of MPAG was 33.7±34.9 mL/min, representing 40% of the eClcr.  The 
kidneys contributed to the elimination of 97% of the MPA dose primarily through excretion of 
MPAG.  The amount of MPAG in the urine over the 0-12 hour interval (513±285 mg) was more 
than the amount in the 12-24 hour interval (378±257 mg), p = 0.017.  The ClR/F was also 
greater in the 0-12 hour (33.7±34.9 mL/min) versus 12-24 hour dosing interval (28.4±36.9 
mL/min), p = 0.0043.   
Unbound Pharmacokinetics 
 Our data showed that 1.0% and 13% of MPA and MPAG, respectively, were unbound in the 
plasma.  Since the unbound MPAG was less than that reported previously 21, we performed 
studies with MPA and/or MPAG spiked heparinized plasma. 17  The plasma that was spiked 
separately demonstrated similar unbound percentages to that found in our ANCA patient data, 
the combination of drug and metabolite resulted in an increase in unbound percentage of MPA 
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and MPAG.  This may be suggestive of competitive binding to albumin as has been reported 
previously. 24  
Since the normal percentage of unbound MPA is 2%, if one aims for a total MPA Ctr of 1.0 
to 3.5 µg/mL then an unbound target would be 0.02 to 0.07µg/mL. 21  Likewise, if suggested 
total AUC goals are 30 to 60 µg h/mL, then unbound AUC goals would be 0.6 to 1.2 µg h/mL.  
Mean unbound Ctr levels were 0.04±0.06µg/mL (consistent at both the 12 and 24 hour time 
points), with five patients exceeding the range and thirteen patients below the range; resulting in 
only 22% of all patients falling within the targeted kidney transplant range.  With regard to 
unbound AUC, the mean exposure was greater than the upper range of 1.2 µg h/mL in only one 
patient, but was less than the targeted range in 15 patients.   
Regression  
 The multiple regression model for MPA Cl/F revealed that race and weight contributed; 
ranked Cl/F= -11.766+0.2035(wt)+4.9578(race), R2 41.8%, p=0.0045. The AUC6-12 showed the 
following relationship: Ln MPA AUC6-12= 3.706 – 0.0094 (eClcr), R2 36.86%, p=0.0021.  In 
analysis of MPA ClR/F, the AUC6-12 was the only significant contributing variable:  ranked MPA 
ClR/F= 30.2674 – 6.2733 (ln AUC6-12); R2 33.2%, p=0.004.  Regression assessment of the 
predictors for unbound MPA clearance indicated that eClcr and age were important:  Ranked 
Clunb= 16.055 + 0.0601 (eClcr) – 0.1994 (age); R2 52.3%, p=0.0013.  MPAG ClR/F analysis 
showed that race and prednisone dose contributed.  Ln MPAG ClR/ F= 2.6645 + 1.1799 (race) –
0.3041 (ranked prednisone dose); R2 88.0%, p=0.0143.   
Comparison Between Groups Based on Clinical Laboratories 
The analysis of differences in pharmacokinetic by clinical grouping of UP:Cr (< 500 vs ≥ 
500) and eClcr (<60 mL/min vs ≥ 60 mL/min) were assessed. (Table 3.2)  There was a 
considerable distribution of eClcr across the population (low 18.3 mL/min and high 182 mL/min).  
Since MPAG is eliminated via the renal route, reductions in renal elimination would be predicted 
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to have more direct effects on MPAG with secondary effects on MPA due to potential enhanced 
MPA AUC 6-12, reflective of enterohepatic recycling.(Table 3.2)    
The MPA Ctr were 3-fold higher in patients with reduced eClcr compared to higher eClcr 
(6.9± 6.8 vs 2.7±1.8, respectively), p=0.0301.  The AUC6-12 demonstrated 3-fold higher values in 
low vs high eClcr grouping (35.9±27.0 vs 16.7±8.8mg h/L, respectively), p=0.0149.  The MPA 
AUC0-12 was 2-fold greater in the low versus high eClcr grouping (95.0±66.9  vs 52.5±22.8 
mL/min, respectively, p=0.0225).  The MPA AUC 0-12 unbound values were significantly higher in 
the low eClcr group (1.29±0.61 vs 0.59±0.56 mg h/mL, p=0.0318), suggesting the presence of 
more pharmacologically active drug.  The MPA Cl unbound was 3-fold reduced in the low eClcr 
group, with a trend toward statistical significance, which may be suggestive of reduced 
metabolism and/or eClcr.  While the ClR/F MPAG was not statistically different between groups, 
the MPAG AUC 0-12 was enhanced 2-fold in the low eClcr patient group (959±664 vs 404±336 
mg hr/L, p 0.0135).  
UP:Cr was selected as a clinical variable secondary to the high plasma protein binding 
characteristics of MPA and MPAG.  To enable at least five observations per group, a cut-point 
of 500 mg/day was selected.  None of the pharmacokinetic parameters were statistically 
significant between the high and low UP:Cr grouping.  Only four patients had UP:Cr > 1.0 g/day, 
preventing a comparison that may be more likely to be clinically relevant.   
Discussion 
 While descriptions of the pharmacokinetics of MPA in kidney transplant patients are 
abundant, there is a paucity of data in autoimmune diseases that affect the kidney.  Our study 
was conducted to comprehensively evaluate the pharmacokinetics of MPA and MPAG after 
chronic therapy in ANCA-associated vasculitis patients.  Additionally, we wanted to understand 
the relevance of clinical and demographic variables in predicting pharmacokinetic parameters.  
eClcr was positively predictive for MPA Clunb and negatively predictive for MPA AUC6-12 .  Race 
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was found to positively predict both MPA Cl/F and MPAG ClR/F, whereby non-Caucaisn race 
had higher clearances, suggesting an influence on both metabolism and renal clearance.  
Prednisone dose was negatively associated with MPAG ClR/F, suggesting an influence on 
active renal secretion.  Unfortunately, the influences of UP:Cr and serum albumin on 
pharmacokinetic variables were not able to be fully assessed secondary to limited distribution of 
UP:Cr and relatively conserved values of serum albumin.  A previous MPA study in lupus 
nephritis showed that at a UP:Cr of ≥1 g/day, Ctr and AUC0-12 were significantly reduced and 
Cl/F was significantly increased. 17 We previously reported higher MPA Clunbound and MPAG 
ClR/F in lupus nephritis patients with serum albumin levels < 4g/dL vs those with levels ≥ 
4g/dL.17 
 Creatinine clearance significantly affected pharmacokinetics of MPA and MPAG in ANCA-
associated vasculitis.  Although MPA itself is not highly eliminated by the kidneys, exposure was 
markedly enhanced in the low eClcr grouping; with the dosing interval (AUC 0-12), enterohepatic 
recycling (AUC 6-12), and unbound (AUC 0-12unb) exposures being significantly greater.  Since 
MPAG is primarily eliminated by renal excretion, reductions in eClcr may predispose patients to 
higher levels of MPAG, which, through recycling can increase systemic exposure to MPA.  
These results suggest that patients with diminished kidney function can reach targeted MPA 
exposure ranges with lower dosages; minimizing adverse events.  Lower unbound MPA (e.g. 
AUC) would not be predicted to be increased through a purely restrictive clearance mechanism 
and our patients were not hypoalbuminemic, hence our data may suggest the influence of 
additional factors affecting plasma concentrations in patients with glomerular kidney diseases.  
Assessment of MPA Ctr values showed a consistent 2-3 fold higher value in patients with a 
eClcr<60mL/min compared to eClcr>60mL/min.  When we performed a post-hoc ANOVA to 
evaluate for the differences in pharmacokinetics based on eClcr groupings, we found that 
significant differences in Ctr, recycling AUC, unbound AUC, and unbound clearance were all 
 64 
 
demonstrated between the stage 3 /4 vs 1 group.  Only unbound clearance was found to also 
be significant between the stage 3 /4 vs stage 2 group.    
 The pharmacokinetics of MPA in ANCA patients are comparable with renal transplant 
patients, with the exception of Cl/F, which is about 2 -fold greater in vasculitis.  Reasons for 
enhanced Cl/F can include increased systemic metabolism secondary to either up-regulated 
glucuronidation, increased MPA unbound fraction, or enhanced renal excretion.  Regarding 
enhanced glucuronidation, patients receiving concurrent steroids (enzyme inducers) had similar 
Cl/F estimates to patients who were not receiving steroids (data not shown).  We are currently 
evaluating the contribution of enhanced catalysis polymorphisms in the uridine diphosphate 
glucuronosyltransferase (UGT) enzymes as factors altering MPA clearance.  The metabolic 
ratio, a reflection of metabolite to parent AUC was 8.67±5.57 in our study, considerably less 
than the 25.6±8.7 that was previously reported in kidney transplant recipients. 23  The unbound 
fraction was relatively normal (~1%) in our patients as they had essentially normal serum 
albumin concentrations (3.6 to 5.2 g/dL).  Enhanced renal clearance can result from increased 
eClcr, loss of highly protein bound drugs with urinary protein, or enhanced secretory transport 
mechanisms.  Our ANCA-vasculitis patients had a mean eClcr of 84mL/min with a range 
between 18 and 182mL/min. Although renal elimination of MPA is limited, enhanced eClcr could 
result in increased clearance secondary to renal clearance of the polar metabolite MPAG.  
Enhanced renal clearance secondary to loss of the highly protein bound MPA with the urinary 
protein could also account for an increase in Cl/F.  However, when we evaluated ClR/F between 
patients with UP:Cr <500 mg/day and those with UP:Cr ≥500 mg/day, the results were similar.  
The magnitude of differences in ClR/F between UP:Cr groups may have been underappreciated 
based on our selected cut-point.  MPAG is a substrate for MRP2, an efflux transporter found on 
the luminal surface of the proximal tubule.  Theoretically, single nucleotide polymorphisms in 
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this transport gene can result in enhanced activity and could increase the renal excretion of 
MPAG, limiting the effect of recycling.   
 Renal transplant recipients, similar to our ANCA-vasculitis patients generally have 
reductions in eClcr.  A previous publication used a multivariate analysis and demonstrated that 
24% of the MPA Cl/F could be explained by proteinuria (yes/no), glomerular filtration rate, and 
diabetes mellitus. 25  Unfortunately, the range of proteinuria required to designate a yes versus 
no categorization was not reported.  Our regression data showed that eClcr was predictive for 
both Clunb and AUC6-12.  Previous data from our laboratory in lupus nephritis showed that 51% of 
MPA Cl/F could be explained by eClcr and serum albumin, two readily measured clinical 
laboratory measures. 17   The contribution of race to MPA Cl/F in our vasculitis patients requires 
assessment of genotype as a confounding variable as genomic effects have been shown to 
influence the pharmacokinetics of MPA. 26  eClcr would generally be predicted to contribute little 
to MPA Cl/F secondary to the low percentage of MPA (1-3%) that is normally excreted by the 
kidneys.  Hence, non-renal clearance, through metabolism of MPA to MPAG would comprise 
the largest bulk of the Cl/F for MPA.  Our regression analyses demonstrated that AUC6-12 was 
the only significant predictor of MPA ClR/F demonstrating an influence of MPA plasma 
concentration on ClR/F.  The regression models are important as they provide insights into the 
mechanisms that may underlie the alterations in pharmacokinetics seen in disease states such 
as ANCA-associated vasculitis.  This is particularly important since there is a paucity of 
published research in medication off-label disease groups, whereby there can be extensive 
variations in medication handling versus in the diseases where the drugs were FDA approved.   
 Unlike our ANCA-vasculitis patients, our previous report of MPA pharmacokinetics in lupus 
nephritis patients showed higher UP:Cr and lower serum albumin and eClcr. 17  The key 
differences in pharmacokinetics of MPA and MPAG between these studies included enhanced 
MPA MRT, MPA ClR/F, metabolic ratio (MPAG AUC:MPA AUC), unbound MPAG %, and MPA 
Cl/Funb, and reduced MPA AUC 0-12, MPA AUC 6-12, MPAG ClR/F, MPA Ctr unb, MPA AUC unb, and 
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normal free MPA % in the ANCA versus lupus nephritis population.  This data generally 
demonstrates lesser MPA exposure in the ANCA-vasculitis patients as opposed to patients with 
lupus nephritis.  While lower MPA dosages in the ANCA-vasculitis patients could reflect reduced 
exposure, our data was dose-normalized to eliminate the dose effect.  The effects of single 
nucleotide polymorphisms in UGT enzymes requires assessment in these autoimmune 
diseases, especially since environmental exposures are thought to play a role in their etiology 
and since the UGT enzymes play a role in the body’s natural defense against environmental 
toxins.  Additionally, the role of inflammation on MPA pharmacokinetics in autoimmune diseases 
requires evaluation as a potential disease component that may modify drug metabolism and 
transport.   
 While we report the contribution of eClcr to MPA clearance and exposure in a model of 
ANCA-vasculitis, there are some limitations to our research.  As noted previously, our patients 
had preserved serum albumin concentrations, preventing the full assessment of the contribution 
of reductions in serum albumin on clearance.  Similarly, since only four patients in our dataset 
had UP:Cr of ~ 1g/day and none had nephrotic range proteinuria (UP:Cr > 3.5 g/day), the full 
contribution of UP:Cr to clearance may actually be under-recognized.  Future analyses of our 
data include assessment of the contribution of genotype for drug metabolizing enzymes and 
transporters on clearance and outcomes, as well as the analysis of the contribution of Ctr and 
AUC to patient outcomes.  Our studies in autoimmune-related kidney diseases are important as 
they provide a framework to understand the contributions of disease-related and unrelated 
factors to MPA exposure.  A goal of our future work is to better define appropriate MPA 
concentration or exposure targets for ANCA vasculitis patients.   
Conclusions 
 MPA therapy in glomerular diseases such as ANCA-vasculitis can be complicated by urinary 
protein excretion, hypoalbuminemia, and reductions in eClcr.  Assessment of pharmacokinetic 
alterations based on eClcr demonstrated enhanced MPA and MPAG exposure in patients with 
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reductions in eClcr, the most significant effects appreciated in patients with eClcr < 60 mL/min.  
Regression models demonstrated the demographic variables nonCaucasian race, increased 
weight, and decreased age were predictors of decreased MPA exposure (AUC) and/or 
increased clearance.  Approaches to comprehensively evaluate the influence of clinical and 
demographic factors on MPA pharmacokinetics are needed in order to begin to identify variable 
that could be used to individualize treatment strategies for patients with ANCA-associated 
vasculitis.   
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Table 3.1 
Pharmacokinetic Parameters in Patients with Anti-neutrophil Cytoplasmic Antibody (ANCA)-
Associated Vasculitis 
Mycophenolic Acid (MPA) Parameters 
Tmax (hrs)    1.46 ± 1.24  
Cmax (µg/mL)a    21.5 ± 20.3  
Ctr12 (µg/mL)a    3.99 ± 4.32  
Lambda (hr-1)    0.07 ± 0.04  
MRT (hrs)    27.2 ± 36.2  
AUCMPA 0-12 (µg hr/mL)a   65.4 ± 44.4 
AUCMPA 6-12 (µg hr/mL)a   22.6 ± 18.3 
MPA Cl/F (mL/min)b   288 ± 154 
MPA ClR/F 0-12 (mL/min)b  5.77 ± 5.80  
Ae 0-12 (mg)    13.6 ± 12.2 
MPA free (%)    1.02 ± 0.66 
 
Mycophenolic Acid Glucuronide (MPAG) Parameters 
Tmax (hrs)    2.51 ± 1.44 
Cmax (µg/mL)a    74.3 ± 58.9 
Ctr12 (µg/mL)a    35.1 ± 32.3 
Lambda (hr-1)    0.07 ± 0.04 
AUCMPAG 0-12 (µg hr/mL)a  573 ± 515 
MPAG:MPA ratio   8.67 ± 5.57 
MPAG ClR/F 0-12 (mL/min)b  33.7 ± 34.9 
Ae 0-12 (mg)    513 ± 285 
MPAG free %     12.9 ± 7.0 
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Free Mycophenolic Acid (MPA) Parameters 
Cmax (µg/mL)a    0.22± 0.24 
Ctr12 (µg/mL)a    0.04 ± 0.06 
AUCMPA 0-12 (µg hr/mL)a   0.76 ± 0.64 
MPA Cl/F (L/min)b   37.0 ± 29.6 
 
a normalized to a 1000 mg dose 
b scaled to a body size of 70 kg using 0.75 power 
 
Ae – amount excreted in the urine 
AUC – area under the plasma concentration time curve 
Cmax – maximal plasma concentration 
Cl/F – oral clearance 
ClR/F – renal clearance 
Ctr12 – trough plasma concentration at 12 hours 
MRT – mean residence time 
Tmax – time to maximal concentration in plasma 
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Table 3.2 
Clinical Grouping of Patients and Pharmacokinetics (by eClcr and UP:Cr) 
Pharmacokinetic Parameter   eClcr Status [Mean (SD)]    P-value 
     Clcr < 60 mL/min  Clcr ≥ 60 mL/min 
     (n = 7)    (n = 16) 
MPA % Unbound    0.9 (0.7)     1.1 (0.7)   0.5979 
MPA Ctr12 (µg/mL) a   6.88 (6.79)   2.72 (1.81)   0.0301 
MPA AUC 0-12 (µg hr/mL) a  95.0 (66.9)   52.5 (22.8)   0.0225 
MPA AUC 6-12 (µg hr/mL) a  35.9 (27.0)   16.7 (8.8)   0.0149 
MPA Cl/F (mL/min) b   210 (86.7)    323 (167)   0.1089 
MPA ClR/F 0-12 (mL/min) b  3.36 (3.07)    6.77 (6.48)   0.3403 
MPA Cl unbound (mL/min) b  15928 (6376)    43539 (31045)   0.0670 
MPA AUC 0-12unb a (mL/min)  1.29 (0.608)   0.592 (0.562)   0.0318 
MPA MRT (hrs)    36.9 (35.9)    23.4 (36.8)   0.4523 
MPAG AUC 0-12 (µg hr/mL)  959 (664)   404 (336)   0.0135 
MPAG ClR/F 0-12 (mL/min) b  21.8 (20.2)    38.9 (39.1)   0.2490 
MPAG AUC0-12/MPA AUC0-12  10.7 (6.19)    7.77 (5.24)   0.2776 
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 UP:Cr Status [Mean (SD)] 
     UP:Cr < 500 mg/day    UP:Cr ≥ 500 mg/day  P value 
     (n = 15)    (n = 6) 
MPA % unbound   0.99 (0.65)   1.21 (0.78)   0.5160 
MPA Ctr12 (µg/mL) a   3.07 (1.79)   6.56 (7.87)   0.3809 
MPA AUC 0-12 (µg hr/mL) a  55.8(22.3)    84.5 (80.6)   0.7910 
MPA AUC 6-12 (µg hr/mL) a  18.9 (9.18)   32.2 (32.6)   0.1532 
MPA Cl/F (mL/min) b   300(163)    285 (165)   0.9699 
MPA ClR/F 0-12 (mL/min) b  5.47 (6.08)    7.31 (6.23)   0.5693 
MPA Cl unbound (L/min) b   43.5 (33.5)    19.7 (12.5)   0.1450 
MPA AUC 0-12unb (µg hr/mL) a  0.82 (0.74)   1.25 (0.82)   0.1859 
MPAG AUC 0-12 (µg h/mL)  467 (366)    860 (798)   0.7333 
MPA MRT (hrs)    24.2 (37.8)    43.4 (36.8)   0.1859 
MPAG ClR/F 0-12 (mL/min) b  28.1 (19.5)    45.9 (62.0   0.7910 
Metabolic ratio    8.46 (5.57)    9.95 (6.48)   0.3403 
 
a normalized to a 1000 mg dose 
b scaled to a body size of 70 kg using 0.75 power 
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Abbreviations: 
Ae – amount excreted in the urine 
AUC – area under the plasma concentration time curve 
Cmax – maximal plasma concentration 
Cl/F – oral clearance 
ClR/F – renal clearance 
Ctr12 – trough plasma concentration at 12 hours 
eClcr – estimated creatinine clearance 
MPA – mycophenolic acid 
MPAG – mycophenolic acid glucuronide 
MRT – mean residence time 
Tmax – time to maximal concentration in plasma 
UP:Cr – urinary protein to creatinine ratio 
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Figure Legends 
Figure 3.1 Mycophenolic Acid and Mycophenolic Acid Glucuronide (MPAG) 12-hour Plasma 
Concentration versus Time Curve in a Small Vessel Vasculitis Patient.  
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Figure 3.1 
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
MPA
MPAG
Time (hours)
Pl
as
m
a 
Co
n
ce
n
tr
at
io
n
( µµ µµ
g/
m
L)
 
 
  
 
 
 
 
Chapter 4 
Population Pharmacokinetics of Mycophenolic Acid and Metabolites in Patients with 
Glomerulonephritis 
 
 
Melanie S. Joy, Pharm.D., Ph.D.1,2 and Wai-Johnn Sam, Ph.D.3 
University of North Carolina, School of Medicine, UNC Kidney Center,1 and Eshelman School of 
Pharmacy,2  Chapel Hill, NC and University of Rhode Island, College of Pharmacy, Department 
of Biomedical and Pharmaceutical Sciences, Kingston, RI3 
 
 
This research was funded by the National Institutes of Health 5K23DK64888, General Clinical 
Research Centers program of the Division of Research Resources (RR00046) and Clinical and 
Translational Science Award (U54RR024383). 
 
 
 78 
 
Abstract 
Background and Objective:  Mycophenolic acid (MPA) is an inosine monophosphate 
dehydrogenase inhibitor used as immunosuppressive therapy for induction and maintenance of 
remission in glomerulonephritis due to systemic lupus erythematosus and small vessel 
vasculitis.  The objective of the current study was to develop a population pharmacokinetic 
model for MPA and its two metabolites, MPA glucuronide (MPAG) and acyl-MPA glucuronide 
(AcMPAG) in patients with glomerulonephritis.   
Methods: Thirty-nine patients with glomerulonephritis and receiving mycophenolate mofetil were 
recruited to participate in a 24-hour pharmacokinetic study.  Blood was collected at times 0, 0.5, 
1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours and urine was collected over the intervals of 0-6, 6-12, 
and 12-24 hours.  Plasma and urine samples were assayed for MPA and MPAG by high-
performance liquid chromatography (HPLC), and for AcMPAG by liquid chromatography / mass 
spectrometry (LC/MS).  Population pharmacokinetic analysis and covariate model building were 
evaluated using Non-linear Mixed Effect Modeling software (NONMEM, version 6.2.0, ICON 
Development Solutions, Ellicott City, MD).    
Results:  The final model for MPA and it’s metabolites consisted of 9 discrete compartments; 1) 
depot gastrointestinal, 2) central MPA, 3) peripheral MPA, 4) gallbladder, 5) MPA urine, 6) 
MPAG central, 7) MPAG urine, 8) AcMPAG central, and 9) AcMPAG urine compartment.  The 
MPA population mean estimates for apparent non-renal clearance (ClNR/F) and apparent central 
volume of distribution were 14.3 L/hr and 21.1 L, respectively.  The mean population estimate 
for apparent renal clearance (ClR/F) was dependent on estimated creatinine clearances (eClcr); 
0.0975 L/hr for eClcr ≤80 mL/min and 0.157 L/hr for eClcr > 80 mL/min.  Covariate analyses 
identified the following significant effects: eClcr on CLNR,MPA/F (P<0.001), eClcr (with a cut-off 
value at 80 ml/min) on CLR,MPA/F (P<0.025), serum albumin on CLNR,MPA/F (P<0.01), eClcr on 
CLR,MPAG/F (P<0.001) and eClcr on CLR,AcMPAG/F (P<0.001). Evaluation of the final model by 
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visual predictive check showed that most of the observed values were within the 95th percent 
prediction interval generated from 100 simulations of the final model. 
Conclusion: The current population pharmacokinetic model demonstrated two key covariates, 
eClcr and serum albumin influenced the renal and nonrenal components of Cl/F in patients with 
glomerulonephritis, suggesting patients with these diseases would have highly altered MPA 
exposures.  
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Introduction 
 The pharmacokinetics of mycophenolic acid (MPA), the pharmacologically active component 
of mycophenolate mofetil (Cellcept, Roche, Nutley, NJ) are well described in transplant 
recipients and population pharmacokinetic models are reported. [1-8]  However, there is 
considerable lack of consensus in the transplant community surrounding optimal limited 
pharmacokinetic sampling strategies to monitor therapy, selection of optimal targets for 
exposure, and/or trough plasma concentrations. [9,10]  Much of this conflict is the result of the 
large inter- and intra-individual variability and unexplained error in pharmacokinetic predictions. 
[9-11]
  Development of therapeutic drug monitoring is the goal for MPA since several publications 
have reported relationships between exposure and treatment-related outcomes in transplant 
patients. [12-19] 
 The knowledge and applicability of MPA pharmacokinetics data from transplant populations 
to other kidney diseases are limited despite its use in induction and maintenance regimens for 
glomerulonephritis including systemic lupus erythematosus (SLE) [20-24] and small vessel 
vasculitis (SVV). [25-27] However, unlike kidney transplant patients who receive a 3-4 drug 
immunosuppressive regimen, glomerulonephritis patients receive only 1-2 immunosuppressive 
drugs.  Previous results from noncompartmental pharmacokinetic analyses have suggested 
altered disposition of MPA in glomerulonephritis, [28,29] a finding that is not surprising given 
urinary protein losses, serum protein reductions, kidney function declines, and inflammation.  
Compartmental pharmacokinetic modeling approaches in patients with glomerulonephritis[30] 
and data supporting relationships between exposure and/or trough plasma concentrations and 
outcomes is currently lacking in glomerulonephritis.   
 The aim of the current study was to develop a population pharmacokinetic model for MPA 
and its two metabolites [MPA glucuronide (MPAG) and acyl-MPA glucuronide in patients with 
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glomerulonephritis using plasma and urine data (AcMPAG)] and followed by covariate 
assessments to determine covariates which influence its pharmacokinetics.   
Methods 
Patients and Samples 
Patients with glomerulonephritis from SLE or SVV and receiving MPA as mycophenolate 
mofetil (Cellcept®, Roche, New Jersey) for at least 2 weeks on a stable dose, were recruited to 
participate in a pharmacokinetic study approved by the institution’s Biomedical Institutional 
Review Board.  Details of these studies and results from noncompartmental pharmacokinetics 
for MPA and MPAG were previously described. [28,29]  Briefly, blood samples were collected at 
times 0, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours and urine was collected from 0-6, 6-12, and 
12-24 hours.  Plasma and urine samples were assayed for MPA and MPAG by a high-
performance liquid chromatography (HPLC) with ultraviolet detection assay. [31]  Plasma and 
urine standard curves for MPA were linear over the range of 0.2-200 µg/mL and 1-50 µg/mL, 
respectively.  Plasma and urine standard curves for MPAG were linear over the range of 1-200 
µg/mL and 5-1500 µg/mL, respectively.  The AcMPAG metabolite was assayed in plasma and 
urine by liquid chromatography / mass spectrometry (LC/MS).  Plasma and urine standard 
curves for AcMPAG were linear over the range of 0.01-50 µg/mL and 1-500 µg/mL, respectively.  
MPAG and AcMPAG concentrations were represented in terms of MPA-equivalents by 
multiplying the MPAG and AcMPAG concentration by 0.646 (molecular mass of MPA to 
MPAG/AcMPAG) and reported in mcg/mL.  The amount of MPA available from a dose of the 
prodrug (mycophenolate mofetil) was estimated as 72% of the dose (molecular mass of MPA to 
mycophenolate mofetil).   
Demographic data (age, weight, race, gender), clinical data (serum creatinine, serum 
albumin, urinary protein to creatinine ratio), and genotype data for single nucleotide 
polymorphisms relevant for MPA metabolism (uridine glucuronosyltransferase genes; UGTs, 
e.g. UGT2B7 C802T, UGT1A7 T622C) or transport (multidrug resistance gene; MDR1/ABCB1, 
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e.g. MDR1 C3435T, and MDR1 C1236T) were abstracted from the medical record or research 
database, where applicable.  Kidney function was assessed by estimated creatinine clearance 
(eClcr) calculated by the Cockroft-Gault equation. [32]  
Population Pharmacokinetic Analysis 
Pharmacokinetics of MPA, MPAG, and AcMPAG were evaluated using Non-linear Mixed 
Effect Modeling software (NONMEM Version 6.2.0, ICON Development Solutions, Ellicott City, 
MD).  Initial visual inspection of semi-logarithmic plasma concentration-time plots for MPA, 
MPAG and AcMPAG demonstrated bi-exponential and mono-exponential decay patterns 
(Figure 1), consistent with a two-compartmental pharmacokinetic model for MPA and one-
compartment pharmacokinetic models for MPAG and AcMPAG.  Pharmacokinetic models were 
parameterized in terms of apparent clearances and volumes with the subroutines ADVAN6 
TRANS1 and incorporated a gallbladder compartment to account for enterohepatic recycling of 
MPA via MPAG.  The enterohepatic recycling process was modeled by introducing a rate 
constant describing the transfer from the MPAG central compartment to a gallbladder 
compartment.  During gallbladder emptying, MPAG was transferred and converted back to the 
parent MPA in the depot compartment.  Double precision and first-order conditional estimation 
(FOCE) were used.  Inclusion of urine data allowed estimation of apparent renal clearance 
(CLR/F) and apparent nonrenal clearance (CLNR/F).  Both MPAG and AcMPAG 
pharmacokinetics were modeled as a central metabolite compartment for plasma that was 
connected to the central MPA compartment.  Each metabolite compartment had a non-
reversible elimination pathway to a urine compartment, and an additional elimination pathway 
such as through enterohepatic recycling through the gallbladder compartment for MPAG.     
Intersubject variability in structural model parameters was estimated by an exponential error 
model (Equation 1). 
Pj = θ·e ηj     (1) 
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Where Pj is the individual value for P in the jth individual, θ is the population mean value of the 
pharmacokinetic parameter P (e.g. CL/F, Vc/F, etc), and ηj is a random error term (the difference 
between the typical value and individual value).  
Residual variability εij,k (k=1, 2, 3, 4, 5, 6), which is the discrepancy between the individual 
observed (Cobs, ij) ith plasma or urine concentration measured in the jth individual for the MPA, 
MPAG, and AcMPAG and the respective individual model-predicted plasma or urine 
concentrations (Cpred, ij) in the natural logarithm domain and was modeled according to an 
additive error model (Equations 2-7). 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,1 for MPA plasma    (2) 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,2 for MPAG plasma    (3) 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,3 for AcMPAG plasma    (4) 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,4 for MPA urine     (5) 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,5 for MPAG urine    (6) 
Ln (Cobs, ij) = Ln (Cpred, ij) + εij,6 for AcMPAG urine    (7) 
 
Random effect parameters η and ε were assumed to be symmetrically distributed with 0 mean 
and variances of ω2 and σ2, respectively.  Different pharmacokinetic models were tested and the 
best structural model was chosen based on goodness-of-fit criteria including diagnostic plots, 
minimum objective function value (MOFV) after accounting for the number of fitted parameters, 
precision, and physiological plausibility of parameter estimates. 
Covariate Model Building 
Covariate models were created [33] to evaluate for the influence of patient demographics 
(age, weight, gender), clinical status (serum creatinine, eClcr, serum albumin, urinary protein to 
creatinine ratio), and genotypes (UGT2B7 C802T, UGT1A7 T622C, MDR1 C3435T, and MDR1 
C1236T) on the pharmacokinetic parameters.     
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For continuous covariates (age, weight, serum creatinine, eClcr, serum albumin, urinary 
protein to creatinine ratio), Equation 8 was used: 
P =   θ * (covariate/median covariate) θcovariate     (8) 
where θ is the population mean value of P for a patient with the median covariate value and 
θcovariate is the estimated effect for the covariate on P. For some continuous covariates which 
influenced P only below a critical cutoff value, the covariate model was modified as shown in 
Equations 9 and 10: 
 P =   θ1 * (covariate/median covariate) θcovariate for covariate ≤ cutoff value (9) 
 P = θ2         for covariate > cutoff value      (10) 
where θ1 is the population mean value of P for a patient with the median covariate value 
below or equal to the cutoff value, θcovariate is the estimated effect of the covariate on P below or 
equal to the cutoff value, and θ2 is the population mean of P for a patient with a covariate value 
above the cutoff value. The critical cutoff values were determined graphically from the plots of 
the posthoc pharmacokinetic parameter estimates versus covariates. 
For categorical covariates (race, gender, genotypes) on P was modeled according to 
Equations 11 and 12: 
P = θ   for reference covariate     (11) 
P = θ * θcovariate   for investigated covariate     (12) 
where θ is the population mean value of P (e.g. CL/F, Vc/F, etc), θcovariate is the estimated 
fractional change in θ for the investigated covariate. Likelihood ratio tests to compare 
hierarchical models were performed by comparing differences in MVOF between models to χ2 
distributions with degrees of freedom equal to the difference in the number of parameters  A 
reduction in MVOF of >3.84 (1 degree of freedom) from the base or previous model to the 
current model was designated as statistically significant at p<0.05.   
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The incorporation of covariates in the final model was determined by stepwise forward 
addition followed by backward elimination. During forward addition, covariates at the p < 0.05 
level were included in the model, and during backward elimination, covariates at the p < 0.01 
level were retained in the model.   
Predictive Ability 
 A visual predictive check was employed to evaluate the predictability of the model.  One 
hundred data sets were simulated each for plasma and urine MPA, MPAG, and AcMPAG from 
the final model. The observed data were superimposed with the 2.5th, 50th, and 97.5th 
percentiles of the simulated data calculated at each time point.  
Results 
 The characteristics from the combined set of 39 lupus nephritis and ANCA-associated 
vasculitis patients are presented in Table 4.1.  The patients were predominantly Caucasian 
(60%) and African-American (28%) race.  A minimal to moderate level of kidney dysfunction 
was present; eClcr 91.3±45.7 mL/min and urinary protein to creatinine ratio 0.8±1.6, with 
conserved serum albumin (4.2±0.5 g/dL).  Approximately 40% of patients were receiving double 
immunosuppressant therapy with glucocorticoids (31%) or cyclosporine (8%).   
 A full steady-state 12-hour plasma concentration vs time profile was generated for all 39 
patients.  The entire dataset produced a total of 444 MPA, 441 MPAG, and 362 AcMPAG 
plasma and a total of 130 MPA, 130 MPAG (n=130), and 71 AcMPAG urine concentrations.  
Figure 4.1 shows the observed steady state plasma concentration vs time profiles for MPA, 
MPAG, and AcMPAG after orally administered mycophenolate mofetil and demonstrate 
secondary peaks between 4 and 12 hours consistent with enterohepatic recycling of MPA.   
 Similar to the previous work of MPA disposition in kidney transplant recipients [1], a 2-
compartment model with enterohepatic recycling, first-order absorption, and linear elimination 
was selected as the base model.  While several patient plasma concentration time curves 
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demonstrated an absorption lag time, its inclusion into models resulted in a reduction of the 
MVOF but with the cost of decreased precision of other data parameters and was therefore not 
incorporated.  Duration of gallbladder emptying was fixed at 0.01 hours. [4,8]  Due to insufficient 
data collected around the secondary peak, the transfer rate constant of MPAG from the 
gallbladder to the depot compartments (k41) was fixed  at  67.5 hr-1 [8].  The final model 
parameters are presented in Table 4.2.  Figure 4.2 is a schematic representation of the final 
model employing plasma and urine concentration data for MPA, MPAG, and AcMPAG.   
 The covariates were examined to determine their relationship with eta values for apparent 
Clr/F, apparent Clnr/F, and the central compartment volume (Vc/F).    Stepwise forward addition 
identified the following significant covariate effects: eClcr on CLNR,MPA/F (∆MVOF=-19.602, 
P<0.001), eClcr (with a cut-off value at 80 ml/min/1.73m2) on CLR,MPA/F (∆MVOF=-8.803, 
P<0.025), serum albumin on CLNR,MPA/F (∆MOF=-6.627, P<0.01), eClcr on CLR,MPAG/F 
(∆MVOF=-18.699, P<0.001) and eClcr on CLR,AcMPAG/F (∆MVOF=-11.033, P<0.001). All these 
covariates remained significant (p<0.01) during backward elimination. 
 Table 4.2 shows the population parameter estimates and covariate relationships for MPA, 
MPAG, and AcMPAG for the final model.  In general, parameters were estimated with 
acceptable precision (7-53% relative standard error, %RSE). eClcr ≤80 mL/min had a covariate 
effect on ClR,MPA/F (Equation 13).   
     CLR MPA creatinine clearance ≤ 80 /F L/hr = 0.0975 L/hr * (eClcr/54.93)1.33  (13) 
 For apparent CLNR/F, eClcr had a positive effect, while serum albumin was found to have an 
inverse effect (Equation 14).   
  CLNR MPA  L/hr = 14.3 L/hr * (eClcr/88.54)0.831 (albumin/4.2)-1.35  (14) 
For MPAG and AcMPAG, increased eClcr resulted in increased apparent CLR/F for each 
respective metabolite. (Equations 15 and 16). 
  CLR MPAG L/hr = 1.77 L/hr * (eClcr/88.54)0.641     (15) 
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  CLR AcMPAG  L/hr = 1.75 L/hr * (eClcr /88.54)1.00     (16) 
None of the UGT2B7, UGT1A7, and MDR1 genotypes were found to be significant in the final 
model.   
 Model diagnostic plots for plasma MPA, MPAG and AcMPAG data are shown in Figures 4.3, 
4.5 and 4.7, respectively.  Model diagnostic plots for urine MPA, MPAG and AcMPAG data are 
shown in Figures 4.4, 4.6 and 4.8, respectively.  These plots showed that our comprehensive 
models adequately described the data.  The results of the visual predictive check evaluation for 
plasma and urine MPA, MPAG, and AcMPAG are presented in Figures 4.9 and 4.10, 
respectively. Most of the observations are contained within the 95th % prediction intervals. This 
analysis suggests that the final model provided an adequate fit to the data.  
 Table 4.3 demonstrates the predicted population values for MPA Cl/F, CLR/F, and CLNR/F in 
a glomerulonephritis population exhibiting selected values for eClcr and serum albumin that are 
clinically relevant. 
Discussion 
 The current study reported a population pharmacokinetic analysis of MPA and its 
metabolites MPAG and AcMPAG, in a group of patients with glomerulonephritis secondary to 
SVV and SLE.  This study was necessary to investigate the influence of patient-level 
characteristics including kidney function (e.g. eClcr) and kidney structure (urinary protein to 
creatinine ratio), and serum protein (serum albumin concentration) that are altered in 
glomerulonephritis.  Additionally, demographic and genotype variables were investigated for 
their influence on MPA pharmacokinetics.  The population approach enabled us to estimate 
mean pharmacokinetic parameters, inter-individual variability, residual variability, and covariate 
effects.  As opposed to kidney transplant recipients, little is known about pharmacokinetic 
variability of MPA in glomerulonephritis, despite being used off-label for this indication for almost 
a decade.   
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 As compared to the previous study in kidney transplant patients, the glomerulonephritis 
population had higher population mean (%RSE) absorption rate constant (Ka) [1.16 hr-1 (15.2%) 
vs 0.67 hr-1 (24.8%)], higher apparent intercompartmental clearance (Q/F) [23.4 L/hr (16.4%) vs 
8.11 L/hr (24.2%)], and lower VC/F. [21.1 L (34.1%) vs 25.9 L (34.9%)]. [1]  In the current study, 
we evaluated mycophenolate mofetil versus mycophenolate sodium, [1]  which may have 
accounted for variability in Ka.  Other MPA population models in kidney transplant patients have 
reported population mean Ka estimates that range from 2.27 hr-1 to 4.1 hr-1 [5,7,34], which are also 
greater than the current estimate.  Additionally, mean population estimates for VC/F  from 10.3 
to 97.7 L [4,5,7,35] , consistent range with the current study.  The population mean (%RSE) VP/F 
was substantially higher in the current study over what was previously reported [1240 L (23.4%) 
vs 39.6 L (86.9%)] in kidney transplant patients, suggesting a larger degree of uncertainty with 
this estimate. [1]  In the current study, we collected urine samples, which enabled estimation of 
the ClR/F component to apparent oral clearance (CL/F).  Two population mean ClR/F estimates 
for MPA were provided based on two categories of eClcr; levels ≤80 mL/min and > 80 mL/min.  
The ClR/F estimate was nearly 2-fold higher in patients with eClcr values of > 80 mL/min versus 
≤80 mL/min.  Apparent renal clearance estimates of MPAG and AcMPAG were an order of 
magnitude greater than MPA estimates.  As would be expected, the ClNR/F estimate (%RSE) for 
MPA was significantly greater [14.3 L/hr (8.04%)] than the ClR/F estimates [0.0975 L/hr (20.8%) 
and 0.157 L/hr (20.5%)] as MPA is primarily metabolized by the liver.  The previously published 
MPA pharmacokinetic models did not measure urine concentrations and hence did not provide 
estimates for the ClR/F.  Previous studies have reported ranges for MPA CL/F of 11.9 L/hr to 33 
L/hr. [4,5,7,35]  A recent publication in 38 patients with glomerulonephritis receiving mycophenolate 
mofetil reported higher mean (%RSE) VC/F [52.4 L (17%)], higher Ka [6.2 hr-1 (22%)], lower VP/F 
[262 L (5%)], and lower Q/F [16.2 L/hr (22%)] than our current study. [30]  Differences between 
the glomerulonephritis populations were a higher percentage of females, more diverse racial 
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make-up, higher kidney function (eClcr), and a lower percentage of patients on concomitant 
glucocorticoids in the current versus earlier study.   
 The volumes of the central metabolite compartments are not uniquely identifiable in this 
analysis.  A recent study, however, estimated the central MPAG compartment apparent volume 
as 4.4 L. [8]  If we make the same assumption for our MPAG compartment volume, the 
percentage of MPAG clearance that underwent recycling through the gallbladder in 
glomerulonephritis patients would be estimated as 17.9%.  A previous model had gallbladder 
being filled continuously from the central compartment, but many parameters in the model were 
required to be fixed secondary to insufficient data collection surrounding the occurrence of 
recycling. [30]    The percentage of MPA clearance that underwent recycling through gallbladder 
was fixed at 37%, and this recycling was attributed solely to the parent MPA. [30]  Another study 
reported that 29.1% of total absorbed MPA was recycled from MPAG. [8] The current model 
shows that AcMPAG undergoes rapid reversible interconversion with the parent MPA in plasma. 
This is consistent with recent animal data from our laboratory which suggests that AcMPAG is 
actually cleaved to MPA by nonspecific esterases within the liver (data not shown).  This is in 
contrast to MPAG, which is thought to be cleaved by β-glucuronidases in the intestine. [36]  
 In the current study, the final structural model that fit the MPA pharmacokinetic data 
obtained from the glomerulonephritis patients consisted of nine compartments.  This model is 
slightly more complex than the six compartment model we previously employed in kidney 
transplant recipients. [1]  The higher complexity mainly resulted from the incorporation of urine 
compartments for MPA, MPAG, and AcMPAG.  The previously published model in patients with 
glomerulonephritis was different than our current and previous models as it did not employ 
MPAG or AcMPAG plasma compartments, had two separate absorption compartments 
representing a short and lag time, exhibited a different gallbladder component, and did not 
incorporate urine compartments. [30]  Other published structural models for MPA in renal 
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transplant patients include a 4-compartment model with a gastrointestinal compartment [3,4], and 
a 5-compartment model with incorporation of a gallbladder compartment. [8]   
 It is known that there is a large degree of interpatient variability in the pharmacokinetic 
parameters of MPA in kidney transplant patients. [19]  Studies have reported CL/F interpatient 
variability in the range of 28% to 41% [5,6]  Interpatient variability in the VC/F has been reported 
to range from 18% to 87.8% in other studies. [1,3] In this study, estimated interpatient variability 
for MPA pharmacokinetic parameters (%RSE) were as follow: CLR,MPA/F [72.5% (30.9%)], 
CLNR,MPA/F [39.7% (19.1%)], and Vc/F [143% (50.7%)]. This large variability supports the 
therapeutic monitoring of MPA in patients with glomerulonephritis. Residual error analysis for 
plasma data demonstrated the greatest error [standard deviation (%RSE)] in MPA [1.81 µg/mL 
(18.7%)] followed by AcMPAG [1.54 µg/mL (7.83%)] and MPAG [1.50 µg/mL (7.54%)]. Residual 
error analysis for urine data demonstrated the greatest error in MPA [2.49 µg/mL (16.6%)] 
followed by MPAG [1.77 µg/mL (14.0%)] and AcMPAG [1.31 µg/mL (24.6%)].  The reasonable 
residual error estimates likely were reflective of the sensitive assay methods used.   
 Covariate modeling demonstrated a significant effect of eClcr on increasing MPA ClR/F 
(covariate coefficient 1.33) in patients with eClcr values of ≤80 mL/min and increasing MPA 
ClNR/F (covariate coefficient 0.831).  As demonstrated in Table 4.3, a glomerulonephritis patient 
with eClcr of 60 mL/min would have a 3-fold higher MPA ClR/F than a patient with an eClcr of 30 
mL/min (0.11 L/hr vs 0.04 L/hr).  Serum albumin concentrations were also found to influence 
ClNR/F, with decreased serum albumin resulting in increased ClNR/F (covariate coefficient -1.35).  
An increase in eClcr from 30 to 60 mL/min in the presence of a normal serum albumin (4.4 g/dL) 
would double the calculated ClNR/F from 5.5 to 9.7 L/hr.  For the same increase in eClcr, 
patients with reduced serum albumin to 2.5 g/dL would have a doubling of the calculated 
CLNR/F, above that demonstrated at each level of eClcr in patients with normal serum albumin 
concentrations (from 11.7 to 21 L/hr).  Regarding effects on AUC 0-tau; for the group of patients 
with normal serum albumin concentrations, the AUC 0-tau decreased from eClcr values of 30 to 
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120 mL/min (131 to 41.4 mg hr/L).  When these same patients also had serum albumin values 
reduced to 2.5 g/dL, the AUC 0-tau was reduced another 2-fold at each level of eClcr (from 61.2 to 
19.4 mg hr/L).  While MPA AUC 0-tau targets are not  defined for glomerulonephritis, if one were 
to target the AUC 0-tau values suggested for renal transplant recipients (30 to 60 mg hr/L) as a 
starting point for therapy, the covariate effects would result in many patients either above or 
below MPA AUC 0-tau targets.  In particular, patients with low serum albumin and patients with 
low eClcr would be at highest risk.  As unbound MPA AUC 0-tau may be more relevant to target in 
patients with these clinical manifestations, future assessments should address these unbound 
targets.  However, the relative contribution of unbound levels to efficacy versus availability for 
elimination would dictate the relevance of unbound levels.  Creatinine clearance was also found 
to positively influence the ClR/F of MPA’s metabolites (MPAG and AcMPAG) as well.  
Glomerulonephritis patients with decreased eClcr would be expected to have at least transiently 
increased AcMPAG and MPAG concentrations prior to any recycling processes.  Overall, 
increased metabolism could result in increased MPA exposure through recycling.   
 Creatinine clearance has been reported as a significant covariate in MPA Cl/F in previous 
population pharmacokinetic models. [3,5]  van Hest, et al, reported increased Cl/F of MPA with 
reduced values of eClcr in a kidney transplant population using a population pharmacokinetic 
model of MPA which does not incorporate enterohepatic recycling of MPA since all the patients 
were on concomitant cyclosporine, which is known to inhibit biliary excretion of MPA. [5]  
However, since urinary concentrations of MPA were not obtained, estimation of a ClR/F and 
ClNR/F were not feasible.  The previous authors surmised that kidney disease results in 
reductions in protein binding of MPA to serum albumin secondary to uremic competitors as well 
as MPAG accumulation secondary to loss of kidney function; both factors contributing to 
increased Cl/F. [5]  In contrast, de Winter et al reported a positive correlation of eClcr and MPA 
Cl/F in patients with autoimmune disease. [30]  The authors attributed the difference in correlation 
by the concomitant cyclosporine, which inhibits the enterohepatic recycling of MPA via MPAG.  
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Decreased kidney function will lead to reduced renal clearance of MPAG and increased biliary 
excretion.  As a result, more MPAG will undergo enterohepatic recirculation and conversion 
back to MPA.  Our kidney disease model, e.g. glomerulonephritis, would be predicted to result 
in reductions in protein binding of MPA secondary to reductions in serum albumin due to kidney 
losses and also due to accumulation of metabolites (MPAG and AcMPAG) secondary to the 
loss of kidney function.  Since we measured MPA and metabolites in the urine, the ClR/F 
component could be estimated and the ClNR/F component could also be calculated.  Our results 
suggest that the ClNR/F component of MPA Cl/F is influenced to a greater extent than ClR/F in 
patients with glomerulonephritis.  Studies into the influences of the systemic diseases that result 
in glomerulonephritis on phase II drug metabolizing processes may elucidate the role of serum 
albumin versus alterations in UGTs on nonrenal clearance.  
Conclusions 
This study reported a population pharmacokinetic model for MPA and its glucuronide 
metabolites in patients with glomerulonephritis secondary to SLE and SVV.  Unlike previous 
models of MPA pharmacokinetics, our model was developed with extensive plasma and urine 
sample collections from a well-defined population of patients.  The resulting parameter 
estimates were considerably different than those obtained in many of the previous publications 
of kidney transplant patients receiving MPA.  Two covariates, eClcr and serum albumin, 
influenced the renal and nonrenal components to apparent clearance.  The clinical relevance of 
the current study can be realized when using the population parameters to simulate AUC 0-tau 
values under scenarios of altered creatinine clearance and/or altered serum albumin.  We 
demonstrated that patients with glomerulonephritis would have highly altered MPA exposures 
when one includes assessment of covariates on renal and nonrenal apparent clearance 
estimates.  Future work will elucidate unbound exposures and relevance to efficacy, toxicity, 
and metabolic pathways.
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Table 4.1 
Study Patient Characteristics (n=39) 
 
Age (years)     46.9±14.8 
Weight (kg)     85.7±20.9 
Gender (male/female)   11/28 
Race n (%) 
 Caucasian    23 (59) 
 African-American   11 (28) 
 American-Indian   2 (5) 
 Asian     2 (5) 
 Other     1 (3) 
Serum albumin (g/dL)    4.2±0.5 
Serum creatinine (mg/dL)   1.3±0.7 
Estimated Creatinine Clearance (mL/min)a 91.3±45.7 
Urinary protein to creatinine ratio  0.8±1.6 
Concomitant glucocorticoids (%)  12 (31) 
Concomitant cyclosporine (%)  3 (8) 
Mycophenolate mofetil dose (mg)  827±325 
 
a – estimated by Cockroft and Gault equation [32] 
 
Data presented as mean±standard deviation 
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Table 4.2.  Final parameter estimates of the population modeling 
 
 
 
Model parameter (units) 
 
 
 
Estimate (%RSE) 
 
Interindividual 
variability, CV% 
(%RSE) 
Mycophenolic Acid (MPA) 
 
Fixed effects  
     ka (hr-1) 
     CLR, MPA/F [eCLCR ≤ 80 mL/min] (L/hr) 
 
     CLR, MPA/F [eCLCR > 80 mL/min] (L/hr) 
 
     CLNR, MPA/F (L/hr) 
     VC/F (L)   
     VP/F (L)   
     Q/F (L/hr)      
           
Covariate coefficient 
Effect of creatinine clearance on CLR, MPA/F [eCLCR 
≤ 80 mL/min], eCRCL_ CLR, MPA/F a 
Effect of creatinine clearance on CLNR, MPA/F,    
eCRCL_ CLNR, MPA/F b 
Effect of albumin on CLNR, MPA/F, ALB_ CLNR, MPA/F c
  
Residual error estimates (standard deviation) 
     MPA, plasma (µg/mL)    
     MPA, urine
 
(µg/mL)      
 
 
 
1.16 (15.2) 
0.0975 (20.8) 
 
0.157 (20.5) 
 
14.3 (8.04) 
21.1 (34.1) 
1240 (23.4) 
23.4 (16.4) 
 
 
1.33 (33.2) 
 
0.831 (18.5) 
 
-1.35 (31.5) 
 
 
 
1.81 (18.7) 
2.49 (16.6) 
 
 
 
 
72.5 (30.9) 
 
72.5 (30.9) 
 
39.7 (19.1) 
143 (50.7) 
Mycophenolic Acid Glucuronide (MPAG) 
 
Fixed effects     
    CLR, MPAG/F (L/hr) 
    FM1*  
    k84 (hr-1) 
 
Covariate coefficient 
Effect of creatinine clearance on CLR, MPAG/F, 
eCRCL_ CLR, MPAG/F d 
 
Residual error estimates (standard deviation) 
     MPAG, plasma
  
(µg/mL)    
     MPAG, urine
  
(µg/mL)      
 
  
 
1.77 (12.7) 
0.271 (14.9) 
0.0878 (53.2) 
 
 
0.641 (37.0) 
 
 
 
1.50 (7.54) 
1.77 (14.0) 
 
 
 
71.8 (25.4) 
72.7 (37.7) 
 
Acyl-mycophenolic acid glucuronide (AcMPAG) 
 
Fixed effects         
    CLR, AcMPAG/F (L/hr) 
    FM2*  
 
  
 
1.75(18.2) 
0.0142 (24.4) 
 
 
 
95.9 (29.5) 
80.4 (25.9) 
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    k102  (hr-1) 
 
Covariate coefficient 
Effect of creatinine clearance on CLR, AcMPAG/F, 
eCRCL_ CLR, AcMPAG/F e 
 
Residual error estimates (standard deviation) 
     AcMPAG, plasma
  
(µg/mL)     
     AcMPAG, urine
  
(µg/mL)      
 
1.63 (40.3) 
 
 
1.00 (31.4) 
 
 
 
1.54 (7.83) 
1.31 (24.6) 
 
Abbreviations:   
coefficient of variation, CV; estimated creatinine clearance, eClcr; percent relative standard 
error, % RSE; absorption rate constant, ka; apparent renal clearance of MPA, CLR, MPA/F; 
apparent non-renal clearance of MPA, CLNR, MPA/F; apparent volume of central compartment, 
VC/F;  apparent volume of peripheral compartment, VP/F; apparent renal clearance of MPAG, 
CLR, MPAG/F; apparent renal clearance of AcMPAG, CLR, AcMPAG/F; ratio of fraction of MPA 
metabolized to MPAG to volume of distribution of MPAG, FM1*; ratio of fraction of MPA 
metabolized to AcMPAG to volume of distribution of AcMPAG, FM2*; rate constant for the 
transfer of MPAG from central to gall bladder compartment, k84; rate constant for the transfer of 
AcMPAG from central to MPA central compartment, k102; 
 
a CLR, MPA/F individual = CLR, MPA/F [(eCRCL/54.93)CRCL_CLR,MPA]×EXP(η CLR, MPA/F); 
b CLNR, MPA/F individual = CLNR, MPA/F [(eCRCL/88.54)CRCL_CLNR,MPA]×EXP(η CLNR, MPA/F);   
c CLNR, MPA/F individual = CLNR, MPA/F [(ALB/4.2)ALB_CLNR,MPA]×EXP(η CLNR, MPA/F);  
d CLR, MPAG/F individual = CLR, MPAG/F [(eCLCR/88.54)CLCR_CLR,MPAG]×EXP(η CLR, MPAG/F);  
e CLR, AcMPAG/F individual = CLR, AcMPAG/F [(eCLCR/88.54)CLCR_CLR,AcMPAG]×EXP(η CLR, AcMPAG/F) 
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Table 4.3 
Glomerulonephritis Patient Predictions for Mycophenolic Acid Apparent Clearance Terms Based on Creatinine Clearance 
and Serum Albumin  
 
     CLNR/F   CLR/F   CL/Fa   AUC0-Taub 
     (L/hr)   (L/hr)   (L/hr)   (mg hr/L) 
Creatinine Clearance c 
 30 mL/min   5.46   0.04   5.5   131 
 60 mL/min   9.72   0.11   9.83   73.2 
 120 mL/min   17.3   0.16   17.5   41.3 
Creatinine Clearance d 
 30 mL/min   11.7   0.04   11.8   61.2 
 60 mL/min   20.8   0.11   20.9   34.4 
 120 mL/min   37.0   0.16   37.2   19.4 
Serum Albumin e 
 2.0 g/dL   50.1   0.16   50.2   14.3 
 3.0 g/dL   28.9   0.16   29.1   24.8 
 4.4 g/dL   17.9   0.16   18.1   39.9 
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Serum Albumin f 
 2.0 g/dL   15.8   0.04   15.9   45.4 
 3.0 g/dL   9.14   0.04   9.18   78.4 
 4.4 g/dL   5.46   0.04   5.50   131 
 
a: CL/F = CLR/F + CLNR/F 
b: 1000 mg mycophenolate mofetil dose is 720 mg mycophenolic acid dose 
c: serum albumin 4.4 g/dL 
d: serum albumin 2.5 g/dL 
e: creatinine clearance 120 mL/min 
f: creatinine clearance 30 mL/min 
Creatinine clearance estimated by the Cockroft and Gault equation [32] 
Abbreviations 
AUC 0-tau – area under the plasma concentration time curve during a dosing interval 
Cl/F – apparent total oral clearance 
CLNR/F – apparent nonrenal clearance 
ClR/F – apparent renal clearance 
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Figure Legends 
 
Figure 4.1. Observed Plasma Concentration Versus Time After Dose.  Figure shows 
observed plasma concentration versus time after dose for a). mycophenolic acid (MPA), b). 
mycophenolic acid glucuronide (MPAG), and c). acyl-mycophenolic acid glucuronide 
(AcMPAG). 
Figure 4.2. Final Compartment Model for Mycophenolic Acid (MPA), Mycophenolic Acid 
Glucuronide (MPAG), and Acyl-mycophenolic Acid Glucuronide (AcMPAG) Plasma and 
Urine Data.  Abbreviations: mycophenolic acid, MPA; mycophenolic acid glucuronide, MPAG; 
acylmycophenolic acid glucuronide, AcMPAG; absorption rate constant, ka; apparent renal 
clearance of MPA, CLR, MPA/F; apparent non-renal clearance of MPA, CLNR, MPA/F; compartment, 
CMT; apparent volume of central compartment, VC/F;  apparent volume of peripheral 
compartment, VP/F; apparent renal clearance of MPAG, CLR, MPAG/F; apparent renal clearance of 
AcMPAG, CLR, AcMPAG/F; ratio of fraction of MPA metabolized to MPAG to volume of distribution 
of MPAG, FM1*; ratio of fraction of MPA metabolized to AcMPAG to volume of distribution of 
AcMPAG, FM2*; rate constant for the transfer of MPAG from central to gall bladder 
compartment, k84; rate constant for the transfer of AcMPAG from central to MPA central 
compartment, k102; rate constant for the transfer of MPAG from gallbladder to depot; k41. 
Figure 4.3. Mycophenolic Acid in Plasma Goodness-of-Fit Plots.  (Upper left and right 
panels) Natural logarithmic-transformed population and individual predicted plasma 
mycophenolic acid (MPA) concentration vs natural logarithmic-transformed observed plasma 
MPA concentration. (Lower left and right panels) Natural logarithmic-transformed population 
predicted plasma MPA concentration and time after dose vs weighted residuals (WRES). 
Figure 4.4.  Mycophenolic Acid in Urine Goodness-of-Fit Plots. (Upper left and right panels) 
Natural logarithmic-transformed population and individual predicted urine mycophenolic acid 
(MPA) concentration vs natural logarithmic-transformed observed urine MPA concentration. 
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(Lower left and right panels) Natural logarithmic-transformed population predicted urine MPA 
concentration and time after dose vs weighted residuals (WRES). 
Figure 4.5.  Mycophenolic Acid Glucuronide in Plasma Goodness-of-Fit Plots. (Upper left 
and right panels) Natural logarithmic-transformed population and individual predicted plasma 
mycophenolic acid glucuronide (MPAG) concentration vs natural logarithmic-transformed 
observed plasma MPAG concentration. (Lower left and right panels) Natural logarithmic-
transformed population predicted plasma MPAG concentration and time after dose vs weighted 
residuals (WRES). 
Figure 4.6.  Mycophenolic Acid Glucuronide in Urine Goodness-of-Fit Plots. (Upper left 
and right panels) Natural logarithmic-transformed population and individual predicted urine 
mycophenolic acid glucuronide (MPAG) concentration vs natural logarithmic-transformed 
observed urine MPAG concentration. (Lower left and right panels) Natural logarithmic-
transformed population predicted urine MPAG concentration and time after dose vs weighted 
residuals (WRES). 
Figure 4.7.  Acyl-Mycophenolic Acid Glucuronide in Plasma Goodness-of-Fit Plots. 
(Upper left and right panels) Natural logarithmic-transformed population and individual predicted 
plasma mycophenolic acid acyl glucuronide (AcMPAG) concentration vs natural logarithmic-
transformed observed plasma AcMPAG concentration. (Lower left and right panels) Natural 
logarithmic-transformed population predicted plasma AcMPAG concentration and time after 
dose vs weighted residuals (WRES). 
Figure 4.8.  Acyl-Mycophenolic Acid Glucuronide in Urine Goodness-of-Fit Plots. (Upper 
left and right panels) Natural logarithmic-transformed population and individual predicted urine 
mycophenolic acid acyl glucuronide (AcMPAG) concentration vs natural logarithmic-transformed 
observed urine AcMPAG concentration. (Lower left and right panels) Natural logarithmic-
transformed population predicted urine AcMPAG concentration and time after dose vs weighted 
residuals (WRES). 
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Figure 4.9. Visual Predictive Check for Plasma A) MPA, B) MPAG and C) AcMPAG. 
Observed data (●) compared to the 97.5th (upper dotted line), 50th (middle solid line) and 2.5th 
(lower dotted line) percentiles of the simulated (100) data sets.  
Figure 4.10. Visual Predictive Check for Urine A) MPA, B) MPAG and C) AcMPAG. 
Observed data (●) compared to the 97.5th (upper dotted line), 50th (middle solid line) and 2.5th 
(lower dotted line) percentiles of the simulated (100) data sets. 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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Figure 4.5 
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Figure 4.6 
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Figure 4.7 
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Figure 4.8 
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Figure 4.9 
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Figure 4.10 
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Abstract 
Background:  Mycophenolic acid (MPA) is an immunosuppressant used in the treatment of 
glomerulonephritis and transplantation.  MPA is metabolized by several uridine diphosphate 
glucuronosyltransferases (UGTs) and several transporters are responsible for uptake and efflux 
of MPA and its metabolites.  Data concerning the influence of clinical covariates and 
polymorphisms in drug metabolizing genes and transporter genes on the pharmacokinetics of 
MPA have not been described in glomerulonephritis.   
Aim:  The role of pharmacogenomics, clinical and demographic parameters on pharmacokinetic 
predictions was evaluated in patients receiving mycophenolic acid (MPA).  In particular, the 
study focused on the influence of polymorphisms in the less-well described gene-
pharmacokinetic relationships pertaining to MPA. 
Methods: A cohort study design of patients with glomerulonephritis secondary to lupus nephritis 
and anti-neutrophil cytoplasmic antibody (ANCA) small vessel vasculitis was employed.  Forty-
six patients with lupus nephritis and anti-neutrophil cytoplasmic antibody (ANCA) small vessel 
vasculitis and receiving MPA were recruited from the nephrology clinic.  The study assessed the 
relative single and combined roles of genomic, clinical, and demographic characteristics on 
pharmacokinetic (PK) parameters using general linear models.  The study focused on single 
nucleotide polymorphisms in UGT1A7, UGT2B7 and ABCB1/MDR1; all of which have limited 
data available concerning relevance to MPA disposition. 
Measurements: All patients had PK assessments for MPA and its glucuronide metabolites 
(MPAG and AcMPAG).  Genotyping was performed for known variants of UGTs (UGT1A9, 
UGT1A7, UGT2B7), and multidrug resistance protein (ABCB1/MDR1), involved in MPA 
disposition.  Analyses included PK, as well as univariate and multivariate linear modeling. 
Results:  In univariate analyses, UGT2B7 heterozygosity (coefficient 0.3508; R2 0.0873) and 
UGT1A7 heterozygosity (coefficient 0.3778; R2 0.0966) predicted increased MPA apparent oral 
clearance.  UGT1A7 heterozygosity (coefficient -0.4647; R2 0.0897) predicted lower MPA trough 
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concentrations.  In multivariate assessments, higher urinary protein excretion, lower serum 
creatinine, and increased weight predicted greater MPA apparent oral clearance (p<0.0001).  
White race and higher serum creatinine predicted higher MPA trough concentrations 
(p<0.0001).  Higher exposure to MPA was predicted by decreased urinary protein excretion and 
increased serum creatinine. 
Limitations: The main limitation to this study was small sample size to enable a robust 
assessment of the effects of all planned genotypes on MPA PK parameters. 
Conclusions: Clinical and demographic parameters (especially kidney function and urinary 
protein) were 2-4 times more important in MPA disposition than genotypes and explained 30% 
to 40% of the PK parameters.   
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Introduction 
Autoimmune related kidney diseases such as systemic lupus erythematosus (SLE) and anti-
neutrophil cytoplasmic antibody (ANCA) small vessel vasculitis (SVV) are treated with a myriad 
of drugs approved for use in the transplant and cancer populations.  These treatments 
commonly include but are not limited to mycophenolate mofetil/sodium, glucocorticoids, and 
cyclophosphamide.  Treatments with these drugs are considered “off-label” with respect to Food 
and Drug Administration (FDA) labeling.  Intrinsic to off-label usage is the uncertainty pertaining 
to the effects of disease-related clinical covariates on drug disposition (pharmacokinetics).  
Patients with glomerulonephritis can have reductions in serum albumin and kidney function 
(glomerular filtration rate (GFR) or estimated creatinine clearance (eClCr)), and elevations in 
proteinuria, all of which may alter drug disposition.  Kidney transplant patients, on the contrary 
have primarily reductions in GFR and less commonly alterations in serum albumin and urinary 
protein excretion.  Reductions in serum albumin may increase clearance through metabolism 
and excretion by increasing the unbound drug.  Increases in urinary protein excretion may 
increase clearance through clearance of bound drugs.  Among the various forms of 
glomerulonephritis, there can be a predilection for patients of certain ages, races, and genders; 
factors that may result in variable drug disposition.  For drugs such as mycophenolic acid 
(MPA), the active moiety of mycophenolate mofetil and mycophenolate sodium, there is 
inherently wide inter-individual variability in pharmacokinetics. 1,2 Hence the alterations in clinical 
and/or demographic covariates in the glomerulonephritis population as compared to the kidney 
transplant population could lead to variability in pharmacokinetics above and beyond that which 
would be predicted from studies employing the later patients. 
There are several reports in transplant and healthy normal populations that suggest altered 
MPA pharmacokinetics secondary to single nucleotide polymorphisms (SNPs) in the uridine 
glucuronosyltransferase metabolizing enzymes (UGTs). 3-8  Polymorphisms in the UGT1A9 
gene and influence on MPA have been most described.  The UGT1A9 T-275A and C-2152T 
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promotor SNPs have been associated with enhanced metabolism of mycophenolic acid. 3,8  
UGT1A9 SNPs at nucleotide base positions 8 and 98 have been associated with enhanced 
exposure to MPA, suggesting a reduction in metabolism.  Less well descrbied are the effects of 
polymorphisms in the UGT2B7 gene, with one report describing an increase in MPA exposure in 
patients with the UGT2B7 C802T variant. 3 Several limitations exist for these published 
pharmacogenomic reports.  The studies were comprised of mostly Caucasian and Asian 
populations and therefore generalizability to patients of other ethnic subpopulations receiving 
MPA may be limited.  Also, there is not always consistency in results between in vitro and in 
vivo approaches; reduced intrinsic clearance was noted in an in vitro evaluation of the effects of 
UGT1A8 *2 and *3 while in vivo studies showed a lack of effect by UGT1A8 variants on MPA 
disposition. 3,5,7  In addition to polymorphisms in drug metabolizing enzymes, it is know that 
polymorphisms in the ABCC2 gene which encodes the multidrug resistance-associated protein 
MRP2 can influence the disposition of MPA. 9,10  There are more limited data that suggest 
polymorphisms in the multidrug resistance transporter gene ABCB1 or MDR1 may also 
influence the disposition of MPA. 11,12  These studies support the need to evaluate SNP 
frequencies within the populations of specific glomerular diseases and within patient 
demographic subpopulations to understand the contribution of pharmacogenetics as opposed to 
effects of demographics or clinical covariates on variability in MPA pharmacokinetics.   
In this study, we investigated the ability of genomic, clinical, and demographic patient 
characteristics to predict the pharmacokinetic outcomes of MPA (bound and unbound) and its 
phenolic- and acyl- glucuronide metabolites (MPAG and AcMPAG) in patients with 
glomerulonephritis secondary to SLE and ANCA SVV using linear statistical models.  In order to 
expand on the existing knowledge for MPA and pharmacogenomics, we focused on the less 
well described influence of polymorphisms in UGT2B7, UGT1A7, and ABCB1 genes, but also 
sought to characterize the influences of UGT1A9 genes in glomerulonephritis.  We 
hypothesized that genetic variations in UGT2B7 and UGT1A7 and ABCB1 contribute to the 
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disposition of MPA and its glucuronidated metabolites.  We also explored the separate and 
combined contributions of the pharmacogenomic, disease-related, and demographic patient 
characteristics to the prediction of the disposition of total MPA, unbound MPA, and the 
glucuronide metabolites MPAG and AcMPAG.  
Methods 
Research Subjects  
Patients with biopsy confirmed SLE or ANCA SVV vasculitis with kidney manifestations and 
receiving maintenance therapy on a stable dose of MPA (Cellcept®, Roche, New Jersy) for at 
least two weeks were evaluated for enrollment.  These patients participated in a 24-hour MPA 
pharmacokinetics evaluation approved by the Biomedical Institutional Review Board and 
conducted in the inpatient clinical research center. Details of these studies and results from 
noncompartmental pharmacokinetics for MPA and AcMPAG were previously described. 13,14  
Briefly, blood samples were collected at times 0, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours and 
urine was collected from 0-6, 6-12, and 12-24 hours.  Plasma and urine samples were assayed 
for MPA and MPAG by a high-performance liquid chromatography (HPLC) with ultraviolet 
detection assay. 15  Plasma and urine standard curves for MPA were linear over the range of 
0.2-200 µg/mL and 1-50 µg/mL, respectively.  Plasma and urine standard curves for MPAG 
were linear over the range of 1-200 µg/mL and 5-1500 µg/mL, respectively.  The AcMPAG 
metabolite was assayed in plasma and urine by liquid chromatography/mass spectrometry 
(LC/MS).  Plasma and urine standard curves for AcMPAG were linear over the range of 0.01-50 
µg/mL and 1-500 µg/mL, respectively.   
Clinical data was abstracted from medical charts and included serum creatinine (SCr), 
estimated creatinine clearance (ClCr) by Cockcroft and Gault 16, urinary protein to creatinine 
ratio (UP:Cr), serum albumin, and steroid dose.  Abstracted demographic data included age, 
weight, race, and gender.    
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Genotyping Assessments 
A 5 mL whole blood sample was collected into an EDTA containing vacutainer and genomic 
DNA was isolated using a Flexigene Qiagen kit (Qiagen, Inc., Valencia, CA, USA).  Genotyping 
was conducted for several published UGT1A9, UGT1A7,  and UGT2B7 SNPs reported to result 
in alterations in MPA metabolism.(Table 5.1) 3-5,7,8   Additionally, ABCB1/MDR1 polymorphismss 
were evaluated secondary to published data suggesting a role of the P-glycoprotein transporter 
in MPA disposition. 11  (Table 5.1) Genotyping assessments for UGT1A7 T622C 
(c___287260_10, Applied Biosystems, Foster City, CA) and MDR1 C1236T (c___7586662_10, 
Applied Biosystems, Foster City, CA) were conducted using commercially available assays.  
Genotyping for UGT1A9 C98T, UGT1A9 T-275A, and MDR1 C3435T was conducted using 
custom assays manufactured by Applied Biosystems, Foster City, CA.  Allelic discrimination 
was assessed for all Applied Biosystems products using 5 µL of TaqMan Universal PCR Master 
Mix, No AmpErase UNG (2X) (Applied Biosystems), 0.25 µL (of 40X assay) or 0.5 µL (of 20X 
assay), 10 to 20 ng genomic DNA and a total reaction volume of 10 µL per the manufacturer’s 
instructions.  The reactions were cycled with an initial denaturation of 95oC for 10 minutes 
followed by 50 cycles of 92oC for 15 seconds, and then 60oC for 1.5 minutes on an Applied 
Biosystems 7900 Taqman PCR instrument.  Prior to conducting the allelic discrimination 
reactions, a subset of samples were sequenced using the primers noted in Table 5.2 in order 
that they could serve as positive controls for the former assays.  Genotyping for UGT1A9 G8A, 
UGT1A9 C-2152T, and UGT2B7 C802T was conducted by Polymorphic DNA Technologies, Inc 
(Alameda, CA).  All genotyping results were coded as 0 (wildtype/wildtype), 1 (heterozygote), or 
2 (variant/variant). 
Statistical Analysis Strategy and Methods  
Descriptive statistical methods were applied to the pharmacokinetic, demographic, clinical, 
and genotype data.  Graphical visualization of the data and summary tabulations of frequencies, 
means, standard deviations, and ranges were evaluated.  Each of the pharmacokinetic outcome 
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variables was transformed to natural log (ln scale) prior to use in the statistical computations.   
The observed genotype frequencies for each defined locus were used in a chi-square test 
procedure for testing of deviation from Hardy-Weinberg equilibrium. 
 Putative relationships between pharmacokinetic outcomes and patient characteristics were 
explored using descriptive methods (e.g., estimation of spearman correlation coefficients), linear 
models for natural log (ln) scale pharmacokinetic variables, hypothesis testing, and exploratory 
model-building methods (e.g., stepwise variable selection algorithms, all possible regressions, 
etc.)  For these analyses a set of pharmacokinetic outcome variables of interest for total MPA, 
unbound MPA, MPAG and AcMPAG was selected.   
 The clinical and demographic patient characteristics of interest included serum albumin, 
UP:Cr, eClCr, weight, age, race, gender, and glucocorticoid dose.  The genotypes of interest 
focused on allelic variation at each of the targeted SNP loci: UGT1A9 G8A, C98T, C-2152T, T-
275A, UGT2B7 C802T, UGT1A7 T622C, and ABCB1/MDR1 C1236T and C3435T. 
 Following descriptive graphical examinations of the relationships between the ln 
pharmacokinetic outcomes (lnPK) and the various patient characteristic variables, simple 
univariate models were fitted for each of the lnPK variables conditional on the selected clinical, 
demographic or genotype variable.  Univariate relationships with p values <0.05 were employed 
in building multivariate models.  Next, the combined set of genotype, clinical, and demographic 
variables was used to fit various multivariable linear models for the lnPK outcomes via the 
application of variable selection algorithms (e.g., stepwise selection, backward elimination, etc.)  
For each lnPK variable, a final model was selected based on considerations of the statistical 
significance of the candidate predictor variables and the overall model R2 .  
 Auxiliary analyses were also performed to evaluate the plausibility of assumptions made 
(e.g., analysis of residuals) and to evaluate the sensitivity of the results to reasonable 
perturbations of the methods used.  All statistical computations were performed using SAS 
System software (Version 9.1, SAS Institute, Inc., Cary, NC.) 
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Results     
 Noncompartmental pharmacokinetic data (for MPA, MPAG, and acyl-MPAG), demographic 
data, and clinical data were available for 27 SVV patients and 19 SLE patients. (Table 5.3) The 
racial distribution of these 46 patients was 59% Caucasian, 28% African-American, and 13% 
Other (Asian (n=3), Native American (n=2), not specified (n=1)).  Sixty-seven percent of study 
participants were female.  At the time of the pharmacokinetic analysis, these subjects exhibited 
a wide range of clinical laboratories:  eClCr (18.3 to 185 mL/min), UP:Cr (0.0 to 7.9), and serum 
albumin (26 to 52 g/L).  The frequency data for UGT and ABCB1/MDR1 genotypes in the 
evaluated SVV vasculitis and SLE nephritis patients are provided in Table 5.4.  All SNP 
frequencies were in Hardy-Weinberg equilibrium.  The frequencies for the UGT1A9 
polymorphisms were too low to be able to incorporate them into any planned univariate and 
multivariate model assessments.   
Analyses of univariate models for the lnPK outcomes were performed to evaluate the 
separate predictive value of genotype, clinical, and demographic patient characteristics.  The 
univariate models with p,0.05 are summarized in Table 5.5.  For those models evaluating only 
clinical and demographical factors, the fit (R2) ranged from ~0.10 to ~0.32.  Noteable 
contributors (R2 ~0.20 to 0.32) to MPA trough concentrations, exposure (AUC), and oral 
clearance were kidney function measures (Scr and eClcr).  The eClcr was positively related to 
unbound MPA oral clearance and negatively predictive for MPA AUC.  This appears consistent 
with the relationship between unbound drug and glomerular filtration rate on renal clearance, 
e.g. increased unbound drug, increased losses through renal clearance by filtration.  The small 
value for the coefficient mirrors the fact that usually only 3% of a MPA dose is eliminated by the 
kidneys. 17  Urinary protein and serum albumin were moderate contributors (R2~0.13) to MPA 
and metabolite disposition.  Demographic factors (age, race, weight) and glucocorticoid dose 
were less contributory (R2 ~0.10) to the disposition of MPA and MPAG.  However, age 
contributed ~20% toward the exposure (AUC 0-12 and AUC 6-12) of AcMPAG; e.g. increased age 
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led to increased exposure.  Genotype factors were generally less contributory (R2 0.09) to MPA 
disposition.  Genotypes for UGT1A7 (T622C) and UGT2B7 (C802T) appeared to be predictive 
of MPA oral clearance, exposure (AUC), and maximal plasma concentration.  The UGT2B7 
C802T heterozygote predicted increased renal clearance of MPA (R2 0.1974) and AcMPAG 
metabolite and decreased MPA AUC0-12 , AUC6-12, and increased oral clearance.  The 
homozygous variant genotype for UGT2B7 C802T was predictive of increased MPA AUC 6-12 
and decreased renal clearance of MPA (R2 0.0897).  The UGT1A7 heterozygote was predictive 
of increased MPA oral clearance and decreased maximal plasma concentration.  The 
homozygous variant for the UGT1A7 occurred in only one patient, so the contribution of this 
SNP on MPA disposition was not able to be assessed.  The ABCB1/MDR1 SNPs were not 
found to significantly predict lnPK variables in the univariate assessments. 
The clinical, demographic, and genotype variables from univariate models in Table 5.5 were 
assessed in multivariate models to predict the combined influence of these parameters on 
pharmacokinetics. (Table 5.6)  The goodness of fit of the models conditional on all variables 
(clinical, demographic, and genotype) was generally much better than the goodness of fit of the 
models conditional on clinical, demographic, or genotype variables alone.  For MPA, a higher 
UP:Cr and lower SCr appeared to be predictive for increased oral clearance.  One model 
incorporated weight as a significant variable in predicting oral clearance, improving the fit of the 
model R2 from 0.3526 to 0.4397.  A lower UP:Cr and higher SCr were predictive of increased  
AUC0-12 (R2 0.3622) and AUC 6-12 (R2 0.4931), which is consistent with the reciprocal 
relationship between oral clearance and AUC.  White race and higher SCr were both predictive 
of an increased MPA trough plasma concentration (R2 0.4244).  The multivariate model for renal 
clearance (R2 0.2763) incorporated both weight and UGT2B7 genotype.  This later model was 
the only multivariate assessment that incorporated a genotype variable.   
 The significant multivariate relationships observed for the MPAG metabolite included AUC 
and renal clearance.  Increased serum creatinine and Caucasian race were predictors for 
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increased AUC 0-12 (R2 0.2950) and AUC 6-12 (R2 0.3420).  Additionally, decreased Scr and 
female gender were predictors for increased renal clearance (R2 0.2636).  MPAG is primarily 
eliminated by the kidneys and clearance is inversely related to AUC, so it is predictable that Scr 
would influence both AUC and renal clearance. 
 Similar to MPAG, renal function (Scr or eClcr) were also important in predicting the AcMPAG 
AUC and renal clearance.  Increased AUC 0-12 was predicted by Caucasian race and decreasing 
eClCr (R2 0.4542), while AUC 6-12 was predicted by increased age and Scr (R2 0.4092).  Both 
decreased serum albumin and Scr were predictive for increased AcMPAG renal clearance (R2 
0.4239).   
Discussion 
 In this study, we sought to characterize the roles of clinical and demographic factors in 
glomerulonephrits, as well as genomic alterations in selected UGTs (1A9, 1A7, and 2B7) and 
ABCB1/MDR1 on the pharmacokinetics of MPA and its glucuronide metabolites MPAG and 
AcMPAG using linear models.  This research was conducted since MPA is often used in an off-
label indication for the treatment of autoimmune-mediated glomerulonephritis.  When drugs are 
used off-label in patient populations that are different than where the drug was originally 
approved, there is a potential for pharmacokinetic alterations that may require dosing changes 
to enable an appropriate exposure (AUC) that optimizes outcomes and minimizes adverse 
effects.  This is particularly relevant for glomerulonephritis where unlike kidney transplant 
patients with primarily decreases in GFR, glomerulonephritis patients can have reductions in 
GFR in addition to decreases in serum albumin and increases in urinary protein excretion.  
Previous reports by our research team suggested altered MPA oral clearance in patients with 
lupus nephritis and ANCA-associated vasculitis 13,14, as opposed to what was previously 
reported for kidney transplant recipients 17,18.  In smaller patient populations employing less 
sophisticated statistical analyses, we found that nonwhite race 14 (for SVV patients), and 
decreased serum albumin 13 (for SLE nephritis patients) favored increases in oral clearance.  
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However, we also reported an overall reduction in the metabolic capacity (e.g. metabolic ratio; 
MPAG AUC/MPA AUC) in the glomerulonephritis patients 13,14 as compared to kidney transplant 
recipients.  Our current study of an expanded population of glomerulonephritis patients found 
relevant alterations in MPA pharmacokinetics influenced by clinical covariates and 
pharmacogenomic factors.  This study is novel as it describes these former interactions in a 
glomerulonephritis population and seeks to elucidate the relative contribution of each factor on 
pharmacokinetics.  Additionally, this study evaluated the influence on MPA pharmacokinetics by 
less well described polymorphisms in UGT2B7, UGT1A7 and ABCB1/MDR1.  The resultant 
multivariable models explained 30 to 50% of MPA’s pharmacokinetic outcomes.  Genomic 
factors alone explain about 10% of MPA’s pharmacokinetic outcomes. 
 Our current cohort of 46 patients with glomerulonephritis represented a spectrum of 
laboratory abnormalities that would be typical in patients with these disorders, i.e. some patients 
with mild disease and others with moderate to severe manifestations.  The study population was 
hence broad enough in the clinical manifestations of the glomerular disease to be able to make 
inferences about the effects of the disease parameters on the pharmacokinetics of MPA and its 
glucuronide metabolites.  Our regression results (Tables 5.5 and 5.6) suggested a primary 
importance of kidney function, through either SCr or eClcr, on the prediction of most 
pharmacokinetic parameters for MPA and its metabolites.  This finding is important as it reminds 
clinicians to be mindful of the effects of kidney disease on the disposition of drugs such as MPA, 
that are not readily eliminated unchanged by the kidneys.  It is consistent with suggestions by 
others 19, that drug metabolism and transport derangements, among other unknown effects, 
occur in kidney disease and these effects can alter the pharmacokinetics of drugs.  In addition 
to kidney function, UP:Cr also contributed toward the prediction of MPA and metabolites 
pharmacokinetics.  An elevated UP:Cr predicted reduced exposures (AUCs) and increased oral 
clearance for MPA.  Two previous publications by our group also highlights the need to be 
cognizant of the effects of UP:Cr and/or serum albumin on the pharmacokinetics of highly bound 
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drugs, particularly when assessing total drug concentrations. 13,20  According to multivariate 
regression data from the present study, a UP:Cr increase from 0.5 to 3.5 at a stable SCr of 2 
mg/dL (176.8 moles/L) would result in a MPA AUC0-12 decrease of 25 units (from 76 µg h/mL to 
51 µg h/mL).  Similarly, at a stable UP:Cr of 0.5, an increase in SCr from 2 mg/dL to 5 mg/dL 
(176.8 moles/L to 442 moles/L) would result in a tripling of the AUC0-12 (from 76 µg h/mL to 228 
µg h/mL).   
The glomerulonephritis study population reported here included mostly Caucasian and 
African-American patients (59% and 28%, respectively), but relatively few patients of other 
races to enable ascertainment of a multitude of race-related effects on MPA disposition.  
Caucasian race was predictive of higher MPA trough concentrations, and higher exposures 
(AUC) to the metabolites MPAG and AcMPAG.  Our results contrast with data from the kidney 
transplant literature that have not reported associations between race and MPA disposition. 21,22  
Our multivariate regression results show that at a stable SCr of 2 mg/dL (176.8 moles/L), 
Caucasian patients have a 2-fold higher Ctr concentration than non-Caucasians.  Within 
Caucasian patients, a doubling of SCr would result in an 8-fold increase in Ctr concentration. 
Females were adequately represented in our study (67%) but have historically been under-
represented in biomedical research.  Our results suggest that female gender may predict a 
higher renal clearance of the MPAG metabolite.  Since SCr was also contributory to increased 
renal clearance in the linear regression model, our data suggests that either there exists an 
added effect of female gender above the effect of decreased SCr on MPAG renal clearance 
and/or there is an interaction between decreased SCr and female gender.  Since it is generally 
assumed that females have a lower SCr value for level of kidney function as compared to 
males, the later explanation may be warranted.  However, the MPAG metabolite is a known 
substrate for the multidrug resistance associated proteins (MRPs)23 and this transporter is 
located in the kidney tubules.  Previous animal data (rats) suggest increased liver expression 
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and increased activity of MRP2 in females as compared to males 24,25 , and this differential 
activity of MRP2 may also explain the gender-related influence on renal clearance of MPAG.   
Four SNPs in three genes were evaluated in the glomerulonephritis patients to assess their 
role in the disposition of MPA and its metabolites.  The specific SNPs were selected based on 
their hypothesized, yet limited in vivo data on the influences on human MPA pharmacokinetics. 
3,4,26
  The UGT2B7 C802T has been purported to result in increases of 25% in total AUC and 
48% in unbound AUC for MPA, as well as increases in maximal plasma concentrations and 
urinary AcMPAG. 3,4,26  Our univariate models employing only genotype showed increased 
recycling (AUC6-12) and decreased renal clearance for MPA in the variant homozygous group.  
Increased oral clearance, decreased AUC 0-12 and AUC 6-12, and increased renal clearance was 
demonstrated in patients exhibiting heterozygosity for UGT2B7 C802T.  Increased AcMPAG 
renal clearance was also demonstrated in the UGT2B7 heterozygous group.  The finding of a 
decrease in MPA AUC0-12 in the heterozygous group cannot currently be explained, but may be 
due to the intermediate effect of this genotype and its greater frequency as compared to the 
homozygous variant.  In the multivariable models, UGT2B7 heterozygosity was the only genetic 
factor remaining, where it predicted increased MPA renal clearance.  A recent study has 
described the expression of UGT2B7 in the kidney, 27 suggesting a greater contribution of the 
metabolic enzyme toward renal clearance of MPA through its metabolites.  Regarding the 
UGT1A7 T622C SNP, a previous study in Japanese patients failed to detect any MPA 
pharmacokinetic alterations. 6  In our univariate assessments analyzing only genotype variables, 
genotypes heterozygosity for the UGT1A7 variant contributed toward increased oral clearance 
and decreased maximal plasma concentration values.  While there are currently no human 
studies demonstrating effects of ABCB1/MDR1 polymorphism on MPA pharmacokinetics, an 
animal study in ABCB1/MDR1 deficient mice suggests the possibility of increased MPAG 
concentration when the activity of this protein is low 11, suggesting decreased export function 
resulting in decreased clearance.  We failed to detect any effects of ABCB1/MDR1 C1236T and 
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C3435T on altering systemic pharmacokinetics of MPA, suggesting a minimal to absent role of 
this transporter on MPA pharmacokinetics.   
 Although the current study’s findings demonstrated moderate effects of clinical and 
demographic variables and minimal effects of UGT1A7 and UGT2B7 genotypes on explaining 
the disposition of MPA and its metabolites, the overall effects of these former genotypes should 
not be discounted secondary to limitations in the study.  The main limitation surrounds the 
limited number of patients who contributed to the homozygous variant genotype groups.  
Employing a larger population of patients, perhaps by attempting to select study patients based 
on specific genotypes may have enhanced the evaluation of the effects of various genotypes on 
MPA pharmacokinetics.  Regarding UGT1A7 T622C, only one patient was classified as a 
homozygous variant, limiting our ability to fully evaluate the potential impact of this genotype on 
MPA pharmacokinetics.  Our assessments surrounding the UGT1A7 SNP encompassed the 
homozygous wildtypes and heterozygotes.  Since heterozygotes in drug metabolizing gene 
SNPs often have less alteration in function than homozygous variants, the differences between 
pharmacokinetic variables between these groups may be more difficult to detect in smaller 
studies.  The numbers were somewhat less limited for UGT2B7 genotype assessments where a 
total of 10 patients were included in the homozygous variant group.  Similarly, the 
ABCB1/MDR1 homozygous variants at nucleotide base positions 1236 and 3435 were 
represented by only 4 and 5 patients, respectively, also limiting the ability to evaluate the full 
role of this covariate on MPA pharmacokinetics.  We did not evaluate the influence of genetic 
variations in additional efflux transporters such as ABCC2 since previous studies have 
evaluated for alterations in MPA disposition.  While the patients in this study represented a fairly 
broad range of laboratory values for UP:Cr and serum albumin, they were primarily 
representative of patients with mild to moderate forms of glomerulonephritis.  It is conceivable 
that more acute and/or severe forms of glomerulonephritis may have additional alterations in 
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MPA disposition.  Lastly, as we assessed numerous pharmacokinetic variables in our patients, 
larger studies will be needed to validate the most relevant clinical findings of the current study.   
Conclusions 
The results from this study demonstrated the potential importance of factoring in clinical and 
demographic variables when assessing the disposition of drugs such as MPA in patients with 
glomerulonephritis.  In this glomerulonephritis cohort, the predictive value of clinical and 
demographic covariates, especially kidney function (eClcr and Scr), urinary protein:creatinine 
ratio, serum albumin, and race were more profound than that of the UGT1A7, UGT2B7, and 
ABCB1/MDR1 genotypes on MPA pharmacokinetics.   The former covariates explained 2- to 4- 
times more of the variability in MPA pharmacokinetic variables than did the genotype covariates.  
Our data suggests the need for further research and larger pharmacogenomic studies in 
glomerulonephritis to adequately assess the contributions of genetic- and disease- related 
perturbations on MPA metabolism and transport.    
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Table 5.1 
Single Nucleotide Polymorphisms (SNPs)  
Gene   Location   Sequence with SNP denoted 
 
UGT1A9  G8A    GTTCTCTGATGGCTT[G/A]CACAGGGTGGACCAG 
UGT1A9  C98T    TAGTGCCCA[C/T]GGATGGGAG 
UGT1A9   T-275A    TTAATAATTCTGCT[T/A]CTAAACTTAACATTGCAG 
UGT1A9  C-2152T   CGCTTCCCGGGTT[C/T]AAGTGATTCTCCTGCC 
UGT2B7  C802T    GGAATTTTCAGTTTCCT[C/T]ATCCACTCTTACCAAAT 
UGT1A7   T622C    AGAGAGTA[T/C]GGAACCAC 
ABCB1/MDR1  C1236T   GATCTTGAAGGG[C/T]CTGAACCTGAAGGTGCAG 
ABCB1/MDR1  C3435T   GTCACAGGAAGAGAT[C/T]GTGAGGGCAGCAAA 
 
Abbreviations 
MDR – multidrug resistance  
UGT – uridine diphosphate glucuronosyltransferase  
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Table 5.2   
Sequencing and PCR Primers 
Primer Pair  Location    Sequence (5’-3’)   
1   UGT1A9 G8A and C98T   F – CCTGCTCTCAGCTGCAGTTCTCT 
        R – CTTCACTGTGCAATTCAGTGATCTT 
2   UGT1A9 C-2152T   F – GTAGGTCTTTTACATTTCC 
        R – CCTGAAACAGCAAAACCAA 
3   UGT1A9 T-275A   F – TTGCTTAGAGTATGAGTTGCCATCTT 
        R – TTTGTATGTTTTCCAGACAACAGTAGC 
4   UGT2B7 C802T   F – GTAAATATCTGTGTCATC 
        R – GACTATAGAATCATTTCTACTG 
5   UGT1A7 T622C   F – GTGCCCTGCTCCTCTTTCCTAT 
        R – ACGGGTTTGGGATACTCCAAA 
6   ABCB1/MDR1 C1236T   F – GAAGAGTGGGCACAAACCAGATA 
        R – CATCCCCTCTGTGGGGTCATA 
7   ABCB1/MDR1 C3435T   F – GAGCCCATCCTGTTTGACTG 
        R – GCATGTATGTTGGCCTCCTT 
Abbreviations 
MDR – multidrug resistance 
UGT – uridine diphosphate glucuronosyltransferase
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Table 5.3 
Demographics, Clinical and Pharmacokinetic Data (Mean ± standard deviation) 
Data represents 27 small vessel vasculitis and 19 lupus nephritis prospective patients (total n = 46) 
Data provided as mean (sd); range 
Age (years)   46.0 (15.0); 22-78 
Race (W/B/O)   27/13/6 
Gender (M/F)   15/31 
Weight (kg)   85.1 (19.7); 47-124 
eClCr (mL/min)   93.4 (46.3); 18-185 
UP:Cr     0.76 (1.48); 0-7.9 
Serum Albumin (g/L)  40.9 (50.2); 26-52 
Pharmacokinetics  MPA total  MPA free MPAG   AcMPAG 
    (n = 46)   (n = 46)  (n = 46)   (n = 41) 
Cmax (µg/mL)   20.9 (17.9)  0.30 (0.39) 63.9 (50.2)  0.91 (1.08) 
Tmax (h)    1.46 (1.48)  N/A  3.02 (2.54)  1.68 (1.65) 
Ctr (µg/mL)   4.11 (4.46)  0.07 (0.11) 31.7 (27.8)  0.28 (0.63) 
AUC 0-12 (µg h/mL)  66.3 (43.8)  1.07 (1.57) 498 (433)  3.88 (4.80) 
Cl/F (mL/min)   305 (173)  31.7 (28.6)a N/A   N/A 
AUC 6-12 (µg h/mL)  24.1 (19.9)  N/A  214 (191)  1.53 (2.12) 
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ClR/F (mL/min)   3.74 (4.70)  N/A  46.5 (45.9)  45.9 (53.4) 
Free fraction (%)  1.63 (1.49)  N/A  12.3 (6.74)  N/A 
T ½ (h)    14.5 (18.7)  N/A  16.9 (26.1)  10.4 (8.26) 
AUC 6-12/AUC 0-12 %  35.4 (12.2)  N/A  39.7 (41.9)  0.37 (0.14) 
a – L/min    
Abbreviations 
AcMPAG – acyl MPAG 
AUC 0-12 – area under the plasma concentration time curve from 0-12 hours 
AUC 6-12 – area under the plasma concentration time curve from 6-12 hours 
AUC 6-12/AUC 0-12 – fraction of AUC due to enterohepatic recycling 
Cl/F – oral clearance 
ClR/F – renal clearance 
Cmax – maximum concentration in plasma after a dose 
Ctr – minimum concentration in plasma after a dose 
eClcr – estimated creatinine clearance 
MPA – mycophenolic acid 
MPAG – mycophenolic acid glucuronide 
N/A – not applicable 
Tmax – time to maximum plasma concentration 
T1/2 – half life
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Table 5.4 
Genotype Frequency Distributions (frequency (n)) 
      Small Vessel Vasculitis  Lupus Nephritis  
      n = 27    n = 19   
UGT1A9 
 G8A  G/G   1.0 (28)    1.0 (19)  
   G/A   0 (0)    0 (0)   
   A/G   0 (0)    0 (0)   
 C98T  C/C   0.96 (27)   1.0 (19)  
   C/T   0.04 (1)    0 (0)   
   T/T   0 (0)    0 (0)   
 C-2152T C/C   0.96 (27)   1.0 (19)  
   C/T   0.04 (1)    0 (0)   
   T/T   0 (0)    0 (0)   
 T-275A  T/T   0.96 (27)   1.0 (19)  
   T/A   0.04 (1)    0 (0)   
   A/A   0 (0)    0 (0)   
UGT1A7   
 T622C  T/T   0.48 (13)   0.47 (9)  
   T/C   0.52 (14)   0.47 (9)  
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   C/C   0 (0)    0.06 (1)  
UGT2B7 
 C802T  C/C   0.30 (8)    0.47 (9)  
   C/T   0.44 (12)   0.37 (7)  
   T/T   0.26 (7)    0.16 (3)  
ABCB1/MDR1 
 C1236T C/C   0.36 (10)   0.53 (10)  
   C/T   0.50 (14)   0.47 (9)  
   T/T   0.14 (4)    0 (0)   
 C3425T C/C   0.32 (9)    0.37 (7)  
   C/T   0.54 (15)   0.58 (11)  
   T/T   0.14 (4)    0.05 (1)  
 
Abbreviations 
ANCA – anti-neutrophil cytoplasmic antibody 
MDR – multidrug resistance 
UGT – uridine diphosphate glucuronosyltransferase 
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Table 5.5 
Final Univariate Models for the Separate Effects of Clinical, Demographic, and Genotype Parameters on the Prediction of 
Pharmacokinetic Outcomes 
Dependent Variable * Independent Variable Coefficient  Model P  Model R2 
Clinical and Demographic Factors 
Mycophenolic Acid 
Cmax     Albumin    0.4902  0.0280   0.1051 
    Steroid Dose   0.0485  0.0261   0.1151 
Ctr    Age    0.0191  0.0193   0.1182 
    Race    0.4924  0.0478   0.0861 
    Albumin   0.4940  0.0384   0.0939 
    UP:Cr    -0.2128 0.0099   0.1416 
    Scr    0.6891  <0.0001  0.3218 
    eClcr    -0.0098 0.0004   0.2527 
AUC 0-12   SCr    0.4261  0.0004   0.2490 
    Age    0.0114  0.0494   0.0850 
    Albumin   0.3690  0.0272   0.1060 
    eClcr    -0.0066 0.0006   0.2372 
    UP:Cr    -0.1558 0.0070   0.1537 
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AUC 6-12   UP:Cr    -0.2292 0.0010   0.2219 
    SCr    0.5980  <0.0001  0.3271 
    eClcr    -0.0078 0.0010   0.2193 
Cl/F    Age    -0.0127 0.0305   0.1020 
    Albumin   -0.3733 0.0287   0.1041 
    UP:Cr    0.1595  0.0069   0.1546 
    SCr    -0.4250 0.0006   0.2377 
    eClcr    0.0072  0.0003   0.2642 
    Weight    0.0075  0.0989   0.0607 
ClR/F    Weight    0.0221  0.0225   0.1152 
Cl unb     eClcr     0.0071  0.0326   0.1066 
AUC unb    eClcr    -0.0068 0.0397   0.0991 
Ctrunb     Scr     0.5738  0.0156   0.1343 
    eClcr    -0.0086 0.0276   0.1129 
Mycophenolic Acid Glucuronide 
AUC 0-12   Age    0.0183  0.0325   0.0998 
    Caucasian   0.6100  0.0175   0.1216 
    UP:Cr    -0.1779 0.0415   0.0911 
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    SCr    0.5059  0.0059   0.1596 
AUC 6-12   Age    0.0181  0.0396   0.0928 
    Caucasian   0.6143  0.0200   0.1169 
    UP:Cr    -0.1834 0.0407   0.0918 
    SCr    0.5960  0.0014   0.2100 
    eClcr    -0.0077 0.0108   0.1386 
ClR/F    Age    -0.0204 0.0402   0.0943 
    SCr    -0.6148 0.0030   0.1869 
    eClcr    0.0084  0.0181   0.1232 
    Female   0.6003  0.0518   0.0851 
Acyl-Mycophenolic Acid Glucuronide 
AUC 0-12   Age    0.0437  0.0009   0.2497 
    Caucasian   0.9104  0.0311   0.1137 
    Albumin   1.0663  0.0093   0.1611 
    UP:Cr    -0.2927 0.0311   0.1137 
    eClcr    -0.0182 <0.0001  0.3487 
AUC 6-12   Age    0.0298  0.0067   0.1780 
    UP:Cr    -0.2361 0.0282   0.1205 
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    Scr    0.9490  <0.0001  0.3375 
    eClcr    -0.0160 <0.0001  0.4347 
ClR/F    Age    -0.0320 0.0159   0.1473 
    Albumin   -1.0760 0.0054   0.1913 
    eClcr    0.0130  0.0045   0.1981 
Genotype Factors 
Mycophenolic Acid 
Cl/F     UGT1A7 heterozygote 0.3508  0.0462   .0877 
    UGT2B7 heterozygote 0.3778  0.0355   0.0966 
AUC 0-12    UGT2B7 heterozygote -0.3702 0.0354   0.0967 
AUC 6-12    UGT2B7 heterozygote -0.4844 0.0240    0.1105 
    UGT2B7 variant/variant 0.5968  0.0185   0.1198 
Cmax     UGT1A7 heterozygote -0.4647 0.0432   0.0897 
ClR/F    UGT2B7 heterozygote 1.1748  0.0022   0.1974 
    UGT2B7 variant/variant -0.9237 0.0456   0.0897 
Acyl-Mycophenolic Acid Glucuronide 
ClR/F    UGT2B7 heterozygote 0.8323  0.0408   0.1083 
• The natural logarithmic transformation was used for all dependent variables except for acyl MPAG MR.   
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Abbreviations 
AUC 0-12 – area under the plasma concentration time curve from 0-12 hours 
AUC 6-12 – area under the plasma concentration time curve from 6-12 hours 
AUCunb – unbound area under the plasma concentration time curve from 0-12 hours 
eClcr – estimated creatinine clearance 
Cl/F – oral clearance 
Clunb – unbound oral clearance 
ClR/F – renal clearance 
Cmaxunb – unbound maximum concentration in plasma after a dose 
Cmax – maximum concentration in plasma after a dose 
Ctr – minimum concentration in plasma after a dose 
Ctrunb – unbound minimum concentration in plasma after a dose 
Scr – serum creatinine 
UGT – Uridine diphosphate glucuronosyltransferase 
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Table 5.6 
Final Multivariable Linear Models of the Combined Effects of Genotype, Clinical, and Demographic Parameters on 
Pharmacokinetics 
Dependent Parameters*  Independent Parameters (p value) Coefficient  Model P value  Model R2 
Mycophenolic Acid 
Ctr     Caucasian Race (0.008)  0.5384   <0.0001  0.4244 
     Scr (<0.0001)    0.7074 
AUC 0-12    UP:Cr (0.008)    -0.1346  <0.0001  0.3622 
     Scr (0.0005)    0.3925    
AUC 6-12    UP:Cr (0.0005)   -0.1996  <0.0001  0.4931 
     Scr (<0.0001)    0.5482 
Cl/F (1)    UP:Cr (0.0084)   0.1384   <0.0001  0.3526 
     Scr (0.0008)    -0.3905 
Cl/F (2)    Weight (0.0143)   0.0090   <0.0001  0.4397 
     UP:Cr (0.0053)   0.1387    
     Scr (0.0002)    -0.4153 
ClR/F     Weight  (0.0382)   0.0185   0.0011   0.2763 
     UGT2B7 Het (0.0039)  1.0715 
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Mycophenolic Acid Glucuronide 
AUC 0-12    Caucasian Race (0.0063)  0.6443   0.0005   0.2950 
     SCr (0.0022)    0.5280   
AUC 6-12    Caucasian Race (0.0052)  0.6544   0.0001   0.3420 
     SCr (0.0004)    0.6182 
ClR/F     Female gender (0.0425)  0.5703   0.0016   0.2636 
     SCr (0.0027)    -0.6012   
Acyl-Mycophenolic Acid Glucuronide 
AUC 0-12    Caucasian Race (0.0100)  0.8772   <0.0001  0.4542 
     eClCr (<0.0001)   -0.0182  
AUC6-12    Age (0.0408)    0.0197   <0.0001  0.4092 
     SCr (0.0005)    0.8193   
ClR/F     Albumin (0.0030)   -0.9947  <0.0001  0.4239 
     SCr (<0.0005)    -0.09506 
 
* The natural logarithmic transformation was used for all dependent variables except AcylMPAG AUC0-12 .  Box-Cox transformation was used for 
AcylMPAG AUC0-12 (lambda=0.2). 
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Abbreviations 
AUC 0-12 – area under the plasma concentration time curve from 0-12 hours 
AUC 6-12 – area under the plasma concentration time curve from 6-12 hours 
AUCunb – unbound area under the plasma concentration time curve from 0-12 hours 
eClcr – estimated creatinine clearance 
Cl/F – oral clearance 
Clunb – unbound oral clearance 
ClR/F – renal clearance 
Cmaxunb – unbound maximum concentration in plasma after a dose 
Cmax – maximum concentration in plasma after a dose 
Ctr – minimum concentration in plasma after a dose 
Ctrunb – unbound minimum concentration in plasma after a dose 
Scr – serum creatinine 
UGT – Uridine diphosphate glucuronosyltransferase
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Introduction 
The mRNA expression patterns of drug metabolizing enzymes and transporters in peripheral 
blood cells (neutrophils, lymphocytes, and monocytes) may be important in patient responses to 
treatments for glomerulonephritis since the target of the pharmacological agents (e.g. 
mycophenolic acid and cyclophosphamide) are the lymphocytes (B and T lymphocytes).  For 
mycophenolic acid, the active therapeutic component is transformed to inactive glucuronide 
metabolites after administration.  The pharmacologically active 4-hydroxycyclophosphamide 
metabolite of the prodrug cyclophosphamide is first formed by phase I metabolism through 
cytochrome P450 enzymes and further converted to the phosphoramide mustard.  As exposure 
of the lymphocytes to the active species of a medication is critical for pharmacological effects, 
the balance and direction between exposure to parent drug versus metabolite is necessary to 
enhance efficacy and reduce toxicity.   
Alterations in expression of drug metabolizing enzymes or transporters in lymphocytes could 
affect the exposure of these cells to pharmacologically active components such as 
mycophenolic acid and 4-hydroxycyclophosphamide.  Regarding drug transport, enhanced 
activity and/or expression of cellular efflux genes and their respective proteins relative to uptake 
would be predicted to reduce the intracellular concentration of therapeutic entities, assuming 
active processes guide exposure.  Decreased activity and/or expression of export genes relative 
to uptake would be expected to increase intracellular drug concentrations.  For metabolism, 
expression of drug metabolizing enzymes within the lymphocyte may modulate the exposure of 
the tissue to active (4-hydroxycyclophosphamide) versus inactive (mycophenolic acid 
glucuronide) pharmacologic moieties.  While studies have described the presence or absence of 
uridine diphosphate glucuronosyltransferase (UGT) mRNA in various solid organs (liver, kidney, 
intestine, lung, stomach, brain, breast, prostate, heart, adrenals, bladder, ovary, uterus, and 
testis) within rats and humans 1-4 , the peripheral blood cells have been largely ignored for drug 
metabolism genes and limited studies have reported mRNA expression of selected 
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transporters.5,6  Furthermore, there is currently limited information regarding expression of drug 
transporter genes or drug metabolizing genes in patients representing specific disease models 
or in selected tissues that are important as the targeted pharmacological site of action.   
 Several exogenous and endogenous factors may be responsible for altering mRNA 
expression and subsequent exposure to therapeutic agents at their active site.  Inducers of 
transport and metabolism have been shown to concordantly increase activity and mRNA 
expression within hepatocytes. 7  mRNA expression of drug transporters has been reported to 
be affected by inflammatory condictions (e.g. rheumatoid arthritis, ulcerative colitis, ischemia-
reperfusion injury) and upon direct exposure to inflammatory cytokines (e.g. TNF-α, IL-6). 8-11 
Gender specific effects on UGT mRNA expression in tissues (liver, kidney, lung, intestine, brain, 
nose) have been documented in mice. 12,13  A genotype dependent down-regulation of mRNA 
expression and protein function has also been reported, 14 whereby wild-type and heterozygotes 
for the C3435T single nucleotide polymorphism in the multidrug resistance protein gene 
(ABCB1; MDR1) exhibited less relative mRNA expression in peripheral blood mononuclear cells 
as compared to the homozygous variant genotype. 14  This scenario would imply that the 
intracellular concentration of active therapeutic agent would be enhanced in patients without the 
variant/variant genotype. 
The purpose of the current study was two-fold; 1) to evaluate mRNA expression patterns of 
drug metabolizing enzyme genes (UGT1A7, UGT1A9, UGT2B7, CYP2C9, CYP2B6, CYP3A4) 
and transporter genes (ABCB1, ABCC2, ABCG2, and SLCO1A2) in leukocytes of patients with 
glomerulonephritis secondary to systemic lupus erythematosus (SLE) or small vessel vasculitis 
(SVV), and 2) to evaluate the relationships between mRNA expression and patient-level data 
(including common genotypes for drug metabolizing enzymes and transporters) to understand 
the effects of metabolic processing and transport of cyclophosphamide and mycophenolic acid.   
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Methods 
Specimens 
Patients with glomerulonephritis secondary to SLE (n=36) and SVV (n=35) who participated 
in prospective pharmacokinetic studies to evaluate oral mycophenolic acid 15,16 and intravenous 
cyclophosphamide 17 had 15mL blood drawn into multiple ethylenediaminetetraacetic acid 
(EDTA) vacutainer tubes.  Leukocytes were isolated from blood by incubation (11 minutes) in a 
hypotonic red cell lysis buffer, followed by centrifugation and a wash with Hank’s balanced salt 
solution (HBSS).  The leukocytes were subsequently lysed in RNA Stat 60 solution and stored 
at -70C for up to 2 weeks until processing.   
mRNA Isolation 
The mRNA isolation procedure consisted of adding 200µL chloroform for phase separation.  
The aqueous phase (containing the mRNA) was added to a solution of isopropanol and 
centrifuged.  The pellet was then washed with 1mL 75% ethanol, re-suspended in 100µL 
nuclease free water (Promega, Madison, WI), and centrifuged.  Four microliters RNA secure 
25X (Ambion, Austin, TX) was added to each sample.  The RNeasy kit and protocol (Qiagen, 
Valencia, CA) was used for the remainder of the mRNA preparation.  Briefly, after adding Buffer 
RLT, β-Mercaptoethanol, and 100% ethanol to the samples, the mRNA solution was applied to 
an RNeasy mini spin column for purification.  mRNA was re-treated with RNA secure at 1X 
(Ambion, Austin, TX) after the column elution.  mRNA was quantified by evaluation of the 
absorbance at 260 nm and 280 nm using a spectrophotometer.  The mRNA integrity was 
determined by visualization of the 28S and 18S mRNA bands using 0.5 µg mRNA on a 1% 
agarose gel stained with Sybr Gold (Molecular Probes, Eugene, OR).  mRNA was stored at -
70C. 
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Evaluation of Transcript Levels 
An aliquot of each patient’s mRNA was converted to cDNA via the High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, Foster City, CA). A 20µL reaction was prepared 
that included; 2µL of 10x RT Buffer; 0.8µL of 25x dNTP Mix (100mM); 2µL of 10x RT Random 
Primers; 1µL of MultiScribe Reverse Transcriptase; 4.2µL of Nuclease-free water and 10µL of 
mRNA.  The plate was placed in a thermal cycler under the profile; 25°C for 10 minute, 37°C for 
120 minutes, 85°C for 5minutes, and 4°C for infinity .   
Pre-designed assays containing primers and probes were purchased from Applied 
Biosystems (Foster City, CA) for assessment of transcript levels of the targeted metabolizing 
enzymes (UGT1A7, UGT1A9, UGT2B7, CYP3A4, CYP2C9, and CYP2B6) and transporters 
(ABCB1, ABCC2, ABCG2, and SLCO1A2); UGT1A7 (Hs02517015_s1), UGT2B7 
(Hs02556232_s1), UGT1A9 (Hs02516855_sH), CYP3A4 (Hs00604506_M1), CYP2C9 
(Hs00426397_m1), CYP2B6 (Hs00167937_g1), ABCC2 (Hs00166123_m1), ABCB1 
(Hs00184500_m1), ABCG2 (Hs01053795_m1), and SLCO1A2 (Hs01072338_m1).  
Cytochrome C oxidase was used as the normalization (housekeeping) gene.  The forward and 
reverse primers were designed using Primer Express software (Applied Biosystems, Foster 
City, CA).  The forward primer (TGGCATCTGGAGGTGGTGTT) and reverse primer 
(GTCCAGTCCCTTTGCAGC) were purchased from Applied Biosystems (Foster City, CA).  Sybr 
1:400 was used as the probe in the cytochrome c oxidase assay (Molecular Probes, Leiden, 
Netherlands).   
Taqman® PCR was performed on an Applied Biosystems PRISM 7900 HT sequence 
detection system (Applied Biosystems,Foster City, CA). The duplicate 10µL reactions were 
performed in MicroAmp Optical 384 well plates.  For the commercial assays, the reaction 
mixture was composed of 40ng (4µL) of cDNA; 0.5µL of 20x probe and primer (Applied 
Biosystems, Foster City, CA), 0.5µL nuclease-free water, and 5µL of 2x Universal PCR Master 
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Mix (Applied Biosystems, Foster City, CA).  For the cytochrome C oxidase assay, the reaction 
mixture was composed of 40ng (4µL) of cDNA; 0.1µL of 5uM forward primer; 0.1µL of 5µM 
reverse primer; 0.3µL of 1:400 dilution Sybr Green (Molecular Probes, Leiden Netherlands); 
0.5µL nuclease-free water, 5µl of 2x Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA).  The thermal cycling conditions were; 50°C for 2 minutes, 95°C for 10minutes, 95°C 
for 15 seconds in 50 cycles, 60°C for 1hour.  
Genotype Assessments 
A 5 mL whole blood sample was collected into an EDTA containing vacutainer tube and 
genomic DNA was isolated using a Flexigene Qiagen kit (Qiagen, Inc., Valencia, CA, USA).  
Genotyping was conducted for several published UGT single nucleotide polymorphisms 
(UGT1A9, UGT1A7, and UGT2B7) relevant for alterations in metabolism, 18-22 and 
ABCB1/MDR1 relevant for transport of mycophenolic acid 23  . Genotyping was also conducted 
for polymorphisms in some cytochrome P450 genes (CYP2B6, CYP3A4, CYP2C9) relevant for 
alterations in cyclophosphamide metabolism. 24-26  Genotyping assessments for UGT1A7 T622C 
(c287260-10), ABCB1 C1236T (c7586662-10), CYP2B6 C1459T(c30634242), and CYP2B6 
G516T (c22275631) were conducted using commercially available assays (Applied Biosystems, 
Foster City, CA).  Genotyping for UGT1A9 C98T, UGT1A9 T-275A, CYP2B6 A785G and 
ABCB1 C3435T was conducted using custom assays manufactured by Applied Biosystems, 
Foster City, CA.  Genotyping for UGT1A9 G8A, UGT1A9 C-2152T, and UGT2B7 C802T was 
conducted by Polymorphic DNA Technologies, Inc (Alameda, CA).   
Allelic discrimination was assessed for all Applied Biosystems products using 5 µL of 
TaqMan Universal PCR Master Mix, No AmpErase UNG (2X) (Applied Biosystems), 0.25 µL (of 
40X assay) or 0.5 µL (of 20X assay), 1 to 20 ng genomic DNA and a total reaction volume of 10 
µL per the manufacturer’s instructions.  The reactions were cycled with an initial denaturation of 
95oC for 10 min followed by 50 cycles of 92oC for 15 sec, and then 60oC for 1.5 minutes on an 
 153 
Applied Biosystems 7900 Taqman PCR instrument.  Genotypes for polymorphisms in ABCC2, 
ABCG2 and SLCO1A2 were not assessed. 
Data Analyses 
Stored mRNA from healthy controls; HC (n=10), untreated SLE nephritis patients; LC (n=5) 
and untreated SVV with nephritis; VC (n=5) patients were used as study and disease controls, 
respectively.  The Ct values (the fractional cycle at which the fluorescence intensity equals the 
threshold fluorescence; inversely related to the abundance of transcript in a sample) were 
computed for each sample.  Subsequently ∆Ct values were calculated for each sample by 
subtracting the Ct value for the housekeeping gene (cytochrome C oxidase) from the Ct value 
for the gene of interest.  In order to calculate fold-change, the 2^-∆∆Ct were computed.  The 
∆∆Ct values were calculated by subtracting the ∆Ct of a selected healthy control from the ∆Ct of 
each discrete sample.  The fold-change was calculated by dividing the individual 2^-∆∆Ct values 
by the average of the 2^-∆∆Ct values for healthy control samples.   
Transcript fold-change in each of the five groups (SVV,VC, SLE, LC, HC) were computed 
and recorded as mean±standard deviation.  Significant differences of the median fold-change 
values among patient groups were determined using Kruskal Wallis nonparametric ANOVA.  A 
post-ANOVA Dunn’s Multiple Comparison’s test was used to determine differences in median 
transcript expression.  Patient level data that was evaluated for relationships with transcript fold-
change were: disease (SVV vs SLE), treatment (cyclophosphamide vs mycophenolic acid), 
gender, race (Caucasian vs non-Caucasian), and genotype (UGT1A7, UGT1A9, UGT2B7, 
CYP2C9, CYP3A4, CYP2B6, and ABCB1).  The expression values were converted to the log 10 
and linear regression was used to evaluate these former relationships.  Spearman correlation 
analysis was used to evaluate relationships between fold-change expression values by disease, 
genotypes, treatments, gender, and race within disease groups.  Spearman correlation analyses 
were conducted to evaluate for relationships between continuous mycophenolic acid and 
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cyclophosphamide pharmacokinetic variables; area under the plasma concentration time curve 
(AUC), trough plasma concentration (Ctr), oral/systemic clearance, renal clearance, and 
transcript expression.  Wilcoxon two-samples tests were used to assess for relationships of 
SLCO1A2 transcript expression between gender, race, disease, and treatment.  P values of < 
0.05 was considered statistically significant.  Statistical analyses were performed using InStat 
v3.0 (GraphPad, San Diego, CA) and SAS Statistical Software, Version 9.1 (SAS Institute, Inc., 
Cary, NC). 
Results 
The description of SLE and SVV study subjects who donated blood for gene transcript 
analyses are provided in Table 6.1.  This information was not available (demographics) or did 
not apply (treatment) to the three control groups.  The transcript of transporter genes (ABCC2, 
ABCB1, and ABCG2) were expressed in the leukocytes of 92% to 98% of subjects.  Figure 6.1 
is a representative amplification plot of the ABCB1 transporter transcripts.  The transcript of 
SLCO1A2 was expressed in only 50% of subjects.  Regarding the drug metabolizing enzyme 
genes, the transcript of UGT1A9, UGT1A7, and UGT2B7 were expressed in ~50% of subjects, 
while the CYP2B6 transcript was expressed in 94% of subjects.  Figure 6.2 is a representative 
amplification plot of the UGT1A7 transcript.  The CYP3A4 and CYP2C9 genes were not 
appreciably expressed in the leukocytes of the evaluated subjects.  Fold-change values for each 
gene in each patient group (SVV, VC, SLE, LC, HC) are recorded as mean±SD in Table 6.2.  
Differences were noted in expression of UGT1A7, ABCB1, and ABCC2 across the evaluated 
patient populations.  Regarding UGT1A7, the SVV (0.17±0.42; p<0.05) and SLE (0.03±0.10; 
p<0.05) groups had statistically lower expression values than the HC subjects (0.79±2.02).  For 
ABCB1, the SLE group had significantly lower mean expression values (0.33±0.21; p<0.05) 
than the HC group (1.00±0.82).  For the ABCG2 gene, the SVV group had lower mean 
expression values (0.17±0.14; p<0.05) than the HC subjects (1.00±1.82). Differences in 
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expression of ABCC2 approached statistical significance, with the VC patients (2.02±1.13) 
exhibiting higher expression than the SVV patients (1.06±1.11; p=0.05).   
Genotype frequencies for the UGT1A7, UGT2B7, ABCB1, and CYP2B6 single nucleotide 
polymorphisms evaluated in the 67 treated SLE and SVV patients are shown in Table 6.3.  
Genotype frequencies for all evaluated polymorphisms were in Hardy-Weinberg equilibrium.  
Genotype analyses are not reported for the UGT1A9 polymorphisms that were planned to be 
evaluated secondary to their extremely low frequency in this glomerulonephritis population. 
Several important findings resulted from the evaluation of the relationships between 
transcript expression and patient-level data. (Table 6.4)  However, none of the relationships 
resulted in R2 values of greater than 0.10 secondary to the dichotomous nature of the patient-
level data.  Among the SVV and SLE groups receiving treatment with either mycophenolic acid 
or cyclophosphamide, ABCC2 expression was different by race (1.26±1.82 Caucasian versus 
1.37±0.86 non-Caucasian; p=0.049); CYP2B6 expression was different by treatment (2.07±2.94 
cyclophosphamide versus 0.45±0.50 mycophenolic acid; p=0.010).  Results of borderline 
significance were ABCB1 expression by ABCB1 C3435T genotype (0.43±0.55 wildtype versus 
0.63±0.88 variants; p=0.076), ABCC2 expression by disease type (1.20±1.50 SVV versus 
1.43±1.29 SLE; p=0.078), and ABCG2 expression within SLE patients by gender (0.34±0.34 
female versus 0.11±0.07 male; p=0.074).  Assessments of relationships between UGT or 
SLCO1A2 expression and patient-level variables were not attempted secondary to the higher 
percentage of subjects with absent transcript in leukocytes.  Additionally, too few subjects 
exhibited the evaluated single nucleotide polymorphisms in the UGT1A9 gene to enable 
evaluation with transcript expression. 
Assessments of relationships between transcript expression and pharmacokinetic 
parameters for mycophenolic acid and cyclophosphamide were evaluated by patient treatment 
to ascertain whether clinically relevant medication effects were demonstrated.  For patients 
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receiving cyclophosphamide, significant negative correlations were noted between ABCC2 
expression and cyclophosphamide clearance (r2 -0.449; p=0.041), and 4-
hydroxycyclophosphamide AUC (r2-0.536; p=0.012).  For patients receiving mycophenolic acid, 
significant negative correlations were noted between ABCG2 gene expression and 
mycophenolic acid Ctr (r2-0.378; p=0.043).  No other correlations were noted.           
Discussion 
The current study is the first to describe expression of drug metabolizing enzyme and drug 
transporter transcript in the leukocytes of patients with kidney disease secondary to 
glomerulonephritis.  This research is relevant as therapies for the treatment of 
glomerulonephritis are directed primarily toward the peripheral blood cell lymphocyte 
populations.  This study selectively assessed only those genes thought to be involved in the 
transport and metabolism of the two primary glomerulonephritis treatments; mycophenolic acid 
and cyclophosphamide.  Our results showed leukocyte expression of the ABCC2, ABCB1, 
ABCG2 transcripts in ~90% and SLCO1A2 transcript in ~50% of patients with 
glomerulonephritis, respectively.  The expression of genes for the drug metabolizing enzymes 
UGT1A9, UGT1A7, and UGT2B7 were demonstrated in the leukocytes of ~50% of patients.  
However, the leukocyte expression of CYP2B6 was evident in >90% of patients while CYP3A4 
and CYP2C9 expression was virtually absent.  Treatment-related differences in expression were 
assessed in mycophenolic acid- versus cyclophosphamide-treated patients.  Our results 
showed that cyclophosphamide-treated glomerulonephritis patients had 4-fold higher expression 
for CYP2B6 (2.07±2.94 vs 0.45±0.50; p=0.010) than mycophenolic acid-treated patients.  While 
it is tempting to attribute this finding to induction of gene transcription by cyclophosphamide, this 
scenario is unlikely since previous doses had been administered at least 30 days prior, doses 
were lower (0.8±0.2 g/m2) than reported for enzyme induction 27, and blood was obtained prior 
to and not after the next planned dose.  We cannot rule-out the possibility, however, that 
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concomitant daily glucocorticoid therapy could have induced expression of CYP2B6.  Significant 
differences in transporter transcript expression by race (ABCC2), disease (ABCC2, ABCG2), 
and genotype (ABCB1) were also found.  Significant relationships in cyclophosphamide 
clearance/4-hydroxycyclophosphamide AUC (ABCC2) and mycophenolic acid Ctr (ABCG2) 
were also found. 
Evaluation of expression in ABCG2, ABCB1, and ABCC1 transcript in lymphocytes and 
monocytes of healthy patients 6 previously showed cell type dependent expression only in 
ABCB1 transcript, with greater expression of ABCB1 in lymphocytes (lymphocytes 9.67±5.53 
versus monocytes 0.821±0.263).  Since we did not assess expression in individual cell types 
(lymphocytes, neutrophils, monocytes), and neutrophils normally out-number lymphocytes by a 
factor of two to three, it is conceivable that a reasonable expression of the UGT and SLCO1A2 
genes in the lymphocytes may have been obscured by a dilutional effect of other cells in 
patients with reduced transcript expression.  Albermann et al, reported the relative order of 
ABC-transporter gene expression in peripheral blood mononuclear cells as ABCC1> ABCG2> 
ABCB1> ABCC2.5  While we did not assess ABCC1, the relative order of magnitude in 
expression for glomerulonephritis patients was ABCC2>SLCO1A2>ABCB1=ABCG2 for SLE 
and SLCO1A2>ABCC2>ABCB1>ABCG2 for SVV.  These data suggest that the MRP2 and 
OATP transporters most pertinent to overall mycophenolic acid dispositionhave the highest 
expressed transcripts, e.g. ABCC2 and SLCO1A2 within the leukocytes of SLE and SVV 
patients (when they are in fact expressed).  The role of MRP2 and OATP in leukocyte transport 
of mycophenolic acid and its metabolites have not yet been assessed in leukocyte cell-based 
studies.     
Differences in mean transcript expression among the subject groups were found in the 
present study.  A notable finding was that healthy controls had higher expression of UGT1A7 
relative to SVV and SLE patients, higher ABCB1 expression than SLE patients, and higher 
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ABCG2 expression than SVV patients.  This data would imply that the transport activity and/or 
capacity though the proteins encoded by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer 
resistance associated protein; BCRP), are reduced in patients with SLE or SVV, possibly 
allowing higher intracellular concentrations of transported substrates.  However, we don’t 
currently know what threshold levels of transcript are necessary to have sufficient activity to 
exhibit a normal versus reduced transport phenotype.  Regarding medications used in the 
treatment of glomerulonephritis, mycophenolic acid is suggested to be a substrate of P-
glycoprotein 23,28,29, and BCRP 30, and glucocorticoids are known substrates for P-
glycoprotein.31,32  Regarding drug metabolizing enzymes, mycophenolic acid is a substrate for 
UGT1A733 and since SLE  and SVV patients have reduced UGT1A7 transcript expression 
relative to healthy normals, our patients would be predicted to have lower turnover of 
mycophenolic acid through metabolism within the leukocytes, with the assumption that gene 
expression correlates significantly with protein expression within these cells.  However, only 
~50% of our patients expressed UGT1A7 in leukocytes.  The affinity of mycophenolic acid for 
UGT1A7 is reportedly greater than the affinity for UGT1A9 33, but the overall relative contribution 
of UGT1A7 to mycophenolic acid metabolism has not been reported. 
We were interested in exploring the effects of patient-level factors on transcript expression 
in the SLE and SVV patients.  These factors (disease, treatment, race, gender, and genotype) 
were included as existing data in the literature supported these evaluations. 7,12,14,34-36  
Regarding disease type, the SLE patients had consistently higher expression of both the 
ABCC2 and ABCG2 gene as compared to the SVV patients.  Higher expression of ABCC2 and 
ABCG2 would be predicted to reduce intracellular exposure to mycophenolic acid in the SLE 
patients as compared to SVV patients if active transport modulates expression more than 
passive equilibrium with plasma.  While we did not measure this directly or in a separate in vitro 
cell-based study, our previous pharmacokinetic publications 15,16 do support higher systemic 
(extracellular) exposures in SLE vs SVV patients.     
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Exposures to concurrent treatments can influence expression of drug metabolizing enzyme 
transcripts.  An in vitro experiment employing CaCo2 cells demonstrated a suppression of 
UGT2B7 transcript expression after exposure to retinoids. 37  Several publications have reported 
suspected isotretinoin-induced vasculitis, 38-40 and we have preliminary data suggesting an 
increased relative risk of SVV in patients with single nucleotide polymorphisms in UGT2B7 
(associated with a decreased metabolic activity phenotype).  A study in mice demonstrated 
inducibility of liver and intestinal UGT1 and UGT2 transcript by microsomal enzyme inducers of 
specific transcription factors (arylhydrocarbon receptor, constitutive androstane receptor, 
pregnane X receptor, peroxisome proliferators-activated receptor alpha, and NF-E2 related 
factor 2). 36 Additionally, a study employing rat and human hepatocytes showed induction of 
UGT transcript by arylhydrocarbon receptor ligands (3-methylcholantrine, β-naphthoflavone, and 
omeprazole). 7  In this same study, human expression of ABCB1 was induced with 
phenobarbital and rifampin, ABCB3 was induced with fenofibrate, and SLCOA was induced by 
pregnenalone-16 carbonitrile and omeprazole.  Differential transcript expression (inducing 
agent) was demonstrated in rat hepatocytes; ABCB11 (dexamethasone), ABCB2 
(dexamethasone), ABCC2 (pregnenalone-16 carbonitrile, dexamethasone), ABCC3 (3-
methylchoantrine, β-naphthoflavone, and omeprazole), and SLCO1A2 (pregnenalone-16 
carbonitrile, dexamethasone, pregnenalone-16 carbonitrile).  While our patients did not receive 
most of these compounds, glucocorticoids were prescribed in 36% of mycophenolic acid-treated 
and 86% of cyclophosphamide-treated patients.  Based on this previous data, glucocorticoids 
could be predicted to induce ABCC2 and possibly SLCO1A2.  This presumption is compatible 
with the finding of high expression of both transcripts in our SLE and SVV patients.   
Since recent publications have reported gender divergent effects on UGT transcript and 
tissue expression in mice 12,13 and reduced activity of UGTs females, 41 we wanted to evaluate 
the gender-stratified expression of our evaluated genes in the glomerulonephritis population.  
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While none of these assessments reached statistical significance, a trend was noted in female 
patients having 3-fold higher expression of ABCG2 than males.  This finding is interesting as 
females compose the majority of SLE patients and we also found higher expression of ABCG2 
in this disease group; implying that a disease-gender interaction may be confounding.  
Regarding race effects, the expression of ABCC2 in leukocytes was found to be lower in 
Caucasian than non-Caucasian SLE and SVV patients.  The non-Caucasian group comprise the 
majority of SLE patients and these patients are disproportionately African-American.  African-
American SLE patients have worse treatment related outcomes42 and it is plausible that reduced 
intracellular concentrations of therapies may be contributing. 
The role of genotype on expression of ABCB1 was recently reported in a study that isolated 
peripheral blood cells from healthy subjects and incubated them in vitro with lipopolysaccharide 
(LPS).14  The investigators evaluated the effect of acute inflammation by LPS as compared to 
baseline, on ABCB1 transcript expression.  The authors stratified their study results according to 
patient genotype at the ABCB1 nucleotide base location 3435.  The results showed decreased 
ABCB1 expression in the blood of patients exhibiting the C/C (wildtype) and C/T (heterozygote) 
genotypes and no effects in those with the T/T genotype.  However, the published data 
concerning P-glycoprotein activity in patients who are homozygous wildtype versus 
homozygous variant for the ABCB1 C3435T polymorphism are conflicting. 43  In the current 
study, we found higher ABCB1 expression in patients who exhibited the C/T and T/T genotypes 
as compared to the wildtype (C/C) genotype, a finding consistent with the literature.  14,43 
Since drug therapy may alter drug metabolizing enzymes and transporters and we had 
existing data on mycophenolic acid and cyclophosphamide/4-hydroxycyclophosphamide 
pharmacokinetics in our glomerulonephritis patients, we evaluated for correlations with 
leukocyte transcript expression.  In providing plausible explanation for these findings, it is 
necessary to make the assumption that leukocyte expression correlated directly with liver and/or 
kidney protein expression.  ABCC2 significantly negatively correlated with both 
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cyclophosphamide clearance and 4-hydroxycyclophosphamide AUC, suggesting enhanced 
clearance of the former and enhanced exposure to the later when the ABCC2 transcript is 
reduced.  Since cyclophosphamide’s metabolism is quite complicated and 4-
hydroxycyclophosphamide is highly reactive, information regarding transport must be inferred 
from assessments of other downstream metabolites.  It has been suggested that MRP2, MRP4, 
and possibly BCRP2 contribute to the disposition of 4-hydroxycyclophosphamide. 44  The protein 
of ABCC2, e.g. MRP2 is localized to the apical (bile cannilicular) membrane of liver and serves 
to efflux organic anions from hepatocytes.  Decreased MRP2 protein in liver would be 
hypothesized to result in reduced loss of 4-hydroxycyclophosphamide from the liver and 
enhanced opportunity for efflux through MRP4 at the basolateral membrane, with increased 
AUC.  We found a negative correlation between ABCG2 expression and mycophenolic acid 
trough concentrations.  This data would imply that increased BCRP protein and/or activity would 
result in increased loss of mycophenolic acid glucuronide by urinary excretion, resulting in a 
decrease in Ctr.  The interplay between drug metabolism and transport should be considered 
when evaluating and predicting overall effects on drug disposition.  45 
Conclusions 
 The current study showed differential expression patterns of drug metabolizing enzyme and 
transporter transcripts in patients with glomerulonephritis as compared to healthy control 
subjects.  Treatment and demographic variables were associated with significant differences in 
expression.  This study adds to the sparse literature describing the transcript expression of drug 
transporters in leukocytes and focuses on a disease in which patients receive therapies targeted 
to the lymphocytes.  Additionally, this study provides initial information pertaining to expression 
of drug metabolizing enzyme transcripts in leukocytes.  This basic knowledge is required as 
transcript and ultimately protein expression of drug metabolizing enzymes and transporters can 
modulate the exposure to active pharmacologic moieties in the blood and tissues.  This inital 
data may guide future investigations into mechanisms for altered responses in order to improve 
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patient-related exposures to therapies targeting leukocytes and to support efforts to measure 
protein expression in tissues by absolute quantitative methods such as mass spectroscopy. 46   
It will be necessary to test the current study’s findings in another cohort of patients to determine 
the generality of these associations.  Large prospectively designed studies with serial 
expression profiles will be necessary to validate cause and affect relationships.  
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Table 6.1 
Demographics of Glomerulonephritis Patients  
Data presented as n (percentage) 
     Small vessel vasculitis  Systemic lupus erythematosus 
  
      (n=35)     (n=36)  
  
Race (%) 
 Caucasian    25 (71%)    8 (22%)  
  
 Non-Caucasian    10 (29%)    28 (78%) 
   
Gender (%Female)    20 (57%)    28 (78%) 
   
Treatment (%) 
 Cyclophosphamide   7 (20%)     15 (42%) 
   
 Mycophenolic acid   28 (80%)    21 (58%) 
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Table 6.2 
Transcript Values in the Evaluated Groups (mean±SD) 
 
   SVV  SVV-Control  SLE   SLE-Control  HC   
   (n=35)  (n=5)   (n=36)   (n=5)   (n=10) 
UGT1A9  0.98±2.24 NA   0.62±1.27  0.34±0.27  0.94±1.73 
UGT2B7  2.46±6.38 0.52±0.00  2.13±4.87  1.35±1.78  1.00±1.64 
UGT1A7  0.17±0.42a 0.27±0.00  0.03±0.10b  0.22±0.21  0.79±2.02 
CYP2B6  0.50±0.57 0.15±0.12  1.49±2.55  0.50±0.62  1.0±0.99 
ABCB1  0.65±0.96 0.54±0.60  0.33±0.21c  0.45±0.31  1.00±0.82 
ABCC2  1.06±1.11 d  2.02±1.13  1.35±1.21  1.60±1.08  1.00±0.41 
ABCG2  0.17±0.14 e 0.01±0.0  0.31±0.33  0.10±0.07  1.0±1.82 
SLCO1A2  1.45±3.68 NA   0.47±0.75  0.01±0   0.84±0.99 
  
a – SVV < HC; p<0.05 
b – SLE < HC; p<0.05 
c – SLE < HC; p<0.05 
d – SVV < SVV-control; p=0.05 
e - SVV < HC; p<0.05 
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Abbreviations 
ABCB1 – multidrug resistance protein  
ABCC2 – multidrug resistance-associate protein  
ABCG2 – breast cancer resistance protein  
ANCA – antineutrophil cytoplasmic antibody 
CYP – cytochrome P450  
HC – healthy control 
NA – not applicable 
SLCO1A2 – organic anion transporting polypeptide  
SLE – systemic lupus erythematosus 
SVV – small vessel vasculitis 
UGT – uridine-glucuronosyltransferase  
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Table 6.3 
Genotype Frequency Distributions (frequency (n)) 
 
      SLE and SVV Patients 
UGT1A7 
 T622C  T/T   0.53 (35) 
   T/C   0.42 (28) 
   C/C   0.05 (3) 
UGT2B7 
 C802T  C/C   0.39 (26) 
   C/T   0.42 (28) 
   T/T   0.19 (13) 
CYP2B6 
 C1459T C/C   0.82 (55) 
   C/T   0.15 (10) 
   T/T   0.03 (2) 
 G516T  G/G   0.49 (33) 
   G/T   0.43 (29) 
   T/T   0.08 (5) 
ABCB1 
 C3435T C/C   0.34 (23) 
   C/T   0.55 (37) 
   T/T   0.11 (7) 
 C1236T C/C   0.43 (29) 
   C/T   0.49 (33) 
   T/T   0.08 (5) 
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Abbreviations 
ABCB1 – multidrug resistance protein  
CYP – cytochrome P450  
UGT – uridine-glucuronosyltransferase  
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Table 6.4 
Relationships Between Transcript Expression and Patient-Level Data In Subjects with Systemic 
Lupus Erythematosus and Small Vessel Vasculitis 
 
Transcript Variable      Patient-Level Variable  Parameter Esitmate P value    
ABCB1 Gender 0.070 0.542 
 Race 0.061 0.558 
 Treatment -0.049 0.660 
 Disease 0.152 0.144 
 
ABCB1 C3435T genotype -0.194 0.078 
 
ABCB1 C1236T genotype -0.092 0.385 
ABCC2 Gender 0.113 0.203 
 Race -0.157 0.049 
 Treatment 0.113 0.184 
 Disease -0.141 0.078 
ABCG2 Gender 0.224 0.093 
 Race -0.070 0.562 
 Treatment 0.058 0.657 
 Disease 0.040 0.831 
CYP2B6 Gender 0.140 0.531 
 Race -0.196 0.330 
 Treatment 0.537 0.010 
 Disease -0.142 0.483 
 
CYP2B6 A785G genotype 0.049 0.906 
 
CYP2B6 C1459T genotype -0.166 0.533 
 
CYP2B6 G516T genotype 0.083 0.680 
 
Transcript expression results were log 10 transformed for analyses. 
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Figure Legends 
Figure 6.1 – Real-time RT-PCR for Quantification (amplification plot) of ABCB1 mRNA in 
Leukocytes of Patients with Glomerulonephritis Secondary to Systemic Lupus Erythematosus and 
Small Vessel Vasculitis.  ABCB1 was expressed in 95% of patients. 
Figure 6.2 – Real-time RT-PCR for Quantification (Amplification Plot) of UGT1A7 mRNA in 
Leukocytes of Patients with Glomerulonephritis Secondary to Systemic Lupus Erythematosus and 
Small Vessel Vasculitis.  UGT1A7 was expressed in 50% of patients. 
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Figure 6.1 
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Figure 6.2 
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Introduction 
The pharmacologically active immunosuppressive agent mycophenolic acid, is used off-
label for the treatment of autoimmune-mediated glomerulonephritis, e.g. systemic lupus 
erythematosus (SLE) and small vessel vasculitis (SVV).  Several studies now published 
regarding the SLE nephritis population support the efficacy and safety of mycophenolic acid for 
induction and maintenance regimens. 1-6  There also appears to be mounting evidence 
supporting the improvement in kidney outcomes in African-American SLE patients receiving 
mycophenolic acid based regimens as opposed to those containing cyclophosphamide. 6,7  Data 
concerning outcomes to mycophenolic acid therapy for SVV patients are more limited and 
consist of mostly small studies.8-11  A recently completed, but unpublished  larger trial 
(IMPROVE) compared maintenance therapy with azathioprine versus mycophenolate mofetil in 
175 patients with SVV.  There is currently a paucity of data that enables clinicians to predict 
which glomerulonephritis patients will respond most or least favorably to mycophenolic acid 
therapy.  Additionally, there is currently no solid evidence supporting any targeted mycophenolic 
acid plasma concentrations or exposures that are most optimal for producing favorable kidney 
outcomes in patients with glomerulonephritis. 
Patients with glomerulonephritis can have alterations in serum albumin, kidney function 
(glomerular filtration rate (eGFR)), and urinary protein excretion, all of which may alter drug 
disposition and could influence therapy responsiveness.  Additionally, studies in the transplant 
literature have reported wide inter-patient variability in pharmacokinetics, limiting the 
applicability of one patient’s data to another. 12,13  Previous mycophenolic acid pharmacokinetic 
studies by our group in patients with SLE nephritis and antineutrophil-cytoplasmic antibody 
(ANCA) SVV patients have been published. 14,15  The reports demonstrated greater urinary 
protein excretion and lower serum albumin in the SLE nephritis population 14, and more severe 
kidney dysfunction as defined by creatinine clearance in the SVV patients 15.  A consistent 
finding in both SLE and SVV population studies was an increased oral clearance of 
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mycophenolic acid as compared to reports in kidney transplant recipients.  The increased oral 
clearance in SLE nephritis patients was associated with increased creatinine clearance and 
decreased serum albumin. 14  Assessment of oral clearance according to urinary protein 
excretion as a marker for kidney structure abnormalities showed enhanced clearance with 
urinary protein excretion values of ≥ 1g/day. 14   Enhanced clearance has the potential for 
reducing plasma concentrations and overall exposure to therapeutic agents.  Positive 
relationships between plasma concentrations and/or subsequent exposure and outcomes may 
require assessment of patient level clinical data to guide therapy decisions and optimize 
treatment-related outcomes.     
In addition to the influence of clinical data on altered mycophenolic acid pharmacokinetics, 
the presence and influence of single nucleotide polymorphisms (SNPs) in the uridine 
diphosphate glucuronosyltransferase metabolizing enzymes (UGTs) have been reported in 
kidney transplant patients. 16-21  Single nucleotide polymorphisms at the UGT1A9 promotor have 
been associated with enhanced metabolism 16,20, while other non-promoter UGT SNPs are 
associated with enhanced exposure to MPA, 16 suggesting a reduction in metabolism.  Reports 
linking SNPs in drug metabolism genes to altered mycophenolic acid pharmacokinetics or 
outcomes in the glomerulonephritis population are currently lacking.  Since the SVV population 
is primarily Caucasian and the SLE population is represented by African-Americans as well as 
Caucasians, it is feasible that pharmacogenomic factors may be contributing at different levels 
to therapeutic outcomes in the two forms of glomerulonephritis.  Data concerning the frequency 
of UGT SNPs in the glomerulonephritis population as compared to other reference populations 
also requires assessment to begin to evaluate for any disease-gene association.  This is an 
intriguing area for exploration as the UGT enzymes exist in the body primarily for detoxification 
of environmental chemicals and toxins and this may be relevant in diseases such as SLE and 
SVV, as both diseases are proposed to have environmental causes. 22-24 Data from the cancer 
literature report disease-UGT associations and cancer risks. 25-28 
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In the current study, we sought to evaluate for predictors of outcomes to mycophenolic acid 
therapy in glomerulonephritis patients with SLE and SVV.  The specific outcomes of interest 
included; attainment of a composite outcome (dialysis, transplantation, death), changes in 
serum creatinine (SCr), changes in estimated glomerular filtration rate (eGFR), and changes in 
urinary protein to creatinine excretion ratio (UP:Cr).  We also investigated the influence of 
genetic polymorphisms in MPA drug metabolizing enzyme genes (UGT1A7, UGT1A9, UGT2B7) 
and a transporter gene (ABCB1/MDR1) associated with efflux of MPA 31, on mycophenolic acid 
therapy outcomes, as well as risk factors for SLE or SVV.  We also explored associations of 
mRNA expression patterns of metabolizing enzyme genes and transporter genes in leukocytes 
and outcomes.  Lastly, we evaluated pharmacokinetic variables representing drug exposure, as 
defined by area under the plasma concentration time curve (AUC) and trough plasma 
concentrations (Ctrough), to assess their relationships with treatment outcomes.   
Methods 
Research Subjects  
A population of 85 patients with glomerulonephritis due to SLE and SVV who were receiving 
or who had received therapy with mycophenolic acid were enrolled in the study.  This treatment 
population had existing long-term follow-up consents in place through the Glomerular Disease 
Collaborative Network (GDCN) and subsequently had clinical and demographic follow-up data 
available.  A subgroup of this population (n=45) was actively recruited to participate in a 
mycophenolic acid pharmacokinetics evaluation requiring an inpatient visit to the clinical 
research center. Details concerning the design, conduct and results from the pharmacokinetic 
studies were recently reported. 14,15  Results for mycophenolic acid exposure (dose normalized 
AUC0-Tau, where Tau is the dosing interval) and dose-normalized trough plasma concentrations 
(Ctrough) were abstracted for evaluation of relationships with treatment outcomes.  These later 
patients also had blood obtained, processed, and assayed for mRNA expression. 
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Four cohorts of 269 patients (SVV, SLE, rheumatoid arthritis, and healthy controls) were 
evaluated for assessment of the frequency of common genetic variants in the MPA drug 
metabolizing enzyme genes UGT1A9, UGT1A7, and UGT2B7 and the drug transporter gene 
multidrug resistance protein (ABCB1/MDR1).  Patients with biopsy confirmed SLE or SVV with 
kidney manifestations were included in the SLE and SVV cohorts.  Patients with rheumatoid 
arthritis, an autoimmune disease without kidney manifestations, and healthy control patients 
with no kidney disease and no autoimmune disease were included into these later two 
respective control cohorts. 
For all SVV and SLE subjects, data was abstracted from medical charts and included kidney 
biopsy activity and chronicity scores, proteinase 3 (PR3)/myeloperoxidase (MPO) antineutrophil 
cytoplasmic antibody (ANCA) status, WHO classification of SLE nephritis 29 , glucocorticoid 
dose (if applicable), mycophenolate mofetil dose at time of evaluation, and duration of disease 
follow-up.  Serum creatinine and UP:Cr were collected at time of biopsy, time of treatment, and 
time of last available follow-up.  Estimated glomerular filtration rate (eGFR) was calculated by 
the four variable Modification of Diet and Renal Disease Equation. 30  Abstracted demographic 
data included age, weight, race, and gender.  The study and consent forms were approved by 
the University’s Institutional Review Board and patient consent was required prior to 
participation. 
Genotyping Assessments 
A 5 mL whole blood sample was collected into an EDTA containing vacutainer and genomic 
DNA was isolated using a Flexigene Qiagen kit (Qiagen, Inc., Valencia, CA, USA).  Genotyping 
was conducted for several published SNPs in UGT1A9, UGT1A7, UGT2B7 and MDR1/ABCB1, 
all previously reported to result in alterations in mycophenolic acid metabolism and/or transport. 
16-18,20,21,31
  Data regarding the assays and conditions for genotyping assessments have 
previously been reported. 32  All genotyping results were coded as 0 (wildtype/wildtype), 1 
(heterozygote), or 2 (variant/variant). 
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mRNA Expression Analyses 
For mRNA expression analyses, a 15mL blood sample was obtained from multiple 
ethylenediaminetetraacetic acid (EDTA) vacutainers.  Leukocytes were isolated from whole 
blood by incubation (11 minutes) in a lysis buffer, followed by centrifugation and a wash with 
Hank’s balanced salt solution (HBSS).  The leukocytes were subsequently suspended in RNA 
Stat 60 solution and stored at -70C for up to 2 weeks until processing.  The procedures for 
mRNA isolation and cDNA conversions have been previously reported. 33  Pre-designed assays 
containing primers and probes were purchased from Applied Biosystems (Foster City, CA) for 
assessment of transcript expression of the targeted metabolizing enzymes (UGT1A7, UGT1A9, 
UGT2B7, CYP3A4, CYP2C9, and CYP2B6) and transporters (ABCB1, ABCC2, ABCG2, and 
SLCO1A2); UGT1A7 (Hs02517015_s1), UGT2B7 (Hs02556232_s1), UGT1A9 
(Hs02516855_sH), CYP3A4 (Hs00604506_M1), CYP2C9 (Hs00426397_m1), CYP2B6 
(Hs00167937_g1), ABCC2 (Hs00166123_m1), ABCB1 (Hs00184500_m1), ABCG2 
(Hs01053795_m1), and SLCO1A2 (Hs01072338_m1).  Cytochrome C oxidase was used as the 
normalization (housekeeping) gene.  The forward and reverse primers were designed using 
Primer Express software (Applied Biosystems, Foster City, CA).  The forward primer 
(TGGCATCTGGAGGTGGTGTT) and reverse primer (GTCCAGTCCCTTTGCAGC) were 
purchased from Applied Biosystems (Foster City, CA).  Sybr 1:400 was used as the probe in the 
assays (Molecular Probes, Leiden, Netherlands).  Data concerning the specific assay conditions 
was previously reported. 33  
Statistical Analysis Strategy and Methods  
 Descriptive statistical methods were applied to the demographic (age, race, gender), clinical 
(SCr, eGFR, UP:Cr), pharmacokinetic data (AUC
 0-Tau, Ctrough), and genotype data (UGT1A9 
G8A, C98T, C-2152T, T-275A, UGT2B7 C802T, UGT1A7 T622C, and MDR1 C1236T and 
C3435T) to provide summary tabulations of frequencies, means, standard deviations, and 
ranges.   
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Differences in demographic and clinical variables were assessed between SLE and SVV 
disease groups by unpaired T Test with Welch Correction for continuous variables and Fisher’s 
Exact Test for categorical variables.  Absolute and percent changes in outcome clinical 
measures (absolute changes in SCr, eGFR, and UP:Cr) were assessed between disease 
groups by Wilcoxan Two Sample Tests.  Kaplan Meier curves were generated to test for 
composite survival probability between disease groups employing the composite outcome of 
dialysis, transplantation, or death.       
For each SNP, tabulated cohort-specific allelic frequencies were used in a chi-square test of 
the null hypothesis, “no differences among the four cohorts (SVV, SLE, rheumatoid arthritis, 
healthy control).”  The observed genotype frequencies for each defined locus were used in a 
chi-square test procedure for testing of the null hypothesis, “no deviation from Hardy-Weinberg 
equilibrium.”  Differences in genotype frequencies between disease groups versus healthy 
control group were evaluated by Fisher’s Exact Test.  The logistic procedure was used to 
evaluate the odds of having SVV, SLE, or rheumatoid arthritis based on genotype, with 
wildtype/wildtype as the comparator genotype.  Relationship between specific genotypes and 
absolute changes in eGFR, SCr, and UP:Cr were assessed by the Kruskal-Wallis Test. 
Relationships between mRNA expression and pharmacokinetics with composite kidney 
outcomes were assessed by the Wilcoxan Two-Sample test.  Spearman Correlation Coefficients 
were used to assess relationships between the absolute changes in eGFR, SCr, and UP:Cr and 
gene expression and pharmacokinetics. 
 Following descriptive graphical examinations of the relationships between the outcomes and 
the various patient variables, simple linear models were fitted for each outcome variable 
conditional on selected clinical, demographic, or genotype variables. Variable selection 
algorithms (e.g., stepwise selection, backward elimination) were also applied to construct a 
multivariable linear model for each outcome variable conditional on clinical, demographic, or 
genotype predictors.  For each outcome variable, a final model was selected based on 
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considerations of the statistical significance of the candidate predictor variables and the overall 
model R2 .  All statistical computations were performed using SAS System software (Version 
9.1, SAS Institute, Inc., Cary, NC.) 
Results     
 Demographic and combined clinical data from 85 patients with glomerulonephritis receiving 
therapy with mycophenolic acid were available; 37 with SLE and 48 with SVV.(Table 7.1)  The 
SLE patients were younger (39±11 versus 54±16 years; p<0.0001) and had a higher percentage 
of African American patients (46% versus 10%; p=0.0003) than SVV patients.  Baseline serum 
creatinine (2.5±2.3 versus 1.5±1.3 mg/dL; p=0.0247) was higher in the SVV patients and UP:Cr 
(2.8±3.4 vs 1.2±1.6; p=0.0450) was higher in the SLE patients.  The patients received an 
average daily mycophenolate mofetil dose of 1600±820 mg and total therapy duration/exposure 
was 1.3±2.1 years.  A total of 96% of patients had exposure to glucocorticoids and 85% had 
exposure to cyclophosphamide throughout their disease course.  Total duration of 
glomerulonephritis follow-up was 4.6±3.6 years.  Available data (75% of patients) concerning 
biopsy staining patterns for ANCA showed; PR3 (n=22; 61%) and MPO (n=14; 36%) sero-
positivity.  Data concerning SLE nephritis classification by WHO criteria was available for 73% 
of mycophenolic acid-treated patients; Class 3, (22%), Class 4 (67%), and Class 5 (22%), with 
some patients having a mixed classification.  Scores from SLE biopsies for activity and 
chronicity were 7±4 and 3±2, respectively.  For the SLE cohort, Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) 34 (3.6±4.2) and Damage Index (DI) 35 (0.9±1.4) scores were 
reported.  For the SVV cohort, Birmingham Vasculitis Assessment Scores (BVAS) 36 (0.59±1.2) 
and Vasculitis Damage Index (VDI) 37 (2.2±1.7) scores were reported.    
Absolute changes and percentage changes in SCr, eGFR, and UP:Cr were calculated at 
disease diagnosis, during mycophenolic acid therapy, and final follow-up for the 85 patients.   
Figure 7.1 and Table 7.2 demonstrate actual values for serum creatinine, eGFR, and UP:Cr at 
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disease diagnosis, treatment, and follow-up.  As noted in Table 7.2, the SVV patients had 
statistically significant lower eGFR and increased SCr as compared to SLE patients at each 
evaluation period.  Overall, the SVV patients had higher serum creatinine and lower eGFR at all 
time points as compared to the SLE patients.  The SCr increased by 0.2±41% and decreased 
by 6.4±60.7% in SLE and SVV patients (p=0.1837) over time, respectively, from disease 
diagnosis to follow-up for an overall change of -3.3±52.4%.  The absolute change in SCr 
between SVV (-0.60±2.5 mg/dL) and SLE (-0.04±0.9 mg/dL) patients was not statistically 
significant (P=0.1207).  A total of 22 (32.0%) patients with available paired serum creatinine 
results (biopsy and follow-up) had at least a 50% increase in serum creatinine from diagnosis to 
the end of follow-up.  The eGFR increased by 93.2±302% and 8.6±44% in SVV and SLE 
patients (p=0.0755), respectively, from disease diagnosis to follow-up for an overall change of 
55.3±229%.  The absolute change in eGFR between SVV (11.1±25.1 mL/min/1.73m2) and SLE 
(0.2±29.3 mL/min/1.73m2) patients was not statistically significance (P=0.2635).  
The SLE patients had higher UP:Cr as compared to the SVV patients at all time points, 
although these differences were not statistically significant.(Table 7.2)  The UP:Cr decreased by 
11.0±106% and increased by 28.5±273% in SLE and SVV patients (p=0.5882), respectively, for 
an overall increase of 9.7±209%.  Absolute changes in UP:Cr  for SLE (-1.3±3.5) and SVV (-
0.2±2.2) patients were not different (p=0.6505).  A total of 7 (16.7%) of patients with available 
paired UP:Cr results had at least a 50% increase in UP:Cr from diagnosis to follow-up.  These 
50% increases in UP:Cr and SCr data suggest that up to ~32% of patients had at least a partial 
disease relapse during the course of their maintenance therapy with mycophenolic acid.   
Kaplan Meier survival curves for the composite outcome of hemodialysis, transplantation, or 
death were generated for patients receiving mycophenolic acid. (Figure 7.2)  Survival estimates 
were similar between the SLE and SVV patients (p=0.1100).  These data show a 2-year and 5-
year estimated kidney survival in SLE patients of 100% and 90.3%, respectively while receiving 
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mycophenolic acid.  The data for SVV patients were similar, with 2-year and 5-year estimated 
kidney survival of 83.9% and 79.9%, respectively. 
A total of 269 discrete DNA samples were available for genotyping assessments.  The 
patient groups and numbers included; 101 patients with SVV, 67 patients with SLE, 26 patients 
with rheumatoid arthritis, and 75 healthy controls.  The allelic and genotype frequencies are 
reported in Tables 7.3 and 7.4, respectively.  The expected vs observed genotype frequencies 
within each patient cohort were in Hardy Weinberg Equilibrium.  Fisher’s Exact test 
demonstrated differences between the disease cohorts for the UGT2B7 SNP (p=0.0002) and for 
the UGT1A7 SNP (p=0.0123).  Genotype frequencies across disease cohorts for the UGT2B7 
variant/variant genotype were; healthy control (0), rheumatoid arthritis (0), SLE (0.08), and SVV 
patients (0.17).  For the UGT1A7 variant/variant genotype, frequencies across disease cohorts 
were; SVV (0.07), SLE (0.15), healthy control (0.12), and rheumatoid arthritis patients (0).  
Additional analyses controlling for race were performed to assess disease-genotype 
associations.(Table 7.5)  When controlling for race, the odds of having SVV was 3.073 (C.I. 
1.530-6.172, p=0.0016) when patients were classified as being either heterozygote or 
variant/variant genotype for UGT2B7 C802T.  The odds of having SVV was reduced to 0.414 
(C.I. 0.215-0.796, p=0.0082) when patients were heterozygotes or variant/variant genotype for 
UGT1A7 T622C.   
 The influence of UGT and ABCB1 genotypes on the absolute changes in eGFR, SCr, and 
UP:Cr from diagnosis to follow-up were also examined.(Table 7.6)  For glomerulonephritis 
patients who received mycophenolic acid, a significant genotype-change in kidney function 
parameter UP:Cr was found.  There was a statistical trend between UGT1A7 variant/variant 
genotype (p=0.0706) and increased overall UP:Cr from diagnosis to follow-up as compared to 
wildtype and heterozygotes, who had an overall reduction in change in UP:Cr.   A statistically 
significant finding was shown in ABCB1 C3435T genotype (p=0.0409) with lesser increases or 
actual decreases in UP:Cr seen in the variant/variant and heterozygote groups.  No significant 
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effects of genotypes on SCr or eGFR were noted for patients receiving mycophenolic acid.  We 
were limited in our assessment of the effects of genotypes on composite outcomes in patients 
receiving MPA secondary to the limited number of composite outcomes in this group.  We found 
that being heterzygote or variant/variant for UGT2B7 C802T resulted in a reduction in composite 
outcome, although the p value was 0.0983.  When grouping both mycophenolic acid- and 
cyclophosphamide-treated glomerulonephritis patients by genotype status for ABCB1 C1236T, 
ABCB1 C3435T, UGT1AT 7622C, and UGT2B7 C802T SNPs, no significant differences in 
composite kidney outcomes were demonstrated.   
Pharmacokinetic and mRNA expression data were available for a subset of 45 
glomerulonephritis patients who received mycophenolic acid; 27 SVV and 18 SLE patients.  We 
planned to evaluate the relationships between mycophenolic acid exposure (dose normalized 
AUC0-Tau, dose normalized Ctrough) and kidney outcomes.  Since the AUC 0-Tau (64.4±50 mcg 
h/mL versus 68.9±42.7 mcg h/mL) and Ctrough (4.1±5.5 mcg/mL versus 4.3±4.1 mcg/mL) 
values were similar in SLE and SVV patients, respectively, the two disease groups were 
combined.  As there were too few patients in this subgroup who exhibited the composite 
outcomes of dialysis, transplantation, or death, the results focused on the correlations in 
changes in eGFR, SCr, and UP:Cr from diagnosis to follow-up with AUC0-tau and Ctrough.  No 
significant correlations were demonstrated in kidney function changes and exposure to 
mycophenolic acid.     
As there were no statistical differences in transcript expression of metabolizing enzymes 
(UGT1A9, UGT2B7, UGT1A7) and transporters (ABCC2, ABCG2, SLCO1A2) between the SLE 
and SVV disease groups, they were combined for analyses of the relationship to kidney 
outcomes (changes in eGFR, serum creatinine, and UP:Cr from diagnosis to follow-up).  No 
significant correlations were demonstrated in kidney function changes and transcript expression 
of drug metabolizing enzymes and transporters in peripheral blood cells in patients exposed to 
mycophenolic acid therapy.  Analysis of composite outcomes based on transcript expression 
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patterns in the leukocytes of the combined patients receiving either cyclophosphamide or 
mycophenolate mofetil resulted in ABCB1 transcript expression that was lower (0.2±0.2) in 
patients who had composite outcomes versus those who did not (0.6±0.8); p=0.0150.  
Discussion 
The goal of the current study was to identify predictors of kidney outcomes in a well-
characterized population of patients with glomerulonephritis due to either SLE or SVV who were 
treated with mycophenolic acid.  The purpose for this study was to generate a personalized tool 
kit that clinicians could use to select the candidates for mycophenolic acid therapy who would 
be predicted to have the most benefit in terms of improvement in prevention of kidney function.  
This is particularly relevant for patients with SLE and SVV, since drugs including mycophenolic 
acid are used off-label and were never evaluated in glomerulonephritis patients as a whole via 
rigorous clinical development studies that would have included pharmacokinetic elucidation, 
drug dosing scheme assessments, safety evaluations, and efficacy evaluations.  Our previous 
work, in fact, demonstrated altered pharmacokinetics of mycophenolic acid in patients with SLE 
and SVV as compared to a population of kidney transplant patients, the later subjects in whom 
the drug has FDA approval. 14,15,38,39  Several clinical factors including urinary protein excretion, 
serum creatinine, weight, and race, and to a lesser extent, genomic factors including single 
nucleotide polymorphisms in UGT2B7 and UGT1A7, were found to predict mycophenolic acid 
pharmacokinetic outcomes including oral clearance and trough plasma concentrations. 32  
Regarding pharmacogenomic factors and treatment outcomes, we report in this publication that 
changes in UP:Cr over the treatment course with mycophenolic acid were significantly 
worsened in patients with the UGT1A7 C622T polymorphism and improved with the MDR1 
C3435T polymorphism.  Additionally, the expression of the MDR1 transcript in the leukocytes 
was reduced in patients who experienced the composite kidney outcome of dialysis, 
transplantation or death.  The data also demonstrated a relationship between SVV disease and 
the UGT2B7 C802T polymorphism.  We unexpectedly found a higher risk of SVV disease in 
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patients with the UGT2B7 C802T polymorphism.  However, patients with the polymorphism and 
glomerulonephritis tended to have improved composite outcomes.  As mycophenolic acid is a 
substrate for UGT2B7, decreased liver activity of this enzyme would be predicted to increase 
systemic exposure to mycophenolic acid, leading to improved kidney outcomes.  Our previous 
report did in fact, show increased MPA exposure in patients who were homozygous for the 
C802T polymorphism in UGT2B7. 32  We also showed decreased MPA renal clearance in these 
homozygous patients that could be reflective of a combination of decreased metabolism to the 
acyl glucuronide metabolite and decreased hydrolysis of this later metabolite in the urine.  
However, the hydrolysis of acyl metabolite in urine has not been previously elucidated. 
Since most of the study population was enrolled into the Glomerular Disease Collaborative 
Network’s database within our institution, the patients were well characterized and had outcome 
measures readily available.  However, since the population consisted of both SLE and SVV 
patients, differences in baseline clinical measures and demographics were found.  Predictably, 
the SLE group was younger and consisted of a higher percentage African-American race than 
the SVV group.  Regarding baseline clinical laboratories, the SVV group had higher SCr and the 
SLE group had higher UP:Cr.  Activity indices were higher and damage indices were lower for 
the SLE versus SVV patients using their respective SLEDAI/DI and BVAS/VDI assessment 
tools, respectively.   
Evaluation of changes in the kidney outcome parameters of eGFR, SCr, and UP:Cr during 
mycophenolic acid therapy demonstrated differences between disease groups.  The SVV 
patients had changes that favored non-statistically significant decreases in SCr and increases in 
eGFR over a mean follow-up period of 4.6±3.6 years; albeit the increase in eGFR was on the 
order of 11 mL/min/1.73m2.  The SLE patients had changes in UP:Cr that favored an order of 
magnitude decrease (-1.3) over the SVV patients (-0.2), although these changes were not 
statistically significant.  A 50% increase in SCr and/or UP:Cr, suggesting at least a partial 
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disease relapse on mycophenolic acid therapy was demonstrated in 32% and 17% of patients, 
respectively.   
Previous small studies of mycophenolic acid maintenance therapy in patients with SVV have 
reported stabilization of kidney function and remission at 15 months. 11 In one recent study of 
Asian patients with ANCA vasculitis being treated for induction of remission, 78% of 
mycophenolic acid-treated and 47% of cyclophosphamide-treated patients had complete 
remission, 9 suggesting a better resonse to mycophenolic acid versus cyclophosphamide 
therapy in Asian patients.  Additionally, 44% of patients receiving mycophenolic acid recovered 
kidney function. 9  Lanford, et al reported a relapse rate of 43% for Wegener’s Granulomatosus 
patients receiving mycophenolic acid. 10  Previous reports in the SLE population have reported 
relapse rates of between 19% and 46% in patients receiving mycophenolic acid for maintence of 
remission. 2,3  These previous studies in SLE and SVV have reported relapse rates on 
mycophenolic acid therapy that were similar to our own data.  We also assessed changes in 
urinary parameters and composite outcomes by race (data not shown), the results of which did 
not demonstrate any differences in these outcomes.  We did not evaluate Asians as a group, 
however, since there were limited patients in this race category.  Five year kidney survival was 
similar between glomerulonephritis patients treated with mycophenolic acid; 90% for SLE and 
80% for SVV.  Other publications have not reported estimated 5-year kidney survival based on 
mycophenolate mofetil treatment for maintenance of remission.   
A previous meta-analysis in SLE nephritis reported a reduction in relative risk for all-cause 
mortality (RR 0.709; CI 0.373-1.347) and kidney failure (RR 0.453; CI 0.183-1.121) in patients 
who received either mycophenolic acid or intravenous cyclophosphamide therapies for 
induction. 40  Most recently, the results from the ASPREVA Lupus Management Study, which 
compared mycophenolate mofetil (dosing target of 3 g/day) to intravenous cyclophosphamide 
(monthly dosing target of 0.5 to 1 g/m2) for induction of remission were published. 6  These 
results showed similar primary outcomes in each treatment arm.  The specific outcomes 
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assessed were: decreases in UP:Cr to <3.0 in patients with nephrotic range proteinuria, or 
decreases by ≥50% in patients with sub-nephrotic proteinuria, and stabilization (±25%) or 
improvement in SCr at 24 weeks.  The primary efficacy end-point was reached by 64% of 
mycophenolate mofetil-treated patients and 57% of cyclophosphamide-treated patients. 6  
Overall, 52% of patients showed a ≥50% decrease in UP:Cr and 56% showed a ≥50% 
improvement in SCr from diagnosis while on mycophenolic acid therapy.  Our data seems 
consistent with the results from the ASPREVA study.  An important finding from the ASPREVA 
trial was that the racial group categorized as “other” and primarily comprised of African-
American had a statistically significant reduction in efficacy with cyclophosphamide (38%) as 
opposed to similar efficacy with Caucasians in patients treated with mycophenolate mofetil 
(60%).6  In the age of personalized medicine, this finding suggests that mycophenolic acid may 
be preferred over cyclophosphamide for African-American SLE patients.  Another recent study 
reported clinical responses in only ~50% of Hispanic patients with SLE being treated with either 
mycophenolate mofetil or cyclophosphamide, 41 presenting an opportunity to evaluate the 
comparable efficacy of other therapies in this patient group. 41  Studies to evaluate the etiologies 
for differences in response to selected therapies are warranted to enable a comprehensive 
individualized therapy approach in glomerulonephritis.   
The influence of genetic polymorphisms in MPA drug metabolizing enzyme (UGT1A7, 
UGT1A9, UGT2B7) and transporter (MDR1) genes on therapy outcomes were assessed in 
order to evaluate pharmacogenomics/genetics as a tool for individualizing therapy in 
glomerulonephritis patients receiving mycophenolic acid.  A rheumatoid arthritis and healthy 
control cohort were included in our genomic evaluations to facilitate our understanding of allelic 
frequencies in SLE and SVV patients as compared to another autoimmune disease that does 
not afflict the kidneys and healthy patients.  This information was pertinent for our understanding 
of the association between autoimmune kidney diseases and alterations in metabolizing genes 
and transporters.  This hypothesis was reasonable given that numerous drugs and 
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environmental substances are substrates of these enzymes and transporter proteins.  Based on 
the genetic background of the study population, an adequate frequency for polymorphisms in 
the UGT1A7, UGT2B7, and MDR1 genes enabled the planned assessments.  Some statistically 
significant differences across disease cohorts were demonstrated for UGT1A7 and UGT2B7.  
The SVV cohort had a higher frequency of the UGT2B7 C802T variant/variant than healthy 
controls or rheumatoid arthritis cohorts (where it was absent in both cohorts), and had a 2-fold 
increase in the polymorphism frequency over the frequency in the SLE cohort.  The UGT1A7 
T622C variant/variant was found in a similar frequency in the SLE and healthy control 
populations, a 2-fold lower frequency was found in the SVV cohort, and the polymorphism was 
absent in the rheumatoid arthritis cohort.   
The polymorphisms that we evaluated have been purported to have various effects on the 
pharmacokinetics of mycophenolic acid and its metabolites and this could partly explain 
treatment-related outcomes.  The UGT2B7 C802T polymorphism has been purported to result 
in a 25% increase in mycophenolic acid area under the plasma concentration time curve of total 
as well as unbound drug, and increases in Cmax, suggesting a phenotype of reduction in 
UGT2B7 enzyme activity. 16,17  We previously showed decreased renal clearance and increased 
AUC of mycophenolic acid in patients who were heterozygotes for the UGT2B7 C802T 
polymorphism. 32  Since renal clearance is a component of total clearance, this finding of 
enhanced AUC is likely reflective of a reduction in the renal and nonrenal components of total 
clearance.  A study compared plasma concentrations after an oral mycophenolate mofetil dose 
in mdr1 and mrp2 deficient mice to clarify the roles of each transporter in MPA disposition.  The 
results showed increased brain concentrations of MPA in the mdr1 deficient, but not the mrp2 
deficient mice, suggesting the possibility of mycophenolic acid being a substrate for P-
glycoprotein. 31  Additionally, a slight reduction in plasma concentration was seen only in the 
sampling time just after dose in the mdr1 deficient mice, but no effect on overall disposition was 
demonstrated.  We previously reported that UGT1A7 T622C heterozygosity predicted increased 
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oral clearance and decreased Ctrough of mycophenolic acid, but we did not have adequate 
numbers of patients who were variant/variant to assess this genotype. 32  In this study, we 
expanded our previous research by assessing patient-related outcomes to mycophenolic acid 
therapy in accordance with genotype.  In mycophenolic acid-treated patients, we noted 
differences in the absolute changes of the UP:Cr in relationship to MDR1 C3435T and UGT1A7 
T622C genotype.  Patients who were heterozygous or homozygous for the UGT1A7 variant had 
a relative increase or only slight decrease in UP:Cr, suggesting a detrimental effect of this 
UGT1A7 SNP on mycophenolic acid efficacy as measured by urinary protein excretion.   
Patients who were heterozygous or homozygous variant for the MDR1 C3435T 
polymorphism had reductions or lesser increases in UP:Cr while receiving mycophenolic acid 
therapy, suggesting a beneficial effect of the MDR1 SNP on immunosuppressant efficacy as 
measured by urinary protein excretion.  P-glycoprotein, the translated protein product of MDR1 
is present in the tubules of the kidneys 42 and is proposed to be engaged in the transport of 
mycophenolic acid 31.  Enhanced activity of P-glycoprotein via the polymorphism would be 
hypothesized to enhance the renal elimination of MPA by either MPA itself or its glucuronide 
metabolites.  The efficacy of MPA, however, should be viewed from its site of action in the 
lymphocytes and not at the kidney level.  Hence, while renal P-glycoprotein may enhance renal 
elimination of MPA or its metabolites, this aspect cannot be translated directly to any 
mechanistic effects of the drug at the level of the kidney.  Any true effects of MPA on surrogate 
measures of kidney function, such as urinary protein excretion or glomerular filtration rate are 
likely mediated through the circulating lymphocytes.  Various publications in other disease 
states have described treatment-related outcomes based on polymorphisms in drug 
metabolizing enzymes and transporters. 43-50  Polymorphisms in MDR1 at the nucleotide 3435 
position and disease outcomes have been assessed in epilepsy, transplantation, and breast 
cancer. 43,44,49  While no effects of MDR1 genotype on epilepsy outcomes were found, cardiac 
transplant patients prescribed standard triple-drug combination of cyclosporine, azathioprine, 
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and prednisolone and who were wildtype homozygous had a 1.8 times increased risk for having 
a rejection event in the first 12 months. 44  The presence of the variant/variant MDR1 C3435T 
genotype predicted clinical response for locally advanced breast cancer to anthracycline 
therapy. 49  These data follow the same positive direction of response as our current study in 
glomerulonephritis; demonstrating a beneficial effect of the variant/variant genotype on 
outcomes.  Single nucleotide polymorphisms in other drug metabolizing enzymes have also 
been associated with various treatment-related outcomes. 45-48,50-52  
Since the SVV cohort exhibited higher frequencies of the evaluated UGT2B7 polymorphism, 
we assessed whether this polymorphism increased the risk of autoimmune disease in SVV, 
SLE, and rheumatoid arthritis patients.  Since the frequency of the UGT2B7 variant allele has 
not been reported in African-American patients and since SLE and SVV patient populations are 
different in terms of racial composition, any analysis to evaluate for a gene-disease association 
requires controlling for race.  When we controlled for race, we found an increased Odds Ratio 
(3.073; C.I. 1.53-6.17) for having SVV when exhibiting heterozygosity or homozygous variant for 
the UGT2B7 polymorphism.  Additionally, our data showed a reduction in Odds Ratio (0.414; 
C.I. 0.21-0.80) for SVV when patients were heterozygous or homozygous variant for the 
UGT1A7 polymorphism.  Previous studies have reported increases in the risk of colorectal, 
breast, bladder, and orolaryngeal cancers in patients with various SNPs in the UGTs, including 
the UGT2B7 C802T polymorphism. 25,27,28,53,54  Polymorphisms in MDR1 have also been found 
to be predictive of end-stage kidney disease progression, regulation of the aldosterone system, 
and susceptibility to inflammatory bowel disease. 55-57  The UGT2B7 polymorphism is a non-
synonymous SNP resulting in a histidine to tyrosine (H268Y) amino acid change and is 
expressed in various tissues including the kidney, lung, liver, breast, brain, and intestine. 58  A 
previous study showed a lower activity of the variant protein toward detoxification/ 
glucuronidation of the tobacco carcinogen NNAL. 59  Endogenous bile acids and steroids, as 
well as therapeutic agents including nonsteroidal anti-inflammatory agents, retinoic acid, and 
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estradiol are substrates for UGT2B7.  Our data is intriguing given that there are proposed 
environmental exposure risk factors for SVV, 22-24 and the UGT enzymes play a central 
detoxification role.  Hence polymorphisms in genes encoding metabolizing enzymes that result 
in reduced detoxification efficacy or efficiency would be hypothesized to be risk factors for 
disease.  We previously published a review on drug exposure associated SVV 60 and many of 
the medications in that report are moieties known to be substrates for metabolism by UGT2B7.   
Pharmacokinetic variables representing drug exposure and leukocyte mRNA expression 
patterns of metabolizing enzymes and transporters were evaluated in the current study to 
assess their relationships with treatment outcomes.  We wanted to evaluate the relationship of 
mycophenolic acid AUC and Ctrough plasma concentrations with outcomes since there is 
ongoing debate in the kidney transplant community surrounding this issue.  In fact, there is 
advocacy for an AUC of 30 to 60 mg hr/L 61-64, and a Ctrough concentration of at least 1 to 3.5 
mg/L 65,66 when patients are receiving triple therapy immunosuppression for prevention of kidney 
transplant rejection.  These recommendations were based on evaluation of acute rejection rates 
in randomized trials that aimed to assess this outcome based on mycophenolic acid exposure.  
Since patients with glomerulonephritis are typically treated with only single or at most, double 
immunosuppressive drugs, it is conceivable that targeted mycophenolic acid AUC and Ctrough 
concentrations should be considerably higher.   
In our previous publication, we identified several patient-level variables that influenced 
mycophenolic acid pharmacokinetics: increased UP:Cr and weight and decreased SCr were 
predictors of increased oral clearance; Caucasian race and elevated SCr were predictors of 
higher mycophenolic Ctrough concentrations 32.  A recent publication in autoimmune 
glomerulonephritis patients receiving mycophenolic acid reported 29% of Ctrough 
concentrations of < 3mg/L were from patients with active disease, whereas only 2% of Ctrough 
concentrations ≥3mg/L were from patients with active disease, suggesting a critical ctrough 
concentration that is associated with disease activity. 67  Additionally, remission maintenance 
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was persistent in patients with Ctrough concentrations of ≥3.5mg/L. 67  Unfortunately, we did not 
detect any significant correlations between either AUC or Ctrough plasma concentrations and 
outcomes as defined by changes in eGFR, SCr, or UP:Cr.  Additionally, we evaluated for 
differences in AUC or Ctrough by patients who had worsened versus improved UP:Cr and 
eGFR and still failed to appreciate any differences (data not shown).  We were also unable to 
assess for composite kidney outcomes due to too few patients exhibiting these outcomes in 
patients who had mycophenolic acid pharmacokinetics assessed.  Possible reasons for failure 
to obtain any significant findings between mycophenolic acid pharmacokinetics and outcomes 
include: 1) the true lack of such a relationship in glomerulonephritis patients, 2) failure to follow 
patients for a sufficiently long enough period of time, and/or 3) failure of the measured 
pharmacokinetics to represent the patients’ actual exposures throughout the course of their 
treatment, secondary to different doses being prescribed and different durations of time spent at 
different doses.   
Previous studies have reported that patterns of mRNA expression within leukocytes are 
important for predicting outcomes and treatment responses in various diseases. 68-70  We have 
evaluated patterns of expression for drug metabolizing enzyme and transporter transcript in 
peripheral blood cells of glomerulonephritis patients undergoing therapy with mycophenolic acid 
or cyclophosphamide. 33  We were interested in whether the expression in glomerulonephritis 
patients correlated with treatment outcomes as there were differences in expression in several 
genes between cohorts.  Matched mRNA expression and genotype data was not significantly 
correlated in the SVV and SLE patients, but there was a borderline result for MDR1 C3435T 
genotype and MDR1 transcript expression; with wildtype genotype having lower expression than 
variant genotypes.  Unfortunately, matched data was not available for healthy controls and no 
expression data was available for any of our rheumatoid arthritis patients.  We were unable to 
demonstrate any significant relationships between kidney outcomes of eGFR, SCr, or UP:Cr 
and mRNA expression in mycophenolic acid treated patients.  When we assessed composite 
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kidney outcomes in our entire cohort of patients (receiving either mycophenolic acid or 
cyclophosphamide), we showed that expression of MDR1 was significantly reduced in patients 
with the composite outcomes of death, dialysis, or transplantation.  This finding is somewhat 
confusing given some previous research that has suggested decreased MDR1 expression and 
enhanced intracellular accumulation of a P-glycoprotein probe substrate. 71  Additionally, in our 
own previous work in assessment of kidney toxicity in transplant recipients, increased 
nephrotoxicity was shown in patients with reduced immunohistochemical staining for P-
glycoprotein; with the possibility of enhanced intra-tubular concentrations of pharmacologically 
active nephrotoxins. 42  For mycophenolic acid, enhanced lymphocyte exposure and 
pharmacological effects would be predicted in conditions of reduced expression of P-
glycoprotein.  However, there is often promiscuity among transporters for various substrates 
and the multi-drug resistance associated proteins (MRPs) are known to transport the 
glucuronide metabolite of mycophenolic acid.  Therefore, a reduction in one transporter and an 
increase in another may negate the effects that would be attributed to one single transport 
protein.  Recent research has suggested that reduced P-glycoprotein expression can reduce the 
release of intracellular cytokines including interferon gamma, interleukin 2, interleukin 4, and 
tumor necrosis factor alpha, 72 and this may be at least partly responsible for worsened 
outcomes in inflammatory autoimmune diseases such as SLE and SVV.   
Conclusions 
The current study sought to identify patient, genomic, and/or pharmacokinetic factors that 
may influence outcomes to mycophenolic acid therapy in patients with glomerulonephritis.  The 
outcomes of interest were changes in kidney function parameters (eGFR, SCr, and UP:Cr) as 
well as composite outcomes (dialysis, death, transplantation).  While there were no differences 
in mycophenolic acid treatment-related outcomes by race, the UGT1A7 polymorphism was 
associated with worsened UP:Cr and the MDR1 C3435T polymorphism was associated with 
improve UP:Cr.  The most intriguing finding was the association of SVV disease with UGT2B7 
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C802T polymorphism.  We are currently assessing this polymorphism in a larger set of 
autoimmune disease patients to confirm our results.  Assessment of relationships between drug 
exposure or trough plasma concentrations and outcomes did not yield any significant findings.  
This research demonstrates the complex relationships between disease risks and/or outcomes 
and individualized factors such as genotype in patients with glomerulonephritis.   
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Table 7.1 
Demographics, Clinical and Pharmacokinetic Data (Mean (standard deviation)) for 
Glomerulonephritis Patients Treated with Mycophenolic Acid 
    All   SLE    SVV 
    n=85   n=37    n=48   
Age (years)   47 (16.0)  39 (11)    54 (16)   
Race (C/AA/O)   55/22/8   15/17/5    40/5/3   
Gender (M/F)   28/57   6/31    22/26   
SCr (mg/dL) at Biopsy  2.1 (2.0)  1.5 (1.3)   2.5 (2.3)  
eGFR (mL/min) at Biopsy 57.6 (40.8)  75.2 (46.8)   41.9 (26.4) 
UP:Cr at Biopsy  2.0 (2.7)  2.8 (3.4)   1.2 (1.6)  
Daily Dose (mg/day)  1600 (820)  1622 (975)   1505 (685) 
Present or previous steroids(%) 96%   93%    98% 
Previous cyclophosphamide(%) 85%   81%    88% 
Duration of Follow-up (yrs) 4.6 (3.6)  5.0 (4.0)   4.3 (3.2) 
 
Abbreviations 
C/AA/O – Caucasian/African-American/Other  eGFR – estimated glomerular filtration rate 
SCr – serum creatinine     SLE – systemic lupus erythematosus 
SVV – small vessel vasculitis    UP:Cr – urinary protein to creatinine ratio 
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Table 7.2:  
Distribution for eGFR, serum creatinine, and UP:Cr between disease groups in patients 
treated with mycophenolic acid  
 
 Disease N obs Mean Std Median P values* 
eGFR_diagnosis       0.0007 
  SVV 48 39 41.9 26.4 38.7  
  SLE 37 32 75.2 46. 8 77.9  
eGFR_treatment        0.0009 
  SVV 48 44 55.2 24.6 52.3  
  SLE 37 35 84.9 42.7 89.3  
eGFR_follow-up       0.0184 
  SVV 48 46 53.9 27.5 49.0  
  SLE 37 35 73.8 39.3 73.7   
SCr diagnosis       0.0012 
  SVV 48 39 2.5 2.3 1.8  
  SLE 37 32 1.5 1.3 1.1  
SCr treatment        0.0013 
  SVV 48 44 1.6 0.9 1.4  
  SLE 37 35 1.2 0.8 0.9  
 SCr follow-up         0.0452 
  SVV 48 46 1.8 1.4 1.4  
  SLE 37 35 1.5 1.3 1.0  
UP:Cr diagnosis       0.0712 
  SVV 48 24 1.2 1.6 0.6  
  SLE 37 24 2.8 3.4 1.0  
UP:Cr treatment        0.1080 
  SVV 48 40 0.8 1.2 0.3  
  SLE 37 33 1.3 1.9 0.6  
UP:Cr follow-up        0.1075 
  SVV 48 36 0.8 1.6 0.2  
  SLE 37 31 1.4 2.1 0.4  
P values were calculated by Wilcoxon two sample test. 
 
 
Abbreviations 
eGFR – estimated glomerular filtration rate   
SCr – serum creatinine   
SLE – systemic lupus erythematosus 
SVV – small vessel vasculitis 
UP:Cr – urinary protein to creatinine ratio 
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Table 7.3 
Allelic Frequency Distributions    
    Study Cohorts      
SVV  SLE  Healthy Control R. Arthritis 
    (n=101) (n=67)  (n=75)   (n=26) 
UGT1A9 
 G8A  G 1.0  1.0  1.0   1.0  
   A 0.0  0.0  0.0   0.0  
 C98T  C 0.99  0.99  0.99   1.0  
   T 0.01  0.01  0.01   0.0  
 C-2152T C 0.97  0.96  0.97   0.94  
   T 0.03  0.04  0.03   0.06  
 T-275A T 0.97  0.94  0.96   0.90  
   A 0.03  0.06  0.04   0.10  
UGT1A7   
 T622C  T 0.78  0.78  0.63   0.71  
   C 0.22  0.22  0.37   0.29  
UGT2B7 
 C802T  C 0.64  0.74  0.79   0.81  
   T 0.36  0.26  0.21   0.19  
MDR1/ABCB1 
 C1236T C 0.60  0.60  0.56   0.69  
   T 0.40  0.40  0.44   0.31  
 C3425T 
   C 0.56  0.66  0.56   0.58  
   T 0.44  0.34  0.44   0.42  
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Abbreviations 
MDR1/ABCB1 – multi-drug resistance gene 
R. Arthritis – rheumatoid arthritis 
SLE – systemic lupus erythematosus 
SVV – small vessel vasculitis 
UGT – uridine diphosphate glucuronosyltransferase 
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Table 7.4 
Genotype Frequency Distributions (frequency (n)) 
      Vasculitis  SLE  Healthy Control Rheumatoid Arthritis  
      n = 101 n = 67  n = 75   n = 26 
UGT1A9 
 G8A  G/G   1.0 (79) 1.0 (51) 1.0 (70)  1.0 (26) 
   G/A   0.0 (0)  0.0 (0)  0.0 (0)   0.0 (0) 
   A/G   0.0 (0)  0.0 (0)  0.0 (0)   0.0 (0) 
 C98T  C/C   0.98 (98) 0.98 (64) 0.99 (72)  1.0 (26) 
   C/T   0.02 (2) 0.02 (1) 0.01 (1)  0.0 (0) 
   T/T   0.0 (0)  0.0 (0)  0.0 (0)   0.0 (0) 
 C-2152T C/C   0.94 (74) 0.92 (47) 0.94 (67)  0.88 (23) 
   C/T   0.06 (5) 0.08 (4) 0.06 (4)  0.12 (3) 
   T/T   0.0 (0)  0.0 (0)  0.0 (0)   0.0 (0) 
 T-275A T/T   0.94 (95) 0.88 (57) 0.91 (64)  0.81 (21) 
   T/A   0.06 (6) 0.12 (8) 0.09 (6)  0.19 (5) 
   A/A   0.0 (0)  0.0 (0)  0.0 (0)   0.0 (0) 
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UGT1A7   
 T622Ca T/T   0.62 (62) 0.45 (29) 0.39 (27)  0.42 (11) 
   T/C   0.31 (31) 0.40 (26) 0.49 (34)  0.58 (15) 
   C/C   0.07 (7) 0.15 (10) 0.12 (9)  0.0 (0) 
UGT2B7 
 C802Tb C/C   0.44 (34) 0.55 (28) 0.58 (41)  0.62 (16) 
   C/T   0.39 (30) 0.37 (19) 0.42 (30)  0.38 (10) 
   T/T   0.17 (13) 0.08 (4) 0.0 (0)   0.0 (0) 
MDR1/ABCB1 
 C1236T C/C   0.38 (37) 0.45 (30) 0.33 (23)  0.38 (10) 
   C/T   0.44 (42) 0.46 (31) 0.47 (33)  0.62 (16) 
   T/T   0.18 (17) 0.09 (6) 0.20 (14)  0.0 (0) 
 C3425T C/C   0.29 (28) 0.43 (29) 0.33 (23)  0.27 (7) 
   C/T   0.54 (52) 0.45 (30) 0.46 (32)  0.62 (16) 
   T/T   0.17 (16) 0.12 (8) 0.21 (15)  0.11 (3) 
a: p=0.0123 for differences across groups  b: p=0.0002 for differences across groups  
Abbreviations: 
MDR1 – multi-drug resistance gene  UGT – uridine diphosphate glucuronosyltransferase 
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Table 7.5 
The Odds of Autoimmune Diseases Among the UGT2B7 and UGT1A7 Genotype Groups When Controlling for Race 
Disease 
Group Predictor   OR (95% CI)* 
P 
Values* 
Vasculitis Race 2 vs.  1 0.908(0.387~2.130) 0.8248 
 
UGT2B7 C802T 1 or 2 vs. 0 3.073(1.530~6.172) 0.0016 
 Race 2 vs.  1 0.823(0.374~1.811) 0.6277 
 
MMF_UGT1A7 T622C 1 or 2 vs. 0 0.414(0.215~0.796) 0.0082 
 Race  2 vs.  1 1.011(0.456~2.241) 0.9790 
 
MDR1 C1236T 1 vs. 0 0.792(0.383~1.636) 0.5282 
  2 vs. 0 0.658(0.266~1.628) 0.3649 
  Race 2 vs. 1 1.027(0.457~2.311) 0.9484 
  
MDR1 C3435T 1 vs. 0 1.242(0.583~2.644) 0.5746 
    2 vs. 0 0.730(0.284~1.877) 0.5132 
Lupus Race 2 vs.  1 7.011(3.017~16.292) <0.0001 
 
UGT2B7 C802T 1 or 2 vs. 0 1.434(0.620~3.320) 0.3998 
 Race 2 vs.  1 6.702(3.000~14.963) <0.0001 
  
UGT1A7 T622C 1 vs. 0 0.971(0.419~2.249) 0.9455 
    2 vs. 0 1.854(0.544~6.310) 0.3235 
  Race 2 vs. 1 6.763(2.970~15.399) <0.0001 
  
MDR1 C1236T 1 vs. 0 0.951(0.406~2.227) 0.9080 
    2 vs. 0 0.642(1.189~2.197) 0.4827 
  Race 2 vs.  1 9.104(3.546~23.373) <0.0001 
  
MDR1 C3435T 1 vs. 0 1.909(0.703~5.179) 0.2043 
    2 vs. 0 1.127(0.319~3.980) 0.8531 
RA Race 1 vs. 2 1.057(0.355~3.146) 0.9201 
  
UGT2B7 C802T 1 or 2 vs. 0 0.887(0.348~2.265) 0.8025 
 Race 2 vs.  1 1.003(0.324~3.106) 0.9961 
  
UGT1A7 T622C 1 or 2 vs. 0 0.922(0.352~2.416) 0.8687 
  Race 2 vs. 1 1.044(0.334~3.268) 0.9411 
  
MDR1 C1236T 1or 2 vs. 0 0.769(0.286~2.067) 0.6032 
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  Race 2 vs. 1 1.088(0.327~3.622) 0.8903 
  
MDR1 C3435T 1 vs. 0 1.592(1.516~4.905) 0.4183 
    2 vs. 0 0.565(0.112~2.840) 0.4880 
 
P value and odds were calculated by Logistic model 
Genotypes were categorized as: 0 for wildtype/wildtype, 1 for heterozygote, and 2 for variant/variant 
Abbreviations 
MDR1/ABCB1 – multi-drug resistance gene; UGT – uridine diphosphate glucuronosyltransferase 
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Table 7.6 
Mean±Standard Deviation Changes in eGFR, SCr, and UP:Cr by Genotype Category in Glomerulonephritis Patients Receiving 
Mycophenolic Acid  
    SNP/Genotype  Delta eGFR  Delta SCr  Delta UP:Cr  
 UGT1A7 T622C WT/WT   1.7±26.1  -0.2±1.2  -1.1±3.8a 
    Heterozygote  11.5±28.9  -0.6±2.4  -0.7±1.5 
    Variant/Variant  -3.6±26.4  0.7±2.0   1.4±2.7 
 UGT2B7 C802T WT/WT   24.0±31.7  -0.1±1.3  -0.2±2.1 
    Heterozygote  4.7±19.5  -0.3±0.6  -1.6±4.0 
    Variant/Variant  6.7±36.5  -0.0±0.9  -0.4±0.3 
 MDR1 C1236T  WT/WT   12.4±31.3  -0.7±2.9  -0.1±2.5 
    Heterozygote  1.8±27.9  -0.3±1.0  -1.5±3.1 
    Variant/Variant  7.8±13.7  0.4±2.0   0.7±4.0 
 MDR1 C3435T  WT/WT   14.4±31.6  -0.9±3.0  0.6±1.8b 
    Heterozygote  4.5±27.6  -0.3±0.8  -2.0±3.3 
    Variant/Variant  -2.0±17.5  0.6±1.7   0.3±2.9 
a: p=0.0706 
b: p=0.0409 
Data represents absolute changes in parameters from diagnosis to last follow-up 
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Abbreviations 
eGFR – estimated glomerular filtration rate 
MDR1 – multidrug resistance  
SCr – serum creatinine 
UGT – uridine diphosphate glucuronosyltransferase 
UP:Cr – urinary protein to creatinine ratio 
WT – wildtype  
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Figure Legends 
 
Figure 7.1: Clinical Measures in Patients with Glomerulonephritis Treated with 
Mycophenolic Acid.  Figure represents changes from diagnosis to follow-up in patients with 
glomerulonephritis treated with mycophenolate mofetil.  A.Serum creatinine; B.Urinary protein to 
creatinine ratio (UP:Cr); C. estimated glomerular filtration rate (eGFR).  
Figure 7.2. Kaplan Meier Survival Curves for Composite Outcomes (Dialysis, Death, or 
Transplantation) During Mycophenolic Acid Treatment.  Abbreviations are: eGFR; 
estimated glomerular filtration rate, SLE; systemic lupus erythematosus, SVV; small vessel 
vasculitus.  SLE is demonstrated by the red/top line and SVV is demonstrated by the 
blue/bottom line. 
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Figure 7.1B. 
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Figure 7.1C. 
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Figure 7.2 
 
 
 
  
 
 
 
 
Chapter 8 
Conclusions 
 
 220 
 
 This dissertation project sought to evaluate pharmacokinetic and pharmacogenomic factors 
that may be associated with altered outcomes to mycophenolic acid (MPA) therapy in 
glomerulonephritis patients with small vessel vasculitis (SVV) and systemic lupus 
erythematosus (SLE).  The goal of this research was to understand treatment responses to 
MPA in these former patient groups in order to implement strategies to improve outcomes.  The 
central hypothesis was that the metabolism and transport of MPA are different in individual 
patients with glomerulonephritis and these differences account for variations in systemic or 
tissue exposure and thus influence renal outcomes.  Three specific objectives were developed 
to investigate the hypothesis. 
Objective 1.  Evaluate the pharmacokinetic parameters for MPA in subjects with SVV and 
SLE with variable levels of kidney function as reported by glomerular filtration rate, 
proteinuria, and disease activity. Develop a population pharmacokinetic model for MPA in 
glomerulonephritis.  
Objective 2.  Evaluate the pharmacokinetics for the glucuronide metabolities of MPA; e.g. 
mycophenolic acid glucuronide (MPAG) and acyl-mycophenolic acid glucuronide (AcMPAG) 
in the SVV and SLE patients as a function of variable kidney function as reported by 
glomerular filtration rate and proteinuria.  Incorporate metabolite plasma and urine data into 
a population pharmacokinetic model in glomerulonephritis. 
Objective 3.  Assess genotype frequencies at sites of known single nucleotide 
polymorphisms in uridine diphosphate glucuronosyltransferases (UGTs) 1A9, 1A7, and 2B7, 
and multidrug resitance gene (MDR1/ABCB1) and evaluate for associations with MPA 
pharmacokinetics and disease outcomes in glomerulonephritis patients.  Determine mRNA 
expression patterns for the drug metabolizing genes UGT1A9, UGT1A7, UGT2B7, and 
transporter genes ABCB1, ABCC2, and SLCO1A2 in leukocytes of glomerulonephritis 
patients and their associations with pharmacokinetics and disease outcomes. 
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 The underlying rationale for evaluating MPA and metabolite pharmacokinetics in patients 
with glomerulonephritis was due to the disease-associated clinical findings of urinary protein 
excretion, hypoalbuminemia, and kidney function decline and the lack of published data that 
have described the impact of these clinical scenarios on the pharmacokinetics of many 
pharmaceutical agents.  Noncompartmental pharmacokinetic results for MPA from these studies 
showed highly increased apparent oral clearance (Cl/F 343 ± 200 mL/min in SLE and 288 ± 154 
mL/min in SVV) values that were 2-fold higher than previously reported in kidney transplant 
recipients.  Multiple regression analyses in SLE patients showed that MPA apparent oral 
clearance was predicted by creatinine clearance (Clcr) and serum albumin (MPA lnCl/F = 5.358 
+ 0.0092 (Clcr) – 0.078 (ranked albumin), R2 51.1%, p = 0.0195). Patients with urinary protein to 
creatinine ratios ≥ 1 g/d had lower trough concentrations and area under the curve (AUC 0-12) 
values, and higher apparent oral clearance compared to patients with urinary protein to 
creatinine ratios < 1 g/d. Patients with serum albumin < 4 g/dL had higher MPA apparent 
unbound clearance and MPAG apparent renal clearance values versus patients with serum 
albumin ≥ 4g/dL. Area under the plasma concentration time curve during the period of 
enterohepatic recycling (e.g. AUC6-12), gender, and age all contributed toward the prediction of 
MPAG apparent renal clearance.  For SVV, weight and race were predictive for MPA apparent 
oral clearance (ranked MPA Cl/F = -11.766 + 0.2035 (wt) + 4.9578 (race), R2 41.8%, p = 
0.0045).  Creatinine clearance (Clcr) < 60 mL/min resulted in higher MPA exposure as 
assessed by  total AUC 0-12, AUC 6-12, and unbound AUC 0-12.  Additionally, the ratio of metabolite 
to MPA exposure (MPAGAUC:MPAAUC) of 8.7±5.6 was lower than previously reported in renal 
transplant recipients.  In summary, the noncompartmental analyses showed that higher 
creatinine clearance and decreased serum albumin were identified as primary contributors to 
increased MPA apparent oral clearance and decreased exposure in SLE.  Higher body weight 
and Caucasian race were primary contributors to increased MPA apparent oral clearance and 
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decreased exposure in SVV.  Additionally, SVV patients with creatinine clearance <60 mL/min 
versus ≥ 60 mL/min had enhanced MPA exposure.  These findings are important as they 
encourage clinicians to be mindful of clinical changes that occur throughout the disease courses 
of SLE and SVV that may subsequently alter MPA pharmacokinetics and exposure. 
 A population pharmacokinetic modeling approach to MPA in the entire cohort of patients 
with glomerulonephritis was developed to enable estimates of key pharmacokinetic parameters 
including renal clearance, nonrenal clearance, and central volume, and to further investigate the 
influence of covariates including measures of kidney function, serum albumin, demographic 
variables and genotype for single nucleotide polymorphisms.  The population approach also 
enabled estimation of MPA inter-individual variability and residual variability.  The final 
pharmacokinetic model was composed of nine compartments and included terms to describe 
biliary drug clearance.  The model fit the data well as demonstrated by the generated goodness 
of fit plots.  Unlike previous models of MPA pharmacokinetics, the model was developed with 
extensive plasma and urine sample collections from a well-defined population of 
glomerulonephritis patients.  The resulting parameter estimates were considerably different than 
those obtained by other investigators who evaluated kidney transplant patients receiving MPA.  
As with the noncompartmental analysis, two key covariates, estimated creatinine clearance and 
serum albumin, influenced the renal and nonrenal components of MPA clearance.  Creatinine 
clearance ≤80 mL/min had a positive effect on MPA renal clearance resulting in a mean 
(%RSE) covariate coefficient of 1.33 (33.2).  For the nonrenal clearance component, creatinine 
clearance had a positive effect (covariate coefficient of 0.831 (18.5)), while serum albumin had a 
negative effect (covariate coefficient of -1.35 (31.5)).  Creatinine clearance also had a positive 
influence on MPAG and AcMPAG renal clearance estimates.  Through simulations of typical 
clinic patients with variations in serum albumin and creatinine clearance, it was demonstrated 
that patients with glomerulonephritis would have highly altered MPA exposures than what would 
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be concluded without weighing these factors in the calculation of the renal and nonrenal 
clearance pathways for MPA.  Future work will be needed to elucidate unbound MPA exposures 
and relevance to efficacy, toxicity, and metabolic pathways.  The current population model 
estimates can now be employed in validation glomerulonephritis populations. 
 After assessing the noncompartmental and population pharmacokinetics of MPA and 
metabolites, the role of pharmacogenomics, alone and in combination with clinical and 
demographic parameters on pharmacokinetic predictions in the entire cohort of 
glomerulonephritis patients receiving MPA was evaluated.  Genotyping was performed for 
known variants of UGTs reported to be primary enzymes for MPA metabolites (UGT1A9, 
UGT1A7, UGT2B7), and known variants for MDR1/ABCB1 that could potentially alter MPA 
disposition.  For assessment of genotype influence on pharmacokinetics, both UGT2B7 
heterozygosity and UGT1A7 heterozygosity predicted increased MPA apparent oral clearance.  
UGT1A7 heterozygosity also predicted lower MPA trough plasma concentrations.  Since the 
numbers of patients in the homozygous variant groups were small relative to the heterozygous 
groups, the clear effects of homozygosity were not able to be fully assessed.  Only UGT2B7 
heterozygosity remained in multivariate models, where it predicted enhanced apparent renal 
clearance.  The reason for disparity in genotype covariate effects between these regression 
models and the population models are not apparent.  In future studies, it will be necessary to 
further investigate the role of the kidneys as a key component to apparent oral clearance 
through the UGT2B7 metabolizing enzyme.  Future pharmacogenomic validation assessments 
will require numbers of patients. 
 Patient-level clinical and demographic data were contributory in both univariate and 
multivariate models.  In multivariate assessments, higher urinary protein excretion, lower serum 
creatinine, and increased weight predicted greater MPA apparent oral clearance.  White race 
and higher serum creatinine predicted higher MPA trough plasma concentrations.  Higher 
exposure to MPA was predicted by reduced levels of urinary protein excretion and higher serum 
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creatinine concentrations.  In summary, clinical and demographic parameters explained 30% to 
50% of MPA pharmacokinetics, while genetic polymorphisms explained only about 10%.  
Unfortunately, we were limited in our ability to fully assess genetic polymorphisms in UGT1A9 
secondary to the low frequency encountered in the glomerulonephritis population.  Hence the 
potential importance of the UGT1A9 polymorphisms in MPA disposition within the 
glomerulonephritis cohort may not be fully appreciated.     
 Since immunosuppressive drugs including MPA have their pharmacological site of action at 
the level of the leukocytes, and limited data was available concerning mRNA expression of drug 
transporters and drug metabolizing enzymes in leukocytes, this area of research was pursued 
within the dissertation research.  In addition to describing mRNA expression patterns in SLE 
and SVV patients, exploratory analyses related to prediction of pharmacokinetics and outcomes, 
and relationships to genotypes were also assessed.  Drug transporter transcripts (ABCC2, 
ABCB1, and ABCG2) were found in the leukocytes of most patients with glomerulonephritis, 
with the exception of SLCO1A2, which was expressed in only half of subjects.  Regarding drug 
metabolizing transcripts, UGT1A7, UGT1A9, and UGT2B7 were expressed in 50% of subjects’ 
leukocytes, CYP2B6 was expressed in over 90% of subjects, and CYP3A4 and CYP2C9 were 
not expressed.  This data would imply that active drugs such as MPA could undergo local 
metabolism within the leukocyte to the inactive MPAG in about half of patients, perhaps limiting 
overall exposure to MPA.  Alternatively, patients without the expression of UGTs would be 
hypothesized to have enhanced MPA local leukocyte exposure, which would be predicted to 
lead to higher efficacy, but with the risk of enhanced toxicity.  Since protein expression was not 
assessed, the direct link between transcript and protein expression cannot be defined 
absolutely.  Newly developed absolute quantitative mass spectroscopy methods will be 
employed in future work to more clearly define the relationship between transcript and protein 
expression.  Additionally, research evaluations to elucidate MPA turnover in lymphocytes is 
planned.  Other relevant findings resulting from the mRNA expression studies were: differential 
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expression patterns of drug metabolizing enzyme and transporter transcripts in patients with 
glomerulonephritis as compared to healthy control subjects, and differences in expression 
according to pharmacologic treatment, disease type, race, and possibly genotype.  This initial 
research will guide future investigations into transcript-mediated mechanisms for altered efficacy 
and toxicity to pharmacological therapies.    
 In the final efforts of this research program, the determinants of kidney outcomes in 
glomerulonephritis patients receiving mycophenolate mofetil therapy were evaluated.  Changes 
in estimated glomerular filtration rate, serum creatinine, and urinary protein excretion from 
diagnosis to follow-up, and the composite outcome of dialysis, transplantation, or death were 
assessed.  Both the SVV and SLE patients had absolute reductions in serum creatinine and 
increases in estimated glomerular filtration rate from diagnosis to follow-up, with the SVV 
patients having a higher magnitude of beneficial change.  However, the SLE patients as 
compared to the SVV patients, exhibited a greater reduction in urinary protein excretion while 
receiving mycophenolate mofetil therapy.  From the data, a 32% relapse rate, as defined by at 
least a 50% increase in serum creatinine, and a 17% relapse rate, as defined by at a least a 
50% increase in urinary protein excretion was inferred.  Both rates were evaluated from the 
period of diagnosis to follow-up.  The results demonstrated similar 2- and 5- year estimated 
composite survival rates for the SVV and SLE patients.   
 Genetic factors appeared to contribute to SVV disease, as well as MPA outcomes in the 
entire glomerulonephritis cohort.  The odds of SVV disease was greater in patients who were 
classified as heterozygous or variant homozygous for the UGT2B7 C802T polymorphism.  The 
odds of SVV disease was reduced in patients who were classified as heterozygous or variant 
homozygous for the UGT1A7 T622C polymorphism.  A trend toward statistical significance was 
found between the UGT1A7 T622C variant homozygous genotype and worsened urinary protein 
excretion.  Additionally, glomerulonephritis patients who were heterozygous or variant 
homozygous for ABCB1/MDR1 C3435T had a more favorable urinary protein excretion 
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response than patients who were wildtype variants.  A trend toward reductions in composite 
outcomes were noted in glomerulonephritis patients who were heterozygous or variant 
homozygous for the UGT2B7 C802T polymorphism.  Trends in outcome differences to 
mycophenolate mofetil therapy were not detected based on drug exposure (as defined by area 
under the plasma concentration time curve or trough plasma concentration) or leukocyte 
expression of drug metabolizing enzyme or transporter transcripts.  Future work will focus on 
more clearly defining the role of genetic determinants to therapy outcomes in patients with 
glomerulonephritis. 
 In summary, the work presented in this dissertation has considerably advanced the 
understanding of the disposition of MPA and its metabolites in patients with glomerulonephritis, 
a disease consisting of several clinical manifestations including urinary protein excretion, 
hypoalbuminemia, and reductions in kidney function.  Consistent with this work evaluating MPA, 
and additional work by the author, glomerulonephritis patients have increased apparent oral 
clearance of highly protein bound small molecule drug moieties.  The noncompartmental 
pharmacokinetics and linear statistical modeling approaches employed in this research 
demonstrated a contribution of increased creatinine clearance and decreased serum albumin on 
increasing apparent oral clearance.  Population compartmental modeling demonstrated that the 
renal component to clearance was impacted by creatinine clearance, while the nonrenal 
clearance component was impacted by serum albumin.  The developed population model can 
now be used in validation work within a larger cohort of glomerulonephritis patients to predict 
MPA pharmacokinetics.  Additionally, the statistical models developed within the work can be 
used prospectively to target defined pharmacokinetic goals for MPA therapy.  While it was 
somewhat disappointing to find only a relatively small effect of genetic polymorphisms on 
disposition of MPA and metabolites, a finding of a gene-disease link was particularly intriguing.  
Ongoing work in a larger subset of patients are planned to validate the association between 
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SVV disease and the condition of being UGT2B7 C802T heterozygous and homozygous 
variant.  This finding could have implications for developing guidelines for exposure to targeted 
therapeutic agents that are metabolized by UGT2B7 in patients who are deemed to be “at-risk” 
individuals for SVV.  Additionally, further work is warranted in defining the contribution of kidney 
localized UGT2B7 toward metabolism of MPA and other substrates.  Lastly, the contribution of 
leukocyte localized drug metabolizing and drug transporting gene transcripts toward overall 
MPA exposure and outcomes is an appealing area for further investigation.   
 
